Wayne State University
Wayne State University Dissertations
January 2020

Evaluating Historical Paradigms Of Sterility In Perinatal
Microbiology And Ramifications For Pregnancy Outcomes
Jonathan Greenberg
Wayne State University

Follow this and additional works at: https://digitalcommons.wayne.edu/oa_dissertations
Part of the Microbiology Commons, and the Obstetrics and Gynecology Commons

Recommended Citation
Greenberg, Jonathan, "Evaluating Historical Paradigms Of Sterility In Perinatal Microbiology And
Ramifications For Pregnancy Outcomes" (2020). Wayne State University Dissertations. 2468.
https://digitalcommons.wayne.edu/oa_dissertations/2468

This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has
been accepted for inclusion in Wayne State University Dissertations by an authorized administrator of
DigitalCommons@WayneState.

EVALUATING HISTORICAL PARADIGMS OF STERILITY IN PERINATAL
MICROBIOLOGY AND RAMIFICATIONS FOR PREGNANCY OUTCOMES
by
JONATHAN MURRAY GREENBERG
DISSERTATION
Submitted to the Graduate School
of Wayne State University,
Detroit, Michigan
in partial fulfillment of the requirements
for the degree of
DOCTOR OF PHILOSOPHY
2020
MAJOR: BIOCHEMISTRY, MICROBIOLOGY, &
IMMUNOLOGY
Approved by:
Advisor

Date

DEDICATION
This dissertation is dedicated to my parents and sister, who have all been immeasurably
supportive over my graduate career and more importantly my entire life. I could not have done
this without you.

ii

ACKNOWLEDGMENTS
There is no way for me to express fully my sincere gratitude to all the individuals who
have had an impact on my life and throughout my time here at Wayne State. None of it would
have been possible without Dr. Kevin Theis. Rotating in his lab was one of the best decisions of
my life and quite literally got me to where I am. His unwavering support throughout my time as
a student and a scientist has meant the world to me, I am so grateful, and his guidance as a
scientist and a professional has been fundamental to my development as a researcher. I would
also like to thank the members of my committee: Dr. Withey, Dr. Pellett, Dr. Chen, and Dr. Luca
who have supported me throughout my research, been patient, and given feedback that has
undoubtedly contributed to my success.
From the Theis Lab, I must thank Dr. Andrew Winters, who has taught me many
laboratory skills and helped sustain me by sharing many home-cooked meals. I also need to
thank Madison Ahmad for always being willing to get coffee with me, supplying candy, and
being a constant in the lab that I could always count on. I would also like to thank Emma
Graffice, a new member of the lab, but one who quickly became invaluable and a supportive
friend. I would like to thank Amruth Atyam, and the other undergraduate researchers who have
spent time in the lab and allowed me to take on a mentorship role. And of course, I must thank
the Perinatal Research Branch for allowing me to be a part of their work.
From the BMI department, I am grateful for the enormous support us students receive
from April Wolak, Mary Dismuke, Joseph Fiore, and Lynette Ray. Mel Clay, you have
contributed to all of our success by aiding us in the routine, but essential tasks that are required
to do good science. Thank you to all the departmental faculty members that have played a role in
making our experiences as students better through the various committees, and especially Drs.
Holland and Thipparthi who were directly involved in my recruitment to Wayne State.
I have to thank my friends, new and old, and especially those I have met since moving to
Detroit, I could not have been this successful without your support. And to Paul Breen, who has
been a great friend and helped keep me accountable during our mutual tenure. And finally, thank
you to my family, my parents Jeff and Liz Greenberg. Your love and encouragement have
allowed me to come this far, and I cannot begin to fathom the sacrifices you have made in order
to support me.

iii

TABLE OF CONTENTS

DEDICATION............................................................................................................................... ii
ACKNOWLEDGMENTS ........................................................................................................... iii
LIST OF TABLES ....................................................................................................................... ix
LIST OF FIGURES ..................................................................................................................... xi
CHAPTER 1: INTRODUCTION................................................................................................ 1
Microbial communities, their diversity, and advancements in their characterization ............ 1
The human microbiome in the context of disease and low microbial biomass tissues ............ 4
Host-microbe interactions and consequences of premature shifts in sterility paradigms....... 9
CHAPTER 2: DOES THE HUMAN PLACENTA DELIVERED AT TERM HAVE A
MICROBIOTA? ......................................................................................................................... 14
I. Abstract .................................................................................................................................. 14
II. Introduction .......................................................................................................................... 15
III. Methods and Materials ........................................................................................................ 21
DNA extraction from placental tissues .................................................................................. 21
Metagenomic sequencing of extracted DNA from placental tissue and background technical
control samples ...................................................................................................................... 23
Metagenomic sequence data processing using MG-RAST .................................................... 24
Reanalysis of published placental data after reclassification into ASVs ........................ 25
ASV sequence data processing using DADA2 ....................................................................... 25
Subsampling of 16S rRNA gene sequence data for ASV vs OTU comparisons ..................... 26

iv

Decontam program for the removal of likely background DNA contaminants ..................... 26
Rationale for use of isNotContaminant method and thresholds ............................................ 26
Filtering of contaminant ASVs from the primary nested dataset using decontam ................ 29
Filtering of contaminant ASVs from the secondary touchdown dataset using decontam ..... 30
Statistical analyses................................................................................................................. 31
Figure generation .................................................................................................................. 32
IV. Results ................................................................................................................................. 32
Metagenomic surveys of the bacterial profiles of placental tissues ...................................... 32
Bacterial profiles of placental tissues and technical controls from the primary nested PCR
dataset characterized using OTU and ASV approaches........................................................ 39
Bacterial profiles of placental tissues from the primary nested PCR dataset after removing
any ASVs that were identified in controls .............................................................................. 39
Bacterial profiles of placental tissues from the primary nested PCR dataset after filtering
out likely background DNA contaminants identified through the program decontam .......... 43
Bacterial profiles of placental tissues and technical controls from the secondary touchdown
PCR dataset characterized using OTU and ASV approaches ............................................... 43
Bacterial profiles of placental tissues from the secondary touchdown PCR dataset after
removing any ASVs identified in controls .............................................................................. 49
Bacterial profiles of placental tissues from the secondary touchdown PCR dataset after
filtering out likely background DNA contaminants identified through the program decontam
............................................................................................................................................... 51
V. Discussion ............................................................................................................................ 55
Metagenomic surveys of a potential placental microbiota .................................................... 56
Classifying 16S rRNA gene sequence data as operational taxonomic units (OTUs) versus as
amplicon sequence variants (ASVs)....................................................................................... 58
CHAPTER 3: DOES THE MOUSE PLACENTA HAVE A MICROBIOTA? CULTURE
AND MOLECULAR SURVEYS OF THE MURINE MICROBIOTA ................................. 62

v

I. Abstract .................................................................................................................................. 62
II. Introduction .......................................................................................................................... 63
III. Methods and Materials ........................................................................................................ 64
Study subjects and sample collection .................................................................................... 64
Mouse tissue processing ........................................................................................................ 66
Mouse tissue cultivation methods .......................................................................................... 67
Taxonomic identification of individual bacterial isolates ..................................................... 68
DNA extraction from plate washes of cultured bacteria ....................................................... 69
16S rRNA gene sequencing of plate wash extracts ................................................................ 69
DNA extraction from swab and tissue samples ..................................................................... 69
16S rRNA gene quantitative real-time PCR (qPCR) ............................................................. 71
16S rRNA gene sequencing of swab and tissue sample extracts ........................................... 72
Statistical analysis ................................................................................................................. 73
IV. Results ................................................................................................................................. 75
Bacterial culture from placental and fetal tissues ................................................................. 75
Bacterial culture from maternal compartments .................................................................... 79
Quantitative real-time PCR (qPCR) of murine and control samples .................................... 81
16S rRNA gene sequencing of murine and control samples .................................................. 83
Comprehensive consideration of individual placental and fetal tissues across
microbiological inquiries....................................................................................................... 87
V. Discussion ............................................................................................................................ 88
CHAPTER 4: A URINARY MICROBIOTA IN PREGNANCY: CULTIVATION- AND
MOLECULAR-BASED COMPARISON OF FOLEY CATHETERIZED URINE, CLEAN
CATCH URINE, AND VAGINAL SWABS FROM THE SAME WOMEN ........................ 94

vi

I. Abstract .................................................................................................................................. 94
II. Introduction .......................................................................................................................... 96
III. Methods and Materials ...................................................................................................... 101
Clinical specimens ............................................................................................................... 101
Study design ......................................................................................................................... 101
Inclusion and exclusion criteria .......................................................................................... 102
Sample collection ................................................................................................................. 103
Bacterial culture of urine..................................................................................................... 103
Genomic DNA extractions ................................................................................................... 104
Quantitative real-time PCR (qPCR) of 16S rRNA genes in samples................................... 106
16S rRNA gene sequencing .................................................................................................. 107
16S rRNA gene sequence processing ................................................................................... 107
Statistical analyses............................................................................................................... 108
IV. Results ............................................................................................................................... 110
Study Component 1 ........................................................................................................... 111
Patient characteristics ......................................................................................................... 111
Quantitative real-time PCR (qPCR) of 16S rRNA gene abundance in urine samples ........ 111
16S rRNA gene profiles of urine samples ............................................................................ 111
Study Component 2 ........................................................................................................... 115
Patient characteristics ......................................................................................................... 115
Bacterial cultivation ............................................................................................................ 118
Quantitative real-time PCR (qPCR) of 16S rRNA gene abundance in urine and vaginal swab
samples ................................................................................................................................ 118
16S rRNA gene profiles of paired catheter urine, clean catch urine, and vaginal swab
samples ................................................................................................................................ 118
vii

V. Discussion .......................................................................................................................... 128
Principal findings of the study ............................................................................................. 128
Urinary Tract Infections (UTIs) and Pregnancy ................................................................. 129
Vulvovaginal contamination of urine samples .................................................................... 130
5.4 ml of urine is an appropriate volume for 16S rRNA sequencing ................................... 131
Our results suggest that a bladder microbiota exists during pregnancy............................. 132
Strengths and limitations ..................................................................................................... 135
Conclusions.......................................................................................................................... 135
Future directions ................................................................................................................. 136
CHAPTER 5: GENERAL CONCLUSIONS.......................................................................... 137
REFERENCES .......................................................................................................................... 141
ABSTRACT ............................................................................................................................... 173
AUTOBIOGRAPHICAL STATEMENT ............................................................................... 175

viii

LIST OF TABLES
Table 2.1. Summary of metagenomic sequence data from placental samples. ..................... 33
Table 2.2. Summary of metagenomic sequence reads from placentas assigned a bacterial
gene function................................................................................................................................ 36
Table 2.3. Summary of metagenomic sequence data from technical controls. ..................... 37
Table 2.4. Comparison of the bacterial profiles of placental samples and technical controls
using OTU and ASV approaches for the primary nested PCR dataset. ................................ 40
Table 2.5. Comparison of the structure of bacterial profiles of placental samples and
technical controls before and after decontam filtering for the primary nested PCR dataset.
....................................................................................................................................................... 44
Table 2.6. Comparison of bacterial community structure of OTU and ASV approaches for
the secondary touchdown dataset. ............................................................................................. 48
Table 2.7. Comparison of the structure of the bacterial profiles of placental samples and
technical controls for the secondary touchdown PCR dataset after decontam filtering of
ASVs. ............................................................................................................................................ 52
Table 3.1. Bacterial cultivation results for placental and fetal brain, lung, liver, and
intestinal samples. ....................................................................................................................... 78
Table 3.2. Bacterial cultivation results for maternal cervical, uterine, and liver samples. .. 82
Table 4.1. Descriptive and clinical characteristics of subjects for Study Components 1 and
2................................................................................................................................................... 112
Table 4.2. Comparisons of alpha diversity of Foley catheter urine and clean catch urine
processed at 5 different volumes and blank controls. ............................................................ 114
Table 4.3. Statistical analysis of bacterial community composition (Jaccard similarity
index) for Foley catheter urine and clean catch urine processed at five different volumes
and compared to blank controls. ............................................................................................. 116
ix

Table 4.4. Statistical analysis of bacterial community structure (Bray-Curtis similarity
index) for Foley catheter urine and clean catch urine processed at five different volumes
and compared to blank controls. ............................................................................................. 116
Table 4.5. Odds ratios of detecting bacterial phylotypes through culture in urine obtained
from a Foley catheter compared to urine collected through the mid-stream clean catch
method. ....................................................................................................................................... 119
Table 4.6. Statistical analysis of bacterial community composition (Jaccard similarity
index) for Foley catheter urine, clean catch urine, and vaginal swabs. ............................... 123
Table 4.7. Statistical analysis of community structure (Bray-Curtis similarity index) for
Foley catheter urine, clean catch urine, and vaginal swabs. ................................................. 123

x

LIST OF FIGURES
Figure 2.1. Histograms of decontam scores for identifying appropriate thresholds for
filtering of the ASV datasets. ..................................................................................................... 28
Figure 2.2. Bacterial profiles of placental samples as determined by metagenomic
sequencing.................................................................................................................................... 34
Figure 2.3. Bacterial profiles of placental samples based on 16S rRNA gene sequencing
data. .............................................................................................................................................. 38
Figure 2.4. Principal Coordinates Analysis (PCoA) comparing the bacterial community
structure of OTU and ASV approaches for the primary nested dataset. .............................. 40
Figure 2.5. Heatmaps of the bacterial profiles from ASV datasets. ....................................... 41
Figure 2.6. Average sequence read count for placental samples from the primary nested
PCR dataset. ................................................................................................................................ 42
Figure 2.7. Unique ASV counts per placental sample type after removal of ASVs that were
identified in control samples. ..................................................................................................... 42
Figure 2.8. Principal Coordinates Analyses (PCoAs) illustrating the structure of the
bacterial profiles of placental samples and technical controls from the primary nested PCR
dataset after various contaminant filtering methods............................................................... 45
Figure 2.9. Heatmaps of the primary nested PCR dataset after decontam filtering. ........... 46
Figure 2.10. Principal Coordinates Analyses (PCoAs) illustrating the structure of the
bacterial profiles of placental samples and technical controls from the secondary
touchdown PCR dataset under different classification and contaminant removal
approaches. .................................................................................................................................. 48
Figure 2.11. Heatmap of the bacterial profiles of placental samples from the secondary
touchdown PCR dataset after the removal of all ASVs identified in technical controls. ..... 50

xi

Figure 2.12. Principal Coordinates Analyses (PCoAs) of the structure of the bacterial
profiles of placental samples and technical controls from the secondary touchdown PCR
dataset after different filtering approaches with the program decontam. ............................. 53
Figure 2.13. Heatmaps of the bacterial profiles of placental samples and technical controls
from the secondary touchdown PCR dataset after different filtering approaches with the
program decontam. ..................................................................................................................... 54
Figure 3.1. Bacterial cultivation results .................................................................................... 76
Figure 3.2. Heat maps illustrating bacterial cultivation results for A) placenta and B) fetal
intestinal tissues........................................................................................................................... 77
Figure 3.3. Quantitative real-time PCR (qPCR) analyses illustrating variation in bacterial
load ............................................................................................................................................... 80
Figure 3.4 Heatmap illustrating the 16S rRNA gene profiles of maternal swab and tissue
samples and background technical controls ............................................................................. 84
Figure 3.5. Principal Coordinates Analysis (PCoA) of maternal samples and controls
illustrating variation in 16S rRNA gene profiles among A) maternal swab samples and
Dacron swab controls, and B) maternal tissue samples and blank DNA extraction kit
controls. 16S rRNA gene profiles were characterized using the Bray-Curtis similarity
index. ............................................................................................................................................ 86
Figure 4.1. Quantitative real-time PCR (qPCR) of the 16S rRNA gene results from urine
sample volumes of 1.0, 1.8, 5.4, 10, and 25 ml. ....................................................................... 113
Figure 4.2. Principal Coordinates Analysis (PCoA) plots:.................................................... 117
Figure 4.3. Heatmap illustrating variation in the profiles of prominent OTUs (≥1% average
relative abundance) among urine samples from subjects, ordered by urine collection
method and sample volume. ..................................................................................................... 117
Figure 4.4. Urine bacterial cultivation results indicating differential recovery of bacterial
phylotypes from catheter urine, clean catch urine, or both. ................................................. 119

xii

Figure 4.5. Quantitative real-time PCR (qPCR) of the 16S rRNA gene results from Foley
catheter urine, clean catch urine, and vaginal swabs. ........................................................... 120
Figure 4.6. Jitter and Principal Coordinates Analysis (PCoA) plots illustrating alpha and
beta diversities of Foley catheter urine, clean catch urine, and vaginal swabs collected from
the same women. ....................................................................................................................... 121
Figure 4.7. Heatmap illustrating variation in the profiles of prominent OTUs (≥1% average
relative abundance) among paired Foley catheter urine, clean catch urine, and vaginal
swab samples from 25 pregnant subjects................................................................................ 124
Figure 4.8. SourceTracker analysis comparing the percentage of OTUs explained by
vaginal swabs among Foley catheter urine and clean catch urine. ...................................... 124
Figure 4.9. Linear discriminant analysis Effect Size analyses identified several bacteria that
were more relatively abundant in blank extraction kits. ...................................................... 126
Figure 4.10. Linear discriminant analysis Effect Size analyses identified several bacteria
that were more relatively abundant in Foley catheter urine over vaginal samples ............ 127

xiii

1

CHAPTER 1: INTRODUCTION
Sterility has had a fundamental place in science and medicine since the introduction of
the germ theory of disease, which posits that microscopic organisms cause contagious diseases
[1-3]. The concept of sterility, as it applies to science and medicine, originated with the idea that
an environment, whether it be a surface or a compartment of an organism or an inorganic object,
is completely devoid of microorganisms; this includes protists, fungi, archaea, and bacteria [4,
5]. The value of sterility in the medical community became clear through the practice of surgery
and the treatment of wounds [3, 6-8]. The importance of sterility developed into the practice of
aseptic technique, which refers to the prevention of introducing foreign microorganisms into
tissues or organs that do not normally contain these microorganisms [9, 10]. Aseptic technique
entails the removal and eradication of any microorganisms from instruments and surfaces,
thorough handwashing, and barrier protection of medical personnel directly involved in a
procedure [4, 6]. The purpose of aseptic technique is to ensure the sterility of medical procedures
and the safety of patients by protecting patients from the unintentional introduction of foreign
and potentially infectious materials. The practice of aseptic techniques in medicine has saved
millions of lives by preventing and reducing cases of infection and concomitantly increasing the
success rate of medical procedures and surgeries [3, 6-8]. Similarly, in science, aseptic technique
serves as a fundamental practice in conducting accurate, controlled, and replicable experiments
that are un-confounded by unknown variables and contamination related to microorganisms [4,
9, 10]; this is necessary for the advancement and development of new technologies and practices.
Microbial communities, their diversity, and advancements in their characterization
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Although sterile workspaces shall continue to be essential in the medical and scientific
fields, microbial populations will undeniably continue to occupy and persist in nearly every
exposed environment on the planet [11-13]. A microbial community is an ecological community
made up of microorganisms [14, 15]. In a specific environment, it is often referred to as a
microbiome, defined as the collective microorganisms, and the genetic and genomic potential of
these microorganisms, inhabiting a particular environmental niche [16]. As sequencing
technologies have improved and become more accessible over the past decade, microbiome
research is no longer restricted to culture-dependent investigations and has resulted in a
considerable increase in the attention and research on microbial communities. Still, much is
unknown, including a great deal regarding the symbiotic relationships between microbiota (the
members of a microbial community constituting a microbiome) and hosts. It is also important to
note that while a microbial community and microbiome encompasses all microbial cells
(bacteria, archaea, and microscopic eukaryotes), for all intents and purposes of this document,
usage of the terms microbes, microorganisms, microbiome, and microbiota will be exclusively
referring to bacteria.
Microorganisms are the most abundant life form on this planet and although their exact
numbers are not possible to calculate, many estimates and formulations have made clear that we
are living in a microbial world. For instance, our oceans alone contain more than 3 x 1028
bacteria, which vastly exceeds the number of stars in the visible universe [11, 12]. Not only are
their numbers great, but microorganisms are capable of inhabiting the most extreme
environments on the planet. Bacteria, for instance, have been detected in deep sea thermal vents
[17], in the deepest layers of the Earth’s crust [18], and in environments with extremely low [19]
and high [20] pH environments – there is very little space on the planet that is unpopulated by
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microorganisms. A recent estimate of the global diversity of bacteria and archaea suggests that
there are more than a million species of bacteria on the planet [13]. The human body is no
exception. Each human harbors more microorganisms in their gastrointestinal tract than there are
people on the planet [21-23]. Indeed, all the external and mucosal surfaces of the human body
are populated by diverse microbial communities. And yet, the historical presumption has been
that the vast majority of internal organs of the human body are sterile.
Given that the human body consists of nearly equal numbers of human and bacterial cells
(bacteria outnumber human cells if red blood cells are excluded), measuring around 1x1013 cells
each [21, 24, 25], the importance of understanding the bacterial side of human health has been
underappreciated and is gradually being rectified. Historically, microbial surveys in medical
microbiology have been largely cultivation-based [26, 27], however, molecular surveys,
especially those of phylogenetic marker genes (e.g. 16S rRNA gene) are becoming increasingly
common [28-31]. Both methodological approaches have strengths and weaknesses, yet they can
complement each other, thereby providing a more robust understanding of the microbial
communities under investigation. Cultivating a microorganism from a clinical sample provides
certainty of its viability [32, 33], and, once a microorganism is obtained in pure culture, its
phenotype and genotype can be effectively characterized [34-36]. However, many
microorganisms are recalcitrant to being cultivated in isolation within the laboratory [33, 36]. As
such, cultivation-based surveys of microbial communities in clinical samples can preferentially
select for community members that do grow well in the laboratory, thereby providing an
incomplete or skewed representation of actual microbial community composition and structure
[37-40]. With the development of next-generation sequencing (NGS) technologies, scientists can
sequence millions of DNA molecules from clinical and research samples and describe the
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genetic content in these samples to characterize their various biological features, including the
compositions of microbial communities associated with these samples. More specifically,
researchers now often utilize 16S rRNA gene sequencing to identify the compositions of
microbial communities and metagenomic, or shotgun, sequencing to study the genomic and
functional potential of these communities [41-53]. Culture-independent approaches like NGS
surveys can provide more encompassing snapshots of microbial communities because they are
not limited by the growth requirements of the bacteria [42, 43]. These new techniques facilitated
the launch of the Human Microbiome Project, a large-scale NIH-funded collaborative project
that utilized NGS in a major push towards understanding healthy human microbiota.
Specifically, using 16S rRNA gene and metagenomic sequencing, the HMP characterized the
bacterial communities of the human body including the mouth, skin, gut, and vagina [42]. The
consortium of scientists and medical professionals involved in the HMP were tasked with
investigating the microbiomes of various body sites of healthy individuals in order to establish a
basic understanding of the diversity and function of the microorganisms in these environments.
Understanding these communities in healthy individuals is a fundamental prerequisite to
understanding their roles in disorders and diseases.
The human microbiome in the context of disease and low microbial biomass tissues
Since the inception of the HMP, thousands of studies have investigated various aspects of
the human microbiome. Links to and associations with the human microbiome have been
described in the context of multiple diseases and disorders, including Clostridium difficile
infection (CDI) [54-56], obesity and Type II diabetes [57-59], dental caries [60-62], urinary tract
disorders [48, 63-69], cystic fibrosis [70], inflammatory bowel disease [71-77], and asthma [7880]. While the HMP and a majority of subsequent studies primarily focused on body sites known
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to be inhabited by microorganisms, there are other body sites that have a much lower microbial
load or have even been historically considered sterile. Next-generation sequencing technologies
have allowed these body sites to be interrogated for potential microbial communities. Most
descriptions of human-associated microbial communities have been from body sites with high
microbial biomass, especially the gut [58, 59, 71, 81-96]. These early uses of NGS technologies
to characterize the human microbiome had a high signal-to-noise ratio, meaning the samples
being described had a high microbial DNA signal that far exceeded the inherent noise introduced
through background DNA contamination in laboratory reagents and environments [97-99]. This
high ratio of signal to noise results in the characterization of legitimate microbial signals in
samples. However, as the microbial load in samples decreases, the signal-to-noise ratio
decreases, or even inverts, such that that the background noise becomes a predominate portion of
the data generated and is ultimately included within the characterization of the putative microbial
community in a sample [99]. In these cases, most, if not all, legitimate biological signals can be
overwhelmed and no longer distinguishable from contamination [97-104]. This caveat is one that
must be addressed as researchers continue to investigate lower microbial biomass environments,
including human body sites historically presumed to be sterile. As exquisitely demonstrated by
Salter et. al. [99], simply by performing serial dilutions on cells from a pure culture of bacteria is
sufficient to obscure legitimate signal. After five serial dilutions (e.g. 108 cells diluted to 103
cells), contaminating sequences from genera such as Pseudomonas and Propionibacterium
comprised between 70-95% of the obtained microbial signal, with some variation depending
upon the sequencing facility that was used to process the samples.
Molecular surveys failing to address caveats associated with low microbial biomass
samples, specifically background DNA contamination, have led some to conclude the existence
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of microbial communities in body sites historically considered sterile, such as the brain [105],
blood [106, 107], endometrium [108, 109], placenta [44, 45, 49, 84, 95, 110-113], and bladder
[114-118]. One significant and ubiquitous caveat with these investigations is that microbial
genes are pervasive in the environment, even in the absence of microbial cells. This issue has led
to much debate and premature conclusions could potentially influence medical science and even
clinical care, which runs the risk of negatively impacting patient care and clinical outcomes. One
of the principal ways this caveat can be properly addressed is through the inclusion of
background DNA contamination controls (i.e. samples that receive no biological input and are
processed and extracted alongside the biological samples) in all studies of low microbial biomass
samples. These technical controls serve to account for the microbial DNA sequences that are
ubiquitous in both DNA extraction kits and PCR reagents [98-100, 102, 104, 119]. Many studies
have specifically evaluated the microbial signals from such technical controls and have described
many microbial taxa as potential contaminants [98-100, 119]. For instance Pseudomonas [99],
Propionibacterium [98, 99, 119], Ralstonia [98-100], Corynebacterium [99, 119], Actinobacteria
[99, 119], Burkholderia [99, 100], Escherichia [102, 119], Pelomonas [98, 99, 119], and
Bradyrhizobium [99, 100] are some of the more commonly reported taxa identified as
contaminants in these studies. These microbial signals, which most often originate from DNA
extraction kit reagents, have been given their own name, the “kitome” [98].
The kitome spreads uncertainty about the conclusions of microbiome work because it
highlights the difficulty in knowing definitively if the presence of microbial DNA in a biological
sample is legitimate or if it is a contaminant from the kitome. Several approaches and tools exist
to help address this issue [120-122], however, there is no perfect way based solely on molecular
surveys, which is why multiple methodologies are critical to validate DNA sequence-based
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surveys. Various molecular techniques can be used to address the kitome such as targeted PCR,
nested PCR, touchdown PCR, and metagenomic sequencing. While alternative PCR methods and
metagenomics have their own biases (such as amplification biases that may exclude or
underrepresent certain taxa [123-125] or limitations of taxonomic assignment based on reference
databases) and can also be influenced by kitome contamination [98-100, 119], consistent trends
in the data, such as one or two consistently detected and biologically relevant taxa across
multiple investigatory approaches would help validate the potential microbiome data. For
instance, conclusions from sequence-based surveys could be validated through Fluorescence in
situ hybridization (FISH) [100], a molecular technique that allows for the visualization of
bacterial cells within tissue samples; FISH is a critical tool for demonstrating the existence of a
bacterial presence in vivo. While validating the presence of bacterial cells in tissue is important,
cultivation persists as the most convincing evidence that bacterial cells are present in the
biological samples and that they are alive. Again, both of these methodologies have their own
caveats. In the case of FISH, fluorescent DNA probes can be cross-reactive or non-specific [126,
127]. For cultivation to be successful, knowledge of the appropriate and required growth
conditions are necessary and many bacteria have unknown or unattainable culture conditions at
this time [36], especially when dealing with mixed bacterial communities.
As previously mentioned, many studies investigating bacterial communities of these
classically sterile sites have failed to employ multiple methodologies or failed to include
appropriate kitome controls. This may lead to spurious conclusions, as these studies were
missing critical information necessary for rejecting the null hypotheses that these sites are sterile.
Bold claims suggesting a typical bacterial presence in tissues of the human body that are contrary
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to historical views will certainly impact the practice of medicine and will, if incorrect, potentially
result in improper patient care and treatment.
While most microbiome studies investigate body sites in the context of disease and/or
rely on comparisons of a diseased cohort to a healthy cohort, this can be precarious when the
organs under investigation are typically considered sterile. In one example, researchers compared
16S rRNA gene signals from post-mortem brains of Alzheimer’s disease (AD) patients to those
from brains of control patients [105]. This study makes two problematic assumptions: 1) there
are bacteria in the brains of both cohorts, and 2) these bacteria were present before death and
post-mortem removal of the organs. While the authors concluded that there exists an increase in
bacteria within Alzheimer brain tissue over normal brain tissue, they failed to address the
inherent caveats associated with low microbial biomass studies. First, although a significantly
greater 16S rRNA gene sequence read count was found in the brains of AD patients compared to
those from normal controls, sequence read count is not a quantitative measure appropriate for
assessing bacterial load. The appropriate approach would be quantitative real-time PCR. Second,
the taxonomic profiles indicated a high relative abundance of Actinobacteria in the brains of AD
patients compared to controls, primarily Propionibacterium acnes (recently reclassified as
Cutibacterium acnes). P. acnes is a ubiquitous human skin bacterium that is frequently detected
in culture and molecular surveys as both a legitimate biological signal and as a contaminant [98,
99, 119, 128]. However, because this study was limited to a single methodology (i.e. 16S rRNA
gene sequencing surveys), any conclusions about the existence of a brain microbiome should be
considered premature. While 16S rRNA gene surveys alone may be appropriate for an
exploratory study, to suggest paradigm-shifting conclusions like the brains of Alzheimer patients
have more bacteria than normal patients is irresponsible and has the potential to cause harm.
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Host-microbe interactions and consequences of premature shifts in sterility paradigms
The importance of accurately evaluating the presence of a microbial community and fully
understanding its relationship with the human body has been made clear through a variety of
noninfectious diseases that have been associated with microorganisms [43, 60, 65, 70, 75-77, 80,
108, 117, 129-133]. These associations reinforce the value of understanding where microbial
communities begin and end in the human body. Should microbial communities be discovered in
an anatomic environment that was previously believed to be sterile, it would open the door to
new exploratory studies and research funding. However, if conclusions are drawn prematurely, it
would put researchers on a fool’s errand with expensive molecular surveys revealing the
taxonomic and functional profiles of exogenous and contaminant DNA. More importantly would
be the consequences on the medical community of the declaration that a body site presumed to
be sterile is not actually sterile. If practitioners begin believing mistakenly that bacteria are
normally present in a body site of healthy individuals, even at low or hard to detect numbers,
practitioners may become laxer with safety and hygiene procedures. This would put patients at a
high risk for infections or at the very least disruption and alteration of these communities. These
theoretical consequences illustrate the diligence we must employ as researchers before
presenting and advocating for shifts in classical paradigms of sterility.
Reevaluating paradigms of sterility in the context of pregnancy has been the focus of my
dissertation research. Because infection is instrumental in pregnancy complications [134-146]
and classically involves microorganisms reaching sterile tissues and causing inflammation, a
thorough and complete understanding of the microbial signals in urogenital compartments is
necessary for the best patient care and treatment. One important issue is that if there are actually
resident microbiomes in the womb or bladder, it is likely that antibiotic use would affect these
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microbial communities. While antibiotic therapy is generally only used when necessary,
secondary consequences can result such as in the case of Clostridium difficile infection (CDI),
which is a nosocomial infection that results from the use of antibiotics disturbing a patient’s
intestinal microbiota and allowing for C. difficile spores to colonize and populate the intestinal
lining of a patient, causing chronic diarrhea and severe intestinal discomfort. Although
antibiotics are often used during pregnancy, there may be consequences previously overlooked
under assumptions of sterility in the bladder and womb. Also, under the presumption that these
sites harbor microbiomes, new therapeutic and diagnostic tools, such as probiotics [69, 147, 148]
or biomarker assays [122], can be explored. I must reiterate, however, these data and must be
vetted before concluding that there are resident microbial communities in the bladder or womb.
CHAPTER 2: DOES THE HUMAN PLACENTA DELIVERED AT TERM HAVE A
MICROBIOTA?
In the second chapter, I will present our study that addressed the literature asserting the
existence of a placental microbiome. In 2014, Aagaard et al. published a pioneering study
suggesting that a placental microbiome exists and that its primary member is Escherichia coli
[44]. Since then, a wide range of studies from multiple groups have published reports either
supporting Aagaard’s claim [45, 49] or refuting it [128, 149, 150]. Chapter 2 will provide an
overview of our own study that addressed the issues and oversights from the previous studies by
approaching the hypothesis that there is a placental microbiome in term pregnancies by
surveying cesarean delivered placentas with multiple methodologies and including extensive
background DNA contamination controls. I will further describe and discuss the metagenomic
analysis portion of the study that I performed. Additionally, I will describe a secondary analysis
of the amplicon 16S rRNA gene sequence data wherein I address the same questions concerning
sterility of the placenta in the context of two sequence classification methods, operational
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taxonomic units (OTUs) [151] and amplicon sequence variants (ASVs) [152]. Operational
taxonomic units were developed as a method for grouping 16S rRNA gene sequences based on a
defined level of sequence similarity (e.g. 97 or 99%). Grouping sequences at a defined similarity
eliminates some of the error inherent in sequencing technologies and permits a small degree of
sequence variation while treating those sequences as though they came from the same
microorganism. A key limitation of the OTU approach is that it lacks taxonomic resolution; the
16S rRNA gene sequences of multiple microorganisms, whether species or strains, can get
grouped into the same OTU. This led to the proposal of ASVs as an alternative method for
grouping and classifying sequences. This newer method increases the resolution of sequences to
single nucleotide differences and this can be vital in differentiating different species and strains
of bacteria. However, caveats exist with this method as well. By increasing the resolution to
single nucleotide differences, researchers run the risk of characterizing sequences that are
products of sequencing error and assuming that these sequences represent authentic and specific
bacteria. Researchers are transitioning toward the use of ASVs as the dominant method for
classifying 16S rRNA gene sequences, however, conclusions on which method is most
appropriate need to be considered in various contexts, such as in investigations of low microbial
biomass environments like the placenta.
CHAPTER 3: DOES THE MOUSE PLACENTA HAVE A MICROBIOTA? CULTURE
AND MOLECULAR SURVEYS OF THE MURINE MICROBIOTA
The third chapter of my dissertation uses an animal model to more comprehensively
address the sterility of the mammalian placental and fetal compartments. By transitioning from
the human model to a mouse model we are able to address several questions that could not be
answered using human participants. One benefit of using a mouse model is that sterile
reproductive tissues and fetuses can be collected and investigated alongside other sterile and low
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and high microbial biomass samples that can serve as controls for discriminating potential
microbial signals. In this chapter, culture results from placental, fetal, and maternal tissues will
be presented and analyzed extensively and compared to the microbial signals evident in murine
tissues with high microbial load. Surprisingly few studies have assessed the broader mouse
microbiome, outside of the intestine, and our data allow us to compare both molecular and
culture-based surveys to determine if the murine placenta and fetus are sterile, compare the
ability of culture to capture what is seen in 16S rRNA gene surveys, and to assess our results in
the context of the established literature for culture and sequencing.
CHAPTER 4: A URINARY MICROBIOTA IN PREGNANCY: CULTIVATION- AND
MOLECULAR-BASED COMPARISON OF FOLEY CATHETERIZED URINE, CLEAN
CATCH URINE, AND VAGINAL SWABS FROM THE SAME WOMEN
The fourth chapter of my dissertation, while still investigating paradigms of sterility in
perinatal medicine, shifts from the placenta to the female bladder in pregnancy. Like the
placenta, the bladder has historically been considered a sterile organ. However, this is being
reconsidered as recent molecular surveys of urine suggest the presence of a bladder microbiota
[48, 63, 115-118, 153, 154]. Since urinary tract infections (UTIs) are the most frequent bacterial
infection in women [155], and can lead to pregnancy complications such as spontaneous preterm
birth [66, 134, 137, 138, 156-165], defining and characterizing bladder microbial communities
could greatly alter how UTIs [69], and other urinary disorders [48, 63, 64, 67] are diagnosed and
treated in pregnancy Additionally, urinary tract catheterization is standard practice for women
delivering via cesarean section and such mechanical procedures can lead to UTIs [166] and
potentially affect resident bladder microbial communities [65], Therefore, the objective of
Chapter 4 is to evaluate the existence of a bladder microbiome in pregnant women, while also
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assessing the effectiveness of different volume and collection methods for acquiring urine for
microbiological investigations.
CHAPTER 5: GENERAL CONCLUSIONS
In closing, I provide a summary of the investigations I have completed, directions for
future studies, and describe the significance of these findings in the context of low microbial
biomass investigations.
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CHAPTER 2: DOES THE HUMAN PLACENTA DELIVERED AT TERM HAVE A
MICROBIOTA?
The metagenomic data presented in this chapter were a fundamental component of the
manuscript “Does the human placenta delivered at term have a microbiota? Results of
cultivation, quantitative real-time PCR, 16S rRNA gene sequencing, and metagenomics”
published March 2019 in the American Journal of Obstetrics and Gynecology by Theis, K.R.,
Romero, R., Winters, A.D., Greenberg, J.M., et al. [150]. Some of the text of this Chapter (i.e.
Methods and Results) appears as it does in the published manuscript. I was an author on this
manuscript and the data presented in this chapter include the portions of that manuscript with
which I was most involved.
I. Abstract
Molecular surveys have allowed investigations of low microbial biomass tissues of the
human body. The human placenta has been of particular interest, and its sterility has been the
subject of recent debate. The majority of evidence suggesting there is a placental microbiota has
relied on 16S rRNA gene sequencing and metagenomic sequencing without addressing the
caveats inherent in low microbial biomass environments. The objective of this chapter was to
determine whether human the placenta delivered at term has a microbiota using multiple modes
of microbiologic inquiry and comparisons to background technical controls. Culture, quantitative
real-time PCR (qPCR), and 16S rRNA gene sequencing were performed on 29 term cesarean
placentas in addition to metagenomic sequencing on a subset of placentas. 28 out of 29 placentas
were negative for culture and the one that was not had three unique bacterial colonies on a single
plate that were not detected in 16S rRNA gene surveys of that placenta. Quantitative real-time
PCR and 16S rRNA gene surveys indicated that the bacterial burden and profiles of placental
samples were not distinct from technical controls. Metagenomic surveys of placental samples
yielded limited bacterial signals and the predominant bacterial taxa included plant-associated and
photosynthetic bacteria, which are ecologically implausible for internal tissues such as the
placenta. Additional analyses of the 16S rRNA gene sequencing data, that utilized a new
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classification method known as amplicon sequence variants (ASVs) and employed additional
tools to control for background DNA contamination, supported the findings observed with the
more traditional 16S rRNA gene classification method of operational taxonomic units (OTUs).
Therefore, through multiple modes of microbiologic inquiry and computational approaches, we
found a lack of evidence for a placental microbiota in the human placenta delivered at term.
II. Introduction
Most tissues within the human body are presumed to be sterile. In fact, nearly all internal
sites, essentially anything not immediately adjacent to mucosal tissue, are viewed as being
devoid of microbes. It is easier to list the mucosal or microbiota-containing sites of the body, i.e.
nasal and oral cavities, lungs, gastrointestinal tract, vagina, and skin, than those considered
sterile, i.e. most everything else. The presence of microbial communities in the urogenital and
upper reproductive tracts, however, has been a source of much recent debate [44, 84, 108, 109,
133, 150, 167-169]. While for both sexes, the distal urethra indisputably contains microbes, the
literature is less clear regarding sterility of the more proximal sites, up to and including the
bladder (further discussed in Chapter 4). Additionally, while the microbial communities of the
vagina and the cervix have been widely described in the literature [170-174], the existence of
microbial communities in the endometrium of the uterus are far less conclusive [108, 109, 168].
In the context of pregnancy, because the placenta implants in the decidualized endometrium of
the uterus, and because the placenta serves as the interfacing organ between the mother and
fetus, the placenta has also become a recent target of microbiome investigation [44, 84, 113,
175].
It is well established that symbiotic microbes can colonize the human placenta and that
this can negatively impact pregnancy outcomes [141, 176-182]. However, a unique, low
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abundance, resident microbiota in the placentas of normal, asymptomatic pregnancies is now
being proposed [44, 183]. Following a landmark study in 2012 by Aagaard et al., the placenta
became a focus of microbiome work; this study made the bold claim that the placenta was not a
sterile organ. The potential for the placenta to harbor a resident microbiota has implications not
only for pregnancy outcome but also for the initial inoculation and development of fetal and
early neonatal microbiota [183-186]. For instance, fetal inoculation with maternal microbes in
utero via the placenta could serve to bolster and shape the early immune system and set the stage
for the colonization and growth of site-specific (e.g., oral cavity, large intestine) microbial
communities upon delivery [186-188]. However, in a recent comprehensive review of the
subject, Perez-Munoz et al. [149] explained that current evidence in support of the in utero
colonization hypothesis is unconvincing. The three principal concerns they highlighted are that
supporting studies 1) have not demonstrated that the microbes captured via molecular surveys of
the placenta and in utero environments were viable, 2) have not given sufficient consideration to
the potential influences of mode of delivery on study outcomes, and they 3) lacked sufficient
technical controls to address potential background contamination. Specifically, when
characterizing and comparing the microbial profiles of low biomass samples via highly sensitive
next-generation sequencing technologies, there is a substantial risk of amplifying, sequencing,
and consequently describing contaminating DNA that is unavoidably present in extraction kits,
PCR and sequencing reagents, and broader laboratory environments [98, 99, 119, 128, 149, 189].
The high sensitivity afforded by the technology also provides susceptibility to false positives.
Notably, one preliminary study that did incorporate sufficient technical controls for background
DNA contamination found similar concentrations of bacterial DNA in placental tissue and
control samples, and the bacterial profiles of the two were not distinguishable [128]. Lauder et al.
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[128] concluded that, when working with low microbial biomass samples and capitalizing on
next-generation sequencing technologies, begin with the null hypothesis that microbial signals
obtained from the biological samples are contamination only. Perez-Munoz et al. [149]
additionally proposed that there is a particular need for studies evaluating this null hypothesis in
healthy term pregnancies, with delivery via caesarean section, in which corroborative evidence is
evaluated across multiple modes of microbiologic inquiry. Therefore, the primary objective of
the study featured in this chapter was to evaluate the existence of a unique resident microbiota in
the placenta from normal term pregnancies using multiple modes of microbiologic inquiry and
incorporating rigorous technical controls for DNA contamination.
As described in Theis et al. [150], the placentas of 29 women delivering via elective
cesarean section at term were evaluated for evidence of a microbiota using bacterial culture, 16S
rRNA gene quantitative real-time PCR, 16S rRNA gene sequencing, and metagenomics. Culture
results were negative for all but one placenta, from which three unique colonies were recovered
from a single agar growth plate. These microbes were common environmental bacteria and their
16S rRNA genes were not detected in the 16S rRNA gene surveys of the placental sample from
which they were “recovered,” suggesting that they were likely laboratory contaminants. Both
16S rRNA gene quantitative real-time PCR and sequencing surveys demonstrated that the
bacterial loads and bacterial profiles of placental tissues were indistinguishable from those of
technical controls, thereby complementing the data obtained from the culture component of the
study. Additionally, secondary qPCR and 16S rRNA gene sequencing analyses further
corroborated the results from the primary analyses briefly described above and further addressed
potential concerns over cross-contamination of bacteria from placental tissues to technical
controls, and biases introduced through PCR methodology and primer design. Lastly, as the first
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aim of this chapter, metagenomics was used to evaluate the existence of a placental
microbiota in normal term pregnancy. Specifically, metagenomic sequencing was performed
on a subset of samples to avoid any potential biases inherent in molecular methods that target
specific genes (e.g. 16S rRNA gene) for amplification and/or sequencing. In metagenomics, all
the DNA in a sample is sequenced with the absence or only minimal use of PCR. The results
from the metagenomic survey reported in this chapter illustrate the importance of using multiple
modes of microbiologic inquiry in reevaluating paradigms of sterility: the bacterial signals
detected in the placenta were largely inconsistent with those obtained from the 16S rRNA gene
surveys, and the bacteria identified were generally ecologically implausible because the placenta
would not be a suitable environment in which for them to grow and reproduce.
The second aim of this chapter is to determine if the manner in which 16S rRNA
gene sequence data are processed influences the conclusions drawn from sequence-based
studies evaluating the existence of a placental microbiota. Since the publication of Theis et
al.[150], a review paper was published that included a reanalysis of the data in Theis et al., and in
another placental microbiota study by Leiby et al. [167], that used a different sequence
processing and classification method [103] than Theis et al. and Leiby et al. had used. Much of
the early research on the microbiome using 16S rRNA gene sequencing was performed using
operational taxonomic units (OTUs) as the predominant classification method for 16S rRNA
gene sequences. Whether OTUs were generated and analyzed using the software programs
Qiime2 [190] or mothur [41], the methodology relied on a user-defined sequence similarity
identity threshold (97% was standard, although other thresholds such as 95% or 99% were
occasionally used), which would group or cluster quality-filtered sequences with ≥ 97%
sequence identity into a single OTU corresponding to a representative 16S rRNA gene sequence
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that is then assigned a specific taxonomic identity/classification. This sequence clustering
approach based on sequence identity can account for sequencing errors that are inevitable with
existing sequencing technologies. However, it has been suggested that the resolution provided by
this clustering method, while valuable for addressing sequencing errors, may obscure microbial
biodiversity patterns in biological samples by disregarding potential species and strain level
differences that can result from as little as a single nucleotide difference in the 16S rRNA gene
[152, 191, 192]. While this issue can be partially ameliorated through OTU clustering at more
stringent sequence identity thresholds, such as 99%, which only allows 1 or 2 nucleotide base
differences across a 250 base amplicon, there are two additional concerns with the OTU
classification method. First, with OTUs, the taxonomic units are constructed based upon the
entire dataset, which can require substantial computational time and resources. Second, OTUs
are typically generated de novo; OTUs from a dataset are specific to that dataset and can
therefore not be directly compared across studies or generated based on a reference database,
which can limit the taxa that are classified based on the thoroughness of the database [192].
While the majority of microbiome studies have relied on the OTU classification method,
an alternative method was recently proposed that identifies exact sequence variants, or amplicon
sequence variants (ASVs), thereby providing resolution in the classification of sequences that
differ by only a single nucleotide. This classification method, which is performed through the
DADA2 [152] package in R [193], addresses the aforementioned caveats associated with OTU
approaches and may allow for elucidating underlying patterns in microbial biodiversity that
would otherwise be overlooked by OTU classification methods. The ASV approach has been
proposed as a more accurate and biologically informative way to classify 16S rRNA gene
sequences, specifically in regard to sensitivity and precision [97]. The strengths of this sequence
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processing pipeline, in addition to the resolution of sequence variants at a single nucleotide
difference, is that ASVs are inferred per sample, rather than per dataset, and are generated based
on their relative abundance within a sample. By factoring in relative abundance, the ASV
approach excludes extremely low abundance sequences based on the assumption that legitimate
sequences are going to occur more frequently than sequences that were resultant from
sequencing error.
Proponents of the existence of a placental microbiota have capitalized on the ASVapproach and argued that prior studies that used OTU-based approaches and determined that the
bacterial profiles of placental tissues and background technical controls were indistinguishable
lacked the resolution required to determine if the molecular signals of bacteria from tissues and
controls were indeed from the same microorganisms [103, 175]. In the review by O’Callaghan
[103], which re-classified publicly available 16S rRNA gene sequence datasets from the two
aforementioned placental microbiota studies [150, 167] using the ASV pipeline, it was suggested
that the results and conclusions of the re-analysis were inconsistent with what had been
previously published using OTU classifications. Therefore, in this chapter, alongside the analysis
of the metagenomic data of placental tissue and technical control samples, I will analyze,
compare, and discuss the 16S rRNA gene sequence data from these samples processed using
both sequence classification methods. Specifically, I will re-assess the publicly available dataset
associated with Theis et al. [150], evaluating the data using ASV and OTU classification
methods, compare the data from both methods to illustrate the differences and similarities
between them in the context of the original publication, and address several points raised by
O’Callaghan et al. [103] that are inconsistent with our analyses (such as their reporting of a high
relative abundance of Ureaplasma sequences in our negative controls). While the published
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manuscript [150] included several datasets generated using multiple PCR methodologies, the
reanalysis presented in this chapter is focused on the primary nested PCR dataset and the
secondary touchdown PCR dataset, as these were the two amplification methods that yielded
large numbers of quality 16S rRNA gene sequences and were not entirely dominated by
Escherichia sequences, a well-established background DNA contaminant in sequence-based
studies [99, 119, 150]. The re-analysis of the data presented here counters the points raised by
O’Callaghan et al. [103] and validates our initial findings and conclusions that there is a lack of
evidence of a placental microbiota in normal term pregnancies.
III. Methods and Materials
Methods and Materials are further detailed in the published manuscript “Does the human
placenta delivered at term have a microbiota? Results of cultivation, quantitative real-time PCR,
16S rRNA gene sequencing, and metagenomics.” [150].
Briefly, tissue samples were taken from the placentas of 29 women delivering by
cesarean section without labor at term. Samples were collected and processed with aseptic
techniques to avoid contamination. Following delivery, placentas were processed in a biological
safety cabinet, wherein a core of tissue (i.e. from the amnion through to the basal plate) was
collected halfway between the edge of the placental disc and the umbilical cord insertion site.
The tissues were placed into sterile containers and frozen at -80° C until DNA extractions were
performed.
DNA extraction from placental tissues
During the DNA extraction process, study personnel wore sterile surgical gowns, gloves,
and masks, and used individually packaged, sterile, and disposable scalpels and forceps. For each
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placental tissue specimen, the amnion and chorion (AC) were collectively cut away from the
villous tree and basal plate (V); no tissue components were excluded and both tissue fractions
likely contained subchorionic tissue. Genomic DNA was extracted from these two tissue
fractions separately. Specifically, DNA was extracted from placental tissues (0.1 to 0.2 g) and
background technical control samples using the MoBio PowerSoil DNA Isolation Kit (MoBio
Laboratories, 12888), according to the manufacturer’s protocol. The DNA extraction kit used,
and the mass of placental tissue from which DNA was extracted, were consistent with prior
studies of potential placental microbiota [44, 128]. Background technical control samples
included extractions performed on: 1) DNA extraction kits without any introduced placental
tissue, processed exactly as the placental samples (N = 6); 2) extraction kits whose bead tubes
had been exposed to a biological safety cabinet for 20 minutes during placental biopsy collection
or processing (N = 16 samples from 3 biosafety cabinets); and 3) extraction kits whose bead
tubes had been exposed for 20 minutes to an operating room or microbiology laboratory utilized
in this study (N = 21 samples from three operating rooms and three laboratories). These control
samples therefore represented five or six technical controls reflecting each potential source of
background DNA contamination (i.e. extraction kits, 3 biosafety cabinets, 3 laboratories, and
operating rooms), with the three contiguous operating room environments being treated as a
single potential contamination source. DNA concentrations of placental tissue and background
technical control samples were 42.0 ± 18.5 (standard deviation) ng/µl and ≤ 0.03 ng/µl,
respectively. Purified DNA was stored at −20° C.
To eliminate the possibility of any bacterial signal coming from the controls being due to
cross-contamination from microbial-populated placental tissues, a secondary series of extractions
and analyses were performed that included background technical control samples processed
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alongside placental samples and independently of placental samples. Secondary DNA extractions
were performed on the collective villous tree & basal plate portion of each of the 29 placental
samples. The extraction protocol was the same as that described earlier, except that at least 4
background technical controls were included in each of four rounds of extractions of the
placental samples. Specifically, in the first three rounds of extractions, we processed eight
placental and four technical control samples. In the fourth round, we processed five placental and
five technical control samples. Additionally, we completed a fifth round of extractions composed
entirely of 12 blank extraction kit controls, which were not exposed to the atmospheres of the
biologic safety cabinets or the laboratories; they were processed exactly as the placental samples.
DNA concentrations of placental tissue and background technical control samples were 56.0 ±
24.3 ng/µl and ≤ 0.03 ng/µl, respectively. Purified DNA was stored at −20° C.
Metagenomic sequencing of extracted DNA from placental tissue and background technical
control samples
In contrast to sequencing surveys targeting a specific bacterial gene (e.g. 16S rRNA
gene), a metagenomic survey entails sequencing all the genes in a clinical sample and assigning
the protein-coding genes of bacterial origin to particular bacterial taxa, even potentially at the
species level. Nine placental and 11 technical control samples were submitted for metagenomic
sequencing using the Illumina HiSeq 4000, 150 paired-end protocol at the University of
Michigan’s DNA Sequencing Core (Ann Arbor, MI). The placental samples included amnionchorion and villous tissue and basal plate samples from each of four subjects (subjects 14, 15, 22,
and 30), and a villous tissue and basal plate placental sample from one subject (subject 19). The
technical control samples included eight biological safety cabinet and three blank extraction kit
samples.
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Metagenomic sequence data processing using MG-RAST
The twenty metagenomic sequence libraries were submitted to the MG-RAST
metagenomes analysis server at the Argonne National Laboratory [194]. Forward and reverse
reads were combined into joined paired-end reads, as applicable, yet those with non-overlapping
paired-ends were retained as well. Default pipeline parameter options were used: assembled (no),
dereplication (yes), and screening (H. sapiens, NCBI v36). Dynamic trimming was also set to
default, except lowest quality base phred score was set to 10, and sequences were trimmed to
contain at most seven bases with a phred score of 10 [195]. Reads more than two standard
deviations from the mean read length were discarded, as were poor quality and artificial
duplicate reads [194]. As the final processing step, sequences were screened for host DNA, in
this case those that matched H. sapiens, via NCBI v36. SortMeRNA [196] was used to identify
rRNA genes with a 70% identity cut-off and CD-HIT [197] was used to cluster those with a 97%
nucleotide similarity. The longest representative from these clusters was run through a BLASTlike alignment tool (BLAT) [198] similarity search against the M5rna database for rRNA
identification [194]. Sequences of potential protein coding regions were identified via
FragGeneScan [199], and predicted protein coding sequences were clustered at 90% identity
with CD-HIT and run through a BLAT search against the M5NR protein database. Protein
features were excluded if they overlapped with ribosomal RNA features. Identified rRNA and
protein sequences were annotated and mapped back to the original sequences. Taxonomic
assignments were made using the GenBank database and the default MG-RAST parameters:
maximum e-value cutoff of 5, minimum percent identity cutoff of 60%, minimum alignment
length cutoff of 15, minimum abundance of 1, and representative-hit classification [194]. For
gene function characterization, sequences were mapped to the KEGG Orthology (KO) database
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[200]. Metagenomic sequencing files are publicly available at MG-RAST (Project ID
PRJNA397876).
Reanalysis of published placental data after reclassification into ASVs
ASV sequence data processing using DADA2
Classification of ASVs was performed as described by Callahan et al. [152] using the
DADA2 tutorial pipeline (benjjneb.github.io/dada2/tutorial.html). The tutorial was followed
using the default parameters except in the following instances: multithreading was changed to
FALSE throughout the pipeline; for the filter and trimming step the truncation length for forward
reads was increased from 240 to 250 (“truncLen=c(250,160)”), and the maximum number of
expected errors was increased from 2 to 7 for reverse reads (“maxEE=c(2,7)”); for the removal
of chimeras, the method was changed to “pooled”; and to assign taxonomy, a minimum
bootstrapping value was added (“minBoot=80”) and the reference database for assigning
taxonomy was changed from the default Silva reference database to the RefSeq RDP 16S
database v2 May 2018, as indicated in the review by O’Callaghan et. al. [103] and the associated
GitHub

repository

(https://github.com/jessicaocallaghan/reproductive_microbiome/blob/master/assign_taxonomy_s
cript).
Following DADA2 processing, ASVs identified as chloroplasts were removed from the
primary nested (n = 2 ASVs) and secondary touchdown (n = 6 ASVs) datasets. After removing
the chloroplast ASVs, the primary nested dataset contained 5,239,414 reads and 714 ASVs, and
the secondary touchdown dataset contained 2,050,376 reads and 704 ASVs. A preliminary
analysis identified a significant proportion of human mitochondrial sequences in the secondary
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touchdown dataset; after these sequences were removed, there were 1,642,769 sequences and
492 ASVs in the secondary touchdown dataset.
Subsampling of 16S rRNA gene sequence data for ASV vs OTU comparisons
Both primary nested and secondary touchdown datasets were subsampled to a sequence
depth of 500, unless otherwise indicated, to mirror the analyses performed by O’Callaghan et al.
[103]. In order to ensure that the bacterial profiles of samples remained sufficiently characterized
after subsampling, samples were only included in analyses if they had a Good’s coverage ≥ 95%.
Decontam program for the removal of likely background DNA contaminants
Decontam is a program that classifies OTUs or ASVs in biological samples as either
contaminants or non-contaminants based upon their distribution among complementary blank
DNA extraction controls [120]. The decontam package was run in R Studio [201] and our ASVspecific analyses were done using two methods. The isContaminant method was used for both
primary nested and secondary touchdown datasets and parameters were kept in accordance with
those used in O’Callaghan et al. [66]: the prevalence method was used with a threshold of 0.5
(default is 0.1). The alternative isNotContaminant method was also used for both datasets, using
the prevalence method and thresholds of 0.5 and 0.6 for the primary nested dataset and 0.2 and
0.5 for the secondary touchdown dataset (default is 0.5). For each analysis, all background
technical control sample types were grouped together as controls in the metadata file.
Rationale for use of isNotContaminant method and thresholds
The alternative method, isNotContaminant, in the decontam package is the most
appropriate method for using in studies with low microbial biomass samples [120]. This method
begins with the assumption that all sequences are contaminants and that the presence of an ASV
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in a greater proportion of biological samples than controls identifies the sequence as a noncontaminant. This method is valuable as it provides greater confidence in describing bacterial
communities from sequence data when a large proportion of contaminant sequences are
expected. It is not appropriate, however, to assume that taxa that remain after filtering are
evidence of a legitimate bacterial community. It is critical that researchers using this tool further
investigate whether the remaining taxa are ecologically plausible and are exceedingly and
consistently present in biological samples more so than in controls.
Additionally, when using decontam, as addressed in Davis et al. [120], it is critical to
assess the distribution of decontam scores for each dataset in order to establish a cutoff or
“threshold” of when sequences can be considered contaminants. This is important because a
particular threshold for contaminant or non-contaminant classification may not be appropriate for
every dataset and, in the case of the isNotContaminant function, the threshold classifies scores
below the designated threshold as non-contaminants (e.g. a threshold of 1.0 would identify all
sequences < 1.0 as non-contaminants). To identify appropriate thresholds for the primary nested
and secondary touchdown datasets, a histogram was generated for each dataset illustrating the
distribution of decontam scores, their presence in placental samples, and the number of ASVs at
each score (Figure 2.1). The default threshold is 0.5 for this method and both datasets were
analyzed at this threshold. Additionally, while the histogram for the primary nested dataset
illustrated that there is a widespread distribution of scores, the large peak at 0.5 can be viewed as
an inflection point for this dataset (Figure 2.1A). Because a large number of ASVs had a score
between 0.5 and 0.6, we performed an additional analysis through decontam with a threshold of
0.6, which would represent a less conservative assessment of the data. The histogram for the
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Figure 2.1. Histograms of decontam scores for identifying appropriate thresholds for
filtering of the ASV datasets. Decontam scores indicating that A) thresholds of 0.5/0.6 for the
primary nested PCR dataset should be appropriate for identifying non-contaminant sequences,
and B) thresholds of 0.2/0.5 for the secondary touchdown PCR dataset appear appropriate owing
to a more disordered distribution of scores.
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secondary touchdown dataset showed several peaks with a much less clear distribution, however,
an early cluster of low scores suggested a very conservative threshold of 0.2 could be appropriate
for this dataset, in addition to the default 0.5 threshold (Figure 2.1B).
Filtering of contaminant ASVs from the primary nested dataset using decontam
Decontam analysis using isContaminant and a threshold of 0.5
After running decontam on the primary nested dataset, 241 of 714 ASVs were identified
as “TRUE” contaminants, leaving 66.2% (473/714) of the ASVs in the analysis. After removing
the contaminant ASVs, the total sequence reads were reduced from 5,239,414 to 3,792,300
(72.4% of the original dataset). Good’s coverage values remained > 98% after contaminant
ASVs were removed, however, one placental sample (23V) and three technical controls
(3Room1, 3Room4, 4Hood4) contained less than 500 sequences and were removed prior to
subsampling. After subsampling, 283 ASVs remained and one placental sample (4V) and three
controls (3Hood5, 4Hood2, 7Hood2) with Good’s coverage values < 95% were removed from
analysis.
Decontam analysis using isNotContaminant and a threshold of 0.5
Applying the 0.5 threshold for the isNotContaminant function, the primary nested dataset
contained 193 ASVs that were classified as non-contaminants. This represented 27.0% (193/714)
of the total ASVs prior to running decontam. After removing the contaminant ASVs, coverage
remained above 95% for all samples, however 16 samples no longer had ≥ 500 sequences. Of
these 16 samples, two were placental samples (13AC, 23V), three were kit controls, four were
hood controls, and seven were room controls (one of which was an operating room control).
These samples were removed from analysis and the remaining samples were subsampled to 500
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sequences. After subsampling, coverage for all samples remained above 95% and 156 ASVs
were represented.
Decontam analysis using isNotContaminant and a threshold of 0.6
Using a less conservative threshold of 0.6, 348 ASVs were classified as noncontaminants. This represented 48.1% (348/714) of the total ASVs prior to running decontam.
After removing the contaminant ASVs, Good’s coverage values remained > 95% for all samples;
however, three samples no longer had ≥ 500 sequences. Of these three samples, two were room
controls and one was an extraction kit control. These samples were removed from analysis and
the remaining samples were subsampled to 500 sequences. After subsampling, the Good’s
coverage values for six samples were < 95% (3V, 6V, 18AC, and 3 Hood controls) and these
samples were removed from analysis. The analysis proceeded with 235 ASVs represented in the
dataset.
Filtering of contaminant ASVs from the secondary touchdown dataset using decontam
To maximize power in discriminating contaminating from non-contaminating ASVs, the
secondary touchdown dataset was processed through decontam using all kit controls (n = 29,
including DNA extraction kits processed alongside as well as independent of placental samples).
There was no difference in the bacterial profiles of controls processed alongside placentas and
those processed alone (NPMANOVA: F = 1.069, p = 0.278). Yet, to be conservative, following
the execution of decontam, the kit controls not processed alongside placental samples were
removed from analyses comparing and contrasting the bacterial profiles of control and biological
samples. The removed kit controls accounted for 549,488 of the 1,642,769 total sequence reads,
and 75 of the 492 total unique ASVs. Placental samples and the remaining controls were retained
if they had ≥ 500 reads after the contaminant ASVs were removed (25/29 placental samples and
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16/17 control samples). The total read count after removing samples with < 500 reads was
1,091,208 and Good’s coverage values were ≥ 99% for all samples.
Decontam analysis using isContaminant and a threshold of 0.5
Of the 417 ASVs left in the dataset, 103 were identified as contaminants leaving 75.3%
(314/417) of the ASVs in the analysis. The read count was reduced to 59.3%
(647,016/1,091,208) and one control sample (TD_B3_3) was removed for having < 500 reads.
All remaining samples had Good’s coverage values ≥ 99% and were subsampled to 500
sequence reads. After subsampling, Good’s coverage values were> 98% and 277 ASVs
remained.
Decontam analysis using isNotContaminant and a threshold of 0.5
For this analysis, 298 ASVs were identified as contaminants, leaving 28.5% (119/417) of
the ASVs in the analysis. The read count was reduced to 45.1% (492,014/1,091,208). Only one
sample was removed due to having < 500 reads (the same control as above: TD_B3_3). All
remaining samples had Good’s coverage values ≥ 99% and were subsampled to 500 sequence
reads. After subsampling, Good’s coverage values were > 98% and 103 ASVs remained.
Statistical analyses
16S rRNA gene profile structure comparisons of the primary nested PCR dataset
Bray-Curtis similarity indices were calculated and differences in bacterial profiles
between placental tissue samples and blank DNA extraction controls were statistically evaluated
using one-way non-parametric multivariate ANOVA (NPMANOVA) with Bonferroni
corrections applied. These analyses were completed using the software program PAST (v. 3.25)
[202].
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16S rRNA gene profile structure comparisons of the secondary touchdown PCR dataset
Bray-Curtis similarity indices were calculated and differences in bacterial profiles
between placental tissue samples and blank DNA extraction controls were statistically evaluated
using NPMANOVA in the vegan [203] package in R (v. 3.61) [193] allowing for the analysis of
multiple group variables and their interaction.
Figure generation
All Principal Coordinates Analysis (PCoA) plots were generated in PAST (v. 3.25) [202].
All heatmaps were generated using Morpheus [204] software. Prior to heatmap generation,
unweighted pair group method with arithmetic mean clustering was performed based on BrayCurtis similarity values in PAST [202].
IV. Results
The results from metagenomic sequencing presented below were published in the
manuscript “Does the human placenta delivered at term have a microbiota? Results of
cultivation, quantitative real-time PCR, 16S rRNA gene sequencing, and metagenomics” [150].
Metagenomic surveys of the bacterial profiles of placental tissues
At least 43,000,000 sequence reads were obtained from each of nine placental tissue
samples (61,027,678 ± 3,190,738 SEM; Table 2.1). On average, 0.05% of these sequences were
classified as bacterial in origin. Good’s coverage values (99.61% ± 0.14 SEM) indicated that the
bacterial profiles of these samples were thoroughly characterized from a taxonomic standpoint.
The survey identified 267 bacterial genera, with 19 being considered prominent, defined as
having an average relative abundance of ≥ 0.1% (Figure 2.2). Only five genera had an average
relative abundance ≥ 1.0%: Cyanothece, Coprobacillus, Candidatus Phytoplasma, Chlorobium,
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Table 2.1. Summary of metagenomic sequence data from placental samples.
Placenta

Total
sequences

%
removed
after
quality
control

GenBank
hits

Bacterial
hits

% of
hits that
were
bacterial

Bacterial
genera
per
sample

Good's
coverage

# of these
genera
detected in
controls
All 5 < 5

14AC

77,603,776

95.63

350,330

40,188

11.47

126

99.8%

125

1

0

14V

63,783,888

95.49

291,868

33,300

11.41

116

99.8%

116

0

0

15AC

60,438,600

95.58

287,700

32,400

11.26

106

99.8%

106

0

0

15V

62,928,591

95.63

278,408

34,638

12.44

112

99.8%

112

0

0

19V

62,542,939

95.62

232,037

34,980

15.08

99

99.8%

99

0

0

22AC

68,611,076

95.37

333,864

37,358

11.19

116

99.8%

116

0

0

22V

52,974,105

95.65

236,102

28,788

12.19

97

99.8%

97

0

0

30AC

56,771,638

95.43

266,375

8,353

3.14

124

98.5%

124

0

0

30V

43,594,487

95.11

249,226

11,309

4.54

92

99.5%

92

0

0

Average

61,027,678

96

280,657

29,035

10.30

110

99.6%
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Figure 2.2. Bacterial profiles of placental samples as determined by metagenomic
sequencing. Heatmap illustrating the relative abundances of prominent bacterial genera among
placental samples. Prominent genera were here defined as those having an average relative
abundance ≥ 0.1% among placental samples. AC indicates amnion and chorionic plate samples,
and
V
indicates
samples
of
the
villous
tree
and
basal
plate.
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and Streptomyces. Escherichia was present in each placental sample, with an average relative
abundance of 0.05%. A small fraction (0.1%) of the bacterial reads were confidently assigned a
gene function (Table 2.2). Broadly, these bacterial gene functions were metabolism (amino acid,
carbohydrate, vitamin and energy metabolism), genetic machinery (DNA translation, replication,
repair and degradation), and environmental processing (membrane transport and signal
transduction), all of which were also heavily represented in the bacterial gene function profiles of
the technical controls (Table 2.3).
Given the necessary differences in metagenomic library preparation for the placental
tissue and technical control samples, their broad bacterial profiles cannot be compared in a
quantitative manner. However, it is reasonable to inquire if there are genera consistently
identified in placental tissue samples that were not also widely present in the sequenced
background technical controls. There were 36 genera present in all nine sequenced placental
tissue samples, and 89 genera present in at least half of these samples. Each of these 125 genera
was present in all 11 sequenced background technical controls. Of the 267 total genera, or
approximate genus-level taxa, identified in placental tissue samples, only one was not found in
every control sample (Table 2.1): an unclassified Myxococcales, present in one placental sample
with a relative abundance < 0.01%.
Of the prominent genera (≥ 1% average relative abundance) identified in the primary 16S
rRNA gene sequencing analysis of this study (Figure 2.3), Clostridium and Propionibacterium
were detected in each of the nine placental samples via metagenomic sampling. Staphylococcus
was present in 8/9, Stenotrophomonas was present in 6/9, Achromobacter was present in 5/9,
Methylobacterium and Paracoccus were present in 3/9, Acinetobacter was present in 2/9, and
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Table 2.2. Summary of metagenomic sequence reads from placentas assigned a bacterial
gene function.
KEGG Orthology

14AC

14V

15AC

15V

19V

22AC

22V

30AC

30V

Amino Acid Metabolism

11

12

10

11

10

2

7

28

4

Biosynthesis of Other
Secondary Metabolites

0

0

0

0

0

0

0

2

0

Carbohydrate Metabolism

4

8

3

3

0

2

0

3

2

Cell growth and death

0

0

2

0

1

0

0

0

Cell motility

0

0

3

0

0

1

4

1

0

Energy Metabolism

0

2

0

2

2

0

1

10

0

Folding, sorting and
degradation

4

1

0

2

0

0

0

2

1

Glycan biosynthesis and
metabolism

1

0

0

0

0

0

0

1

1

Lipid metabolism

0

0

0

5

2

0

0

0

0

Membrane Transport

4

11

8

1

7

9

3

7

3

Metabolism of Cofactors
and Vitamins

6

2

0

2

5

0

1

1

2

Metabolism of Other
Amino Acids

1

0

0

0

0

0

0

0

0

Metabolism of Terpenoids
and Polyketides

0

0

0

1

0

0

0

0

0

Nucleotide metabolism

0

1

0

2

0

0

0

3

0

Replication and repair

0

0

1

0

1

2

2

15

4

Signal transduction

2

2

2

1

0

3

0

3

1

Transcription

0

0

0

0

0

0

0

2

0

Translation

3

3

1

0

0

1

1

8

1

Transport and catabolism

2

0

0

0

0

3

0

2

0

Xenobiotics Biodegradation
and Metabolism

0

2

0

0

2

0

0

0

0
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Table 2.3. Summary of metagenomic sequence data from technical controls.

Total
sequences

%
removed
after
quality
control

GenBank
hits

Bacterial
hits

% of
hits that
were
bacterial

Bacterial
genera
per
sample

Good's
coverage

Average #
of
bacterial
reads
assigned to
a gene
function

4hood1

47,235,826

90.26

604,070

425,500

70.44

604

100.0%

128,294

4hood2

55,527,650

92.52

1,291,131

1,189,969

92.16

630

100.0%

428,646

4hood3

53,435,968

94.75

980,709

871,958

88.91

626

100.0%

308,573

4hood4

55,516,701

95.06

988,718

885,749

89.59

623

100.0%

295,312

7hood1

60,045,409

95.49

349,714

207,703

59.39

608

99.9%

70,931

7hood2

71,332,222

95.09

622,774

463,449

74.42

636

99.9%

161,243

7hood3

58,712,747

94.65

336,649

174,036

51.70

594

99.9%

56,894

7hood5

62,886,028

94.52

1,069,227

916,346

85.70

636

100.0%

323,429

Kit4

36,260,902

90.21

441,464

345,654

78.30

623

99.9%

118,668

Kit5

38,429,367

93.72

744,139

657,313

88.33

629

100.0%

230,137

Kit6

45,929,752

94.24

635,400

528,815

83.23

636

100.0%

192,513

Average

53,210,234

93.68

733,090

606,045

78.38

1750

100.0%

210,422

Control
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Figure 2.3. Bacterial profiles of placental samples based on 16S rRNA gene sequencing
data. Heatmap illustrating similarity in percent relative abundances of prominent operational
taxonomic units (OTUs) among placental samples and technical controls. Prominent OTUs were
defined as those having an average relative abundance ≥ 1% among the placental samples. OTUs
were generated using a 97% sequence similarity cutoff and the primary nested PCR data set.
Asterisks indicate OTUs that were prominent in placental samples but not in technical controls.
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Delftia and Ureaplasma were present in 1/9. Of these genera, only Clostridium was present in
placental metagenomic bacterial profiles at an average relative abundance ≥ 0.1% (Figure 2.2).
Bacterial profiles of placental tissues and technical controls from the primary nested PCR
dataset characterized using OTU and ASV approaches
The results for the primary nested PCR analysis did not change after reanalyzing the
sequence data using the ASV approach (Table 2.4, Figure 2.4). Both statistically and visually,
the bacterial profiles of placental samples and technical controls were indistinguishable using
either classification method (Figure 2.4, Figure 2.5A).
Bacterial profiles of placental tissues from the primary nested PCR dataset after removing any
ASVs that were identified in controls
The primary nested PCR dataset included 714 ASVs and had average read counts for
amnion-chorion and villous tree & basal plate samples of 48,961 and 51,631, respectively
(Figure 2.6). After removing any ASVs that were identified in technical controls, the average
read counts for amnion-chorion and villous tree & basal plate samples dropped to 189 and 154,
respectively (Figure 2.6). Only 118/714 (16.5%) ASVs from the full dataset remained, and these
ASVs were represented by only 0.3% of the total reads from placental samples (Figure 2.7).
After removing these 596 ASVs identified in controls, 9951 reads remained in the dataset
leaving eight amnion-chorion and 10 villous tree & basal plate samples with no reads. After
removing placental samples with no reads, the average read count for amnion-chorion samples (n
= 21) was 261; the average read count for villous tree & basal plate samples (n = 19) was 236. Of
the remaining 118 ASVs, no ASV was detected in more than four placental samples. The only
two ASVs detected in four placental samples were classified within the bacterial families
Alcaligenaceae and Caulobacteraceae. Notably, the three Ureaplasma ASVs in the original
dataset were also removed due to occurrence in controls (4, 1, and 1 reads total for the 3
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Table 2.4. Comparison of the bacterial profiles of placental samples and technical controls
using OTU and ASV approaches for the primary nested PCR dataset. ASV and the original
OTU sample datasets were subsampled to 500 sequences each and only samples with ≥ 95%
Good’s coverage values were included. Non-parametric multivariate analysis of variance
(NPMANOVA) based on the Bray-Curtis index was used to assess variation among placental
samples and technical controls. Results of overall global effect analyses are presented along
with the results of pairwise comparisons that involve placental samples. Probability values for
these permutation tests were not adjusted for multiple pairwise comparisons, because this can be
overly conservative. However, for pairwise tests that were statistically significant, we present the
Bonferroni corrected probability value in parentheses.
Structure (OTUs)
Amnionchorion

Villous tree &
basal plate

Global
Rooms
Hoods
Kits
Global
Rooms
Hoods
Kits

F
1.153
2.275
1.228
0.530
1.217
2.489
1.076
0.829

p-value
.244
.010 (.058)
.256
.885
.188
.008 (.045)
.359
.580

Structure (ASVs)
F
1.126
2.018
0.585
1.353
1.289
1.463
0.670
1.243

p-value
.275
.021 (.128)
.391
.907
.129
.005 (.028)
.859
.082

Figure 2.4. Principal Coordinates Analysis (PCoA) comparing the bacterial community
structure of OTU and ASV approaches for the primary nested dataset. For both datasets,
placental samples and controls overlap illustrating the lack of variation between sample types.
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Figure 2.5. Heatmaps of the bacterial profiles from ASV datasets. Heatmaps of placental
datasets with ASVs ≥ 1% relative abundance illustrating that placental samples cluster
indiscriminately with control samples. A) Primary nested dataset corresponding to the dataset
indicated in Figure 2.3B. All Ureaplasma ASVs were included despite not having an average
relative abundance ≥ 1% in placental samples. B) Secondary touchdown dataset with no ASV
removal and from the same dataset illustrated in Figure 2.10B. Panel C) Secondary touchdown
dataset with mitochondrial ASVs removed and from the same dataset illustrated in Figure 2.10C.
Samples for all panels were clustered by hierarchical clustering using Bray-Curtis similarity
indices based on the ASVs on the Y-axis of each heatmap.
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Average read counts
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48961

51631
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1000
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that occurred in controls
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1
Amnion-chorion Villous tree & basal
plate

Figure 2.6. Average sequence read count for placental samples from the primary nested
PCR dataset. Read counts include before and after removal of ASVs that occurred in controls.
The Y-axis is graphed on a log10 scale.
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Figure 2.7. Unique ASV counts per placental sample type after removal of ASVs that were
identified in control samples.
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Ureaplasma ASVs). Only 18 placental samples had > 100 reads and only 12 samples had > 250
reads. Good’s coverage at either sequencing depth exceeded 97%, yet a subsequent taxonomic
analysis was only performed on placental samples with ≥ 250 remaining reads. Principal
Coordinates Analyses (PCoAs) could not be generated for this dataset because only one ASV
was detected in more than one sample. This was the same Caulobacteraceae ASV reported
above; it occurred in two villous tree & basal plate samples at 942 reads (942/942 total reads)
and one read (1/651 total reads), respectively, in these two samples. The limited magnitude of a
remaining bacterial signal in placental samples, combined with a lack of consistency in the ASVs
detected across samples, suggests that the removal of all ASVs identified in technical controls
from the dataset before the characterization of a potential placental microbiota is not an
appropriate approach. Removing these data essentially removes any analyzable bacterial signal.
Bacterial profiles of placental tissues from the primary nested PCR dataset after filtering out
likely background DNA contaminants identified through the program decontam
After filtering the primary nested PCR dataset through decontam and removing the ASVs
identified as contaminants, statistical analysis of the structure of the bacterial profiles of
placental samples and technical controls did not change compared to the unfiltered dataset
(Table 2.5, Figure 2.8), regardless of the decontam approach used. In fact, in some cases, pvalues of statistical analyses actually increased when compared to the analyses without using
decontam, further supporting the conclusion that the bacterial profiles of placental samples and
technical controls are not distinct (Table 2.5, Figure 2.9).
Bacterial profiles of placental tissues and technical controls from the secondary touchdown
PCR dataset characterized using OTU and ASV approaches
After the reclassification of 16S rRNA gene sequence data into ASVs, the secondary
touchdown PCR analysis did initially appear to reveal an effect of sample type, round of
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Table 2.5. Comparison of the structure of bacterial profiles of placental samples and
technical controls before and after decontam filtering for the primary nested PCR dataset.
The values on the left are identical to those in the right panel in Table 2.4. The other panels are
evaluating variation between placental samples and controls after applying three different
filtering methods through decontam. In the second panel, the isContaminant function in
decontam was used. In the third and fourth panels, the conservative isNotContaminant function
was used at two different thresholds. All sample datasets were subsampled to 500 sequences
(samples were excluded if they had < 500 reads) and only samples ≥ 95% Good’s coverage
values were included. Non-parametric multivariate analysis of variance (NPMANOVA) based
on the Bray-Curtis index was used to assess variation among placental samples and technical
controls. Results of overall global effect analyses are presented along with the results of pairwise
comparisons that involve placental samples. Probability values for these permutation tests were
not adjusted for multiple pairwise comparisons, because this can be overly conservative.
However, for pairwise tests that were statistically significant, we present the Bonferroni
corrected probability value in parentheses.
Bacterial community structure
Decontam filtered

ASVs

Amnion Global
-chorion Rooms

F
1.126
2.018

Hoods
Kits
Global
Rooms

0.585
1.353
1.289
1.463

Hoods
Kits

0.670
1.243

Villous
tissue &
basal
plate

pvalue
.275
.021
(.128)
.391
.907
.129
.005
(.028)
.859
.082

isContaminant
0.5 threshold
pF
value
1.033
.405
1.883
.070

isNotContaminant
0.5 threshold

isNotContaminant
0.6 threshold

F
0.844
0.847

p-value
.655
.537

F
1.318
2.558

0.636
1.138
1.227
2.385

0.968
0.841
0.782
.649

.431
.528
.752
.784

0.621
1.416
1.405
2.775

.853
.916

.512
.437

0.623
1.617

0.785
1.414

.736
.313
.208
.024
(.142)
.593
.175

p-value
.147
.012
(.071)
.790
.193
.087
.005
(.029)
.817
.110
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Figure 2.8. Principal Coordinates Analyses (PCoAs) illustrating the structure of the
bacterial profiles of placental samples and technical controls from the primary nested PCR
dataset after various contaminant filtering methods. Panel A is the same as Figure 2.4B. In
panel B, ASVs identified as contaminants by the isContaminant function in decontam were
removed. In panels C and D, two different thresholds were applied to identify and subsequently
remove contaminants using the alternative function isNotContaminant in the decontam package.
For all panels, sample datasets were subsampled to 500 sequence reads (samples were excluded
if they had < 500 reads) and only samples with ≥ 95% Good’s coverage values were included.
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Figure 2.9. Heatmaps of the primary nested PCR dataset after decontam filtering. Bacterial
profiles of placental samples and technical controls cluster indiscriminately, regardless of
filtering method. The Y-axis indicates ASVs with ≥ 1% average relative abundance across
placental samples for each respective dataset; also included are Ureaplasma ASVs. Samples are
clustered on the x-axis by Bray-Curtis similarities.
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extraction, and an interaction effect between the two, effects which were not evident in the OTU
dataset (Table 2.6). However, 273 of the 704 ASVs could only be classified to the taxonomic
level of Kingdom. A BLAST [205] query of these sequences against the 16S rRNA gene
sequences of bacterial and archaeal type strains indicated that no sequences could be matched
with ≥ 86% sequence identity and with a query coverage ≥ 50%. Widening the BLAST query to
the entirety of organismal type strains in the Nucleotide collection database revealed that
212/273 (77.7%) ASVs had ≥ 98% sequence match for the Homo sapiens neanderthalensis
mitochondrial genome. We therefore suspected that these sequences were most likely obtained
from human mitochondria, and a BLAST query aligning the 273 unclassified bacteria against the
human mitochondrial 16S rRNA gene (GenBank accession # NC_012920) confirmed that these
212 ASVs were ≥ 98.3% matches to human mitochondria. This was in contrast to the primary
nested PCR dataset, which contained only 16 unclassified bacterial ASVs, of which two were ≥
98.9% matches to the human mitochondria 16S rRNA gene. To address the potential influence
of mitochondrial sequences on the secondary touchdown PCR dataset analyses, the analyses
were repeated after removing the 212 mitochondrial ASVs; the other unclassified bacteria were
conservatively left in the dataset. Before subsampling, four placental samples and two technical
controls (one from the 5th extraction round) were removed due to sequence counts below 500.
After subsampling, all samples had ≥ 97.2% Good’s coverage values and there were 430 ASVs
retained from the 492 non-mitochondrial ASVs in the dataset. Statistical analyses of this dataset
indicated that the mitochondrial ASVs had indeed been the primary drivers of the difference
observed between the bacterial profiles of the placental samples, because removing these
mitochondrial ASVs eliminated the difference (Table 2.6, Figure 2.5B & C, Figure 2.10).
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Table 2.6. Comparison of bacterial community structure of OTU and ASV approaches for
the secondary touchdown dataset. ASV and the original OTU datasets were subsampled to 500
(samples were excluded if they had < 500 reads) and only samples ≥ 95% coverage were
included in subsequent analyses.

Classification method
Source

Sample type
Round
Interaction

OTUs
F
0.767
0.902
0.743

Bacterial community structure
ASVs after removing
human mitochondrial
ASVs
sequences

p-value
0.841
0.614
0.872

F
2.081
2.377
1.901

p-value
0.001
0.002
0.005

F
1.040
1.023
0.816

p-value
0.371
0.405
0.855

Figure 2.10. Principal Coordinates Analyses (PCoAs) illustrating the structure of the
bacterial profiles of placental samples and technical controls from the secondary
touchdown PCR dataset under different classification and contaminant removal
approaches. Three variants of the secondary touchdown dataset are illustrated: Panel A with the
OTU approach, Panel B with the ASV approach, Panel C with the ASV approach after removing
ASVs identified as human mitochondria. No differences are seen between Panels A and C,
suggesting that mitochondrial sequences are driving any potential variation seen in Panel B.
Sample datasets were subsampled to 500 sequence reads (samples were excluded if they had <
500 reads) and only samples with ≥ 95% Good’s coverage values were included.
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Bacterial profiles of placental tissues from the secondary touchdown PCR dataset after
removing any ASVs identified in controls
For the secondary touchdown PCR dataset, following removal of any ASVs that were
identified in controls, 121/492 (24.6%) of the non-mitochondrial ASVs were retained. The total
read count dropped from 383,121 to 64,501. Average sequence read counts for the placental
samples dropped from 13,211 to 2,224, with many losing over half of their reads. Despite losing
83.2% of the total reads from the placental dataset, Good’s coverage values for all placental
samples > 92%. While the secondary touchdown PCR dataset retained more reads (16.8%) than
the primary nested PCR dataset (0.3%) after removing all the ASVs identified in technical
controls the same trend of only a modest bacterial signal persisting in placental samples and a
lack of consistency in observed bacterial taxonomies across placental samples was again evident.
While 7/121 (5.8%) remaining ASVs in the dataset occurred in more than four placental samples
(detected in anywhere from 5 to 23 different placental samples, Figure 2.11), six of these were
subsequently matched to human genes. While any mitochondrial ASVs had been removed prior
to this analysis, a BLAST query of these six ASVs against the 16S rRNA Bacteria and Archaea
database revealed no matches. However, querying the entirety of the Nucleotide collection
database revealed that all six of these ASVs had ≥ 99.4 % similarity to human genes. The other
ASV (ASV 217) was identified as Anaerococcus, with an average relative abundance of 2.9%.
This ASV occurred in seven placental samples, at a relative abundance < 3%, with the exception
of one placental sample in which this ASV accounted for 76.0% of the bacterial profile. The
majority (15/27) of prominent ASVs (ASVs with an average relative abundance ≥ 1% in
placental samples) could each be attributed to an individual sample (Figure 2.11) further
illustrating the lack of consistency in bacterial signals across placental samples.
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Figure 2.11. Heatmap of the bacterial profiles of placental samples from the secondary
touchdown PCR dataset after the removal of all ASVs identified in technical controls. Each
column represents a placental sample, and the round of extraction that the sample was processed
in is indicated. Samples on the x-axis were clustered based on the Bray-Curtis similarity index.
ASVs on the Y-axis were clustered using one minus Pearson’s correlation with an average
linkage method.
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Bacterial profiles of placental tissues from the secondary touchdown PCR dataset after
filtering out likely background DNA contaminants identified through the program decontam
The secondary touchdown PCR dataset after decontam filtering also mirrored the analysis
done without decontam filtering for both isContaminant and isNotContaminant approaches
(Table 2.7, Figure 2.12). The exception to this was when using the conservative decontam
threshold of 0.2. Analyses in which this threshold was used indicated that sample type (i.e.
placental sample or technical control) contributed to bacterial profile structure (Table 2.7). This
could partly be explained by the profiles of five blank extraction kits being almost entirely (≥
99.8% of their sequences) composed of a single ASV (ASV8 Pelomonas aquatica), and 6/10 kits
having > 80.4% their profiles being comprised of this ASV (Figure 2.13). Because this ASV
was, in essence, the entire bacterial profile for half of the blank extraction kits, overshadowing
the variation in the other blank extraction kits, a subsequent analysis in which those 5 control
samples were removed had no differences in bacterial profiles between placental samples and the
remaining extraction kit controls (NPMANOVA: Bray-Curtis, sample type, F = 0.730, p =
0.828). Additionally, this ASV was also the most relatively abundant ASV in placental samples,
with an average relative abundance of 15.0%; it was identified in 16/19 (84.2%) placental
samples. Only three ASVs occurred in at least nine (47%) placental samples. These ASVs were
classified as Pelomonas aquatica, Ralstonia syzygii, and a Spartobacteria. In all three cases,
these ASVs were also prominent (≥ 1% average relative abundance) in kit controls. The next
three most frequently detected ASVs in placental samples were identified as human gene
sequences upon BLAST query. Indeed, 6/23 prominent ASVs in placental samples were
identified as human gene sequences, and 5/10 ASVs most frequently occurring (in ≥ 5 placental
samples) were human-derived. Of the remaining 5 ASVs occurring in ≥ 5 placental samples,
three were the previously discussed Pelomonas aquatica, Ralstonia syzygii, and Spartobacteria
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Table 2.7. Comparison of the structure of the bacterial profiles of placental samples and
technical controls for the secondary touchdown PCR dataset after decontam filtering of
ASVs. All datasets had human mitochondrial ASVs removed before filtering and analysis.
Sample datasets were subsampled to 500 sequences each (samples were excluded if they had <
500 reads) and only samples with ≥ 95% Good’s coverage values were included. Nonparametric multivariate analysis of variance (NPMANOVA) based on the Bray-Curtis index was
used to assess variation among placental samples and technical controls. Sample type refers to
placental sample versus technical control. Round refers to the four different rounds of DNA
extractions that were performed; each round of extractions included placental samples and
technical controls.
Bacterial community structure

ASVs

Source
Sample type
Round
Interaction

F
1.040
1.023
0.816

p-value
0.371
0.405
0.855

Decontam filtered
isContaminant isNotContaminant
0.5 threshold
0.2 threshold
F
p value
F
p value
1.034 0.389 2.045
0.026
1.108 0.262 1.218
0.220
0.893 0.678 0.663
0.838

isNotContaminant
0.6 threshold
F
p value
1.140
0.250
1.007
0.411
0.832
0.717
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Figure 2.12. Principal Coordinates Analyses (PCoAs) of the structure of the bacterial
profiles of placental samples and technical controls from the secondary touchdown PCR
dataset after different filtering approaches with the program decontam. Panel A is the same
as Figure 2.9C. In panel B, ASVs identified as contaminants by the isContaminant function in
decontam were removed. For panels C and D, ASVs were removed if they were classified by the
isNotContaminant function in decontam, using a threshold of 0.2 for panel C, and a threshold of
0.5 for panel D. For all panels, sample datasets were subsampled to 500 sequence reads (samples
were excluded if they had < 500 reads) and only samples with ≥ 95% Good’s coverage values
were included. All datasets had human mitochondrial ASVs removed before filtering and
analysis.
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Figure 2.13. Heatmaps of the bacterial profiles of placental samples and technical controls
from the secondary touchdown PCR dataset after different filtering approaches with the
program decontam. Bacterial profiles of villous tree & basal plate (V) samples and background
DNA contamination controls cluster indiscriminately, except for panel B wherein several kits are
composed almost entirely of a single ASV (Pelomonas aquatica). The Y-axis indicates ASVs
with ≥ 1% average relative abundance in placental samples for each respective dataset. Samples
on the x-axis were clustered based on the Bray-Curtis similarity index.
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above and the two other ASVs were a Comamonadaceae and another Spartobacteria. The
Comamonadaceae sequence (ASV 58) was 100% identical to that of Delftia. Delftia is a welldocumented contaminant of sequence-based studies and it was here only present in placental
samples from a single round of extractions. The sequence associated with this ASV was also
identical to that of ASV 634 in the primary nested PCR dataset. In that dataset, ASV 634 was
relatively abundant in both placental samples and technical controls. The ASV classified as
Spartobacteria (ASV 40) was detected in five placental samples among different extraction
rounds, but it was also identified in a kit control. Interestingly, this Spartobacteria was detected
in the same samples as the more prominent Spartobacteria ASV (ASV 17), suggesting ASV 40
could be a result of sequencing error. Overall, however, no consistent pattern in bacterial signal
is evident among placental samples that distinguishes these samples from technical controls
(Figure 2.13A).
V. Discussion
Pregnancy involves an incredibly complex reorganization of physiological and
anatomical processes. Not only does the mother have to sustain new life for 9 months, protection
and tolerance are necessary to ensure a healthy pregnancy and term gestation. Considering the
placenta serves as a critical component to this entire process, complications affecting the
placenta are readily detrimental to the fetus and potentially the mother. Thus, comprehensive
knowledge of the intrauterine and intra-amniotic environments is critical to prevent and treat
these complications. Given that decades of medicine have operated under the understanding that
the placenta and intra-amniotic environments are sterile under healthy conditions, concluding
that this is not the case should require incontestable evidence. In this study, we found no
evidence to support the claim that there is a placental microbiota. We approached the question
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with due consideration for the inherent caveats and limitations associated with the various
molecular microbiological methods that have been employed previously to conclude there is a
placental microbiota [44, 45, 49, 111, 206]. By capitalizing on multiple methodologies, we were
able to demonstrate that there is a lack of evidence of a placental microbiota, consistent with the
recent research of others [128, 149, 167], and that any shift in paradigms of sterility with respect
to the placenta and the fetus would be premature.
Metagenomic surveys of a potential placental microbiota
The metagenomic data presented in this chapter revealed that the bacterial profiles of
placental samples as characterized through metagenomics were not consistent with the those
from 16S rRNA gene surveys and, although limited in our ability to compare these profiles to
those of background technical controls, out of the entire dataset there was only a single bacterial
genus not identified in the controls, which was limited to very low relative abundance in a single
placental sample. In general, the metagenomic data from placental samples were consistent with
DNA contamination in that over one-half of the bacterial sequences were from plant-associated
or photosynthetic bacteria. The importance of recognizing the effects of DNA contamination in
microbiome studies was highlighted in a recent commentary [100], which emphasized that the
data obtained from investigations of low microbial biomass environments should be evaluated
through the lens of microbial ecology. In fact, the authors specifically suggest skepticism
regarding sequence data that indicate photosynthetic bacteria inhabit internal organs in the
human body (e.g. the placenta), which would prohibit photosynthesis. Furthermore, it is unlikely
that microorganisms associated with non-human, non-mammalian environments, such as the
plant pathogens “Candidatus Phytoplasma”, Xanthomonas, and Xyella , the aquatic bacteria
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Beggiatoa, Roseobacter, Hahella, and Halangium, or the algal symbiont Dinoroseobacter, could
readily grow and reproduce within the ecologic niche of the placenta.
In thorough consideration of a placental microbiota, our metagenomic data did identify
sequences

from

ecologically-plausible

microorganisms

warranting

further

discussion.

Coprobacillus was detected in placental samples and constituted 30.5% of the bacterial
sequences. This genus has been detected in two sequence-based studies of term and preterm
placentas at low abundance [45, 207], however, it was not detected in any of our 16S rRNA gene
surveys. Although the primers used to target the 16S rRNA gene in the first round of
amplification in the primary and secondary nested PCRs (27F/1492R; 341F/1061R) were not an
exact match for C. cateniformis, the only member of the genus Coprobacillus [208], the primers
used for the secondary standard and touchdown PCRs (515F/806R) were a perfect match for this
bacterium. Therefore, if Coprobacillus was present in placental tissues and if its 16S rRNA gene
sequence was similar to that of the lone characterized representative of this genus, we should
have identified it in the 16S rRNA gene analyses.
Streptomyces is another microorganism to consider as it was, on average, 1% of the
bacterial sequences in the metagenomic data obtained from placental tissues and has been
previously detected in sequencing studies of placentas at term [44, 45, 84]. In the 16S rRNA
gene surveys of our study only 2 sequences were assigned to Streptomyces, and for this genus,
the V4 primers (515F/806R) were perfect matches for nearly all (98.6%) of the 588 type strains
found in the Ribosomal Database Project [209]. This suggests that if Streptomyces were actually
present in these placental samples, it should have exhibited a stronger signal than two sequences
in the standard 16S rRNA gene PCR and touchdown PCR analyses. Although even less abundant
than Streptomyces ( >0.1% average relative abundance), other bacterial genera identified in the
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metagenomic data of our study and also in other sequence-based studies of placental tissues at
term include Neisseria [44, 45], Rhodococcus [44, 111], Clostridium [210], Streptococcus [49,
95], and Burkholderia [45]. Again however, in our study, sequences for these microorganisms
were detected in all placental samples and background technical control samples and all five
have been identified as contaminant sequences in prior sequence-based studies [99, 119, 211].
Therefore, both alone, and more importantly in consideration with the other methodologies, we
did not find sufficient evidence to conclude that the bacterial signals identified through the
metagenomic sequencing represent evidence of a placental microbiota and, given the diminutive
fraction of reads attributed to functional genes, a functional bacterial ecosystem in this human
organ.
Classifying 16S rRNA gene sequence data as operational taxonomic units (OTUs) versus as
amplicon sequence variants (ASVs)
The caveats and limitations associated with low microbial biomass studies, especially
studies of the placenta, have spawned attention in the field [97-99, 119, 149], including the
recent review by O’Callaghan et al. that contained a reanalysis of our study’s data [103]. While
they did not reach a different conclusion than us regarding the existence of a placenta microbiota,
they did suggest there were some noteworthy results that differed from our original OTU
analysis presented in Theis et al. [150]. However, we identified specific issues with the review’s
analysis. First, samples were grouped together for sequence read counts and heatmaps, which
inflates the magnitude of the signals. Second, their visualization of β-diversity was limited to
eight out of the total 58 placental samples included in our original study, without explanation.
One potential explanation could be that subsampling led to the exclusion of the majority of
samples, but this was not communicated by the authors. Third, they assert that the pooled
placental samples had > 200,000 sequence reads, even after removing the ASVs identified in
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technical controls, yet in our reanalysis, the result is quite different [maximum read count for any
sample was 2206 (not shown), and the average read counts were much lower; Figure 2.6].
Fourth, the review documented the presence of an ASV classified as Ureaplasma in the room
control samples that is completely discordant with our own analyses. Specifically, the review
pooled control sample types and indicated in the heatmap that Ureaplasma parvum had a read
abundance ≥ 3,000 in room controls. However, in our original OTU analysis, individual room
controls contained no more than two reads for Ureaplasma OTUs and no more than one read
after reclassifying the sequences through the DADA2 ASV pipeline, prior to any subsampling.
To help illustrate this in the Results section of this chapter, Ureaplasma ASVs were included in
the heatmaps even if they did not meet the cutoff for inclusion as a prominent ASV in a given
analysis (Figure 2.5A, Figure 2.9).
Although the review provided very limited details regarding how our data were reanalyzed, restricting our ability to replicate the exact analyses done in the review, our reanalysis
was conducted with the methods we have ascertained to be the most appropriate and
comprehensive for this type of microbiome data. We performed the OTU/ASV reanalysis on the
primary nested PCR dataset and the secondary touchdown PCR dataset from Theis et al. [150],
as these were the two PCR amplification methods that yielded large numbers of quality
sequences and yet were not dominated almost exclusively by Escherichia coli sequences, as was
the case with the secondary nested PCR dataset (as discussed in Theis et. al. [150]). With each of
these two datasets, we performed three different analyses to address differences between OTU
and ASV classification approaches, as well as the implementation of the program decontam to
identify and remove likely background DNA contaminants. First, we directly compared the
original OTU dataset with a dataset in which the sequences were reclassified using ASVs. In
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doing so, we subsampled both datasets to a sequence depth of 500 (a depth of 500 sequences was
also used by O’Callaghan et al. [103]). Additionally, all our analyses were limited to samples
with ≥ 95% Good’s coverage, because samples with lower Good’s coverage values are unlikely
to provide thorough representations of the actual diversity in those samples; Good’s coverage
was not addressed in the review. Second, we analyzed the ASV dataset after removing all ASVs
detected in controls without any subsampling (an approach also featured in the review [103]).
Third, we utilized the program decontam [120] to identify and remove any ASVs determined to
be contaminants from the ASV dataset. This analysis was performed two ways: following
methods described by O’Callaghan et al. [103] using the isContaminant function, and using the
isNotContaminant function, which we believe to be the more appropriate way to use the
decontam tool, in the context of low microbial biomass samples, as suggested by Davis et. al.
[120]. Upon re-analysis of our own study after ASV classification and with detailed methods to
account for our results and conclusions, despite some subtle differences to our original work, we
validated our previous findings and conclusions; there is a lack of evidence of a human placental
microbiota from placentas delivered at term.
As technologies improve and new computational tools are explored, the sequencing and
characterization of presumed sterile environments will remain a target of investigation for
microbial signals. Because sequencing surveys produce enormous amounts of data, the way these
data are processed and analyzed can have a significant influence over observed results and
subsequent conclusions. Efforts have been made to create standardized and reproducible ways to
analyze these data, however, preferences among researchers will always exist. In the case of 16S
rRNA gene sequencing, OTUs have been the most common approach for classifying sequences.
While the microbiome community is beginning to embrace ASVs as a valuable tool, suggesting
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they should replace OTUs as the predominant method to classify 16S rRNA gene sequences may
not be appropriate in all circumstances. The thorough reanalysis of the data from our placental
study [150] demonstrates that for these two methods, we found very little difference. It is,
however, critical to consider the context. In this case, the environment being investigated in our
study is one classically considered sterile. The advantages that ASV classification have over
OTU classification will likely be limited to environments with a substantive microbial
community. In the context of low microbial biomass, sequencing technologies are producing a
larger proportion of sequences from background DNA contaminants, which are more likely to be
of lower quality and consequently more prone to sequencing errors. By analyzing 16S rRNA
gene data of this sort as ASVs, the single nucleotide resolution is likely to detect an increased
number of ASVs, an artifact of sequencing the poor quality background DNA that is likely in
greater abundance in low microbial biomass than in high microbial biomass environments.
Analysis of ASV data from a situation like this may lead to an observation of strain level
variation of microbial communities that does not actually exist and thusly, multiple approaches
to the data are warranted (e.g. analysis with multiple tools/methods). This example further
illustrates the caveats associated with studies investigating environments with low microbial
biomass and the importance of robust methodologies and analysis.
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CHAPTER 3: DOES THE MOUSE PLACENTA HAVE A MICROBIOTA? CULTURE
AND MOLECULAR SURVEYS OF THE MURINE MICROBIOTA
The data presented in this chapter are part of the manuscript “No Consistent Evidence for
Microbiota in Murine Placental and Fetal Tissues,” published January 2020 in mSphere by Theis,
K.R., Romero, R., Greenberg, J.M., et al. [212], of which I am third author behind two senior
authors. Some of the text of this Chapter (i.e. Methods and Results) appears as it does in the
published manuscript. Dr. Andrew Winters generated the quantitative real-time PCR data for this
study. Madison Ahmad, a Master’s student in our laboratory, contributed to the bacterial culture
component of this study and was responsible for the plate wash PCR and 16S rRNA gene
sequencing of plate washed samples.
I. Abstract
The existence of a placental microbiota and in utero colonization of the fetus have been
the subjects of recent debate. While the bulk of this work has been focused on humans, the
mouse model presents a unique opportunity for more in-depth investigation of mammalian
pregnancy. In this chapter, my objective was to complement our previous work on the human
placenta by evaluating whether the placental and fetal tissues of mice harbor bacterial
communities using multiple methodologies with comparisons to maternal samples and
background technical controls. Bacterial profiles of the placenta and fetal brain, lung, liver, and
intestine samples were characterized through culture, quantitative real-time PCR (qPCR), and
16S rRNA gene sequencing. Maternal samples included the mouth, lung, liver, uterus, cervix,
vagina, and intestine. Positive bacterial cultures from placental and fetal tissues were rare; of the
165 total bacterial cultures of placental tissues from the 11 mice included in this study, only nine
yielded at least a single colony, and five of those nine positive cultures came from a single
mouse. Cultures of fetal intestinal tissues yielded just a single bacterial isolate: Staphylococcus
hominis, a common skin bacterium. Bacterial loads of placental and fetal brain, lung, liver, and
intestinal tissues were not higher than those of DNA contamination controls and did not yield
substantive 16S rRNA gene sequencing libraries. Overall, from all placental or fetal tissues, there
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was only a single bacterial isolate that came from a fetal brain sample having a bacterial load
higher than that of contamination controls and that was identified in sequence-based surveys of
at least one of its corresponding maternal samples. Therefore, using multiple modes of
microbiologic inquiry, there was not consistent evidence of bacterial communities in the
placental and fetal tissues of mice.
II. Introduction
As previously discussed in the Introduction and Chapter 2 of this thesis, the existence of a
placental microbiota has been the focus of debate for over half a decade. Utilization of molecular
surveys has led some to the conclusion that a placental microbiota exists in healthy pregnancies;
however, as shown in Chapter 2, the caveats associated with these surveys must be thoroughly
complemented

through

alternative

methodologies.

Considering

the

well-documented

relationships between hosts and their microbiota, a placental microbiota would likely have been
conserved among mammals (i.e. if humans have a placental microbiota then other mammals
likely do as well). Several studies have investigated the placenta for bacterial communities in
mice and rats [83, 213, 214], and as with human placental studies [44, 45, 49, 111, 206, 215],
they have concluded that there are bacterial communities in these tissues. Investigation of a
placental microbiota in animal models has the advantage of being able to surgically remove the
placenta and fetal tissues before the onset of labor, a process that can introduce microbes into the
upper reproductive tract [216-218]. Additionally, if in utero colonization is occurring, the source
of the colonizing bacteria must be the mother, and with animal models, researchers can collect an
array of samples from the mother for investigation and contrast that are not obtainable from
human subjects.
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After our evaluation of a placental microbiota in humans and the subsequent lack of
evidence for it [150] presented in Chapter 2, I transition from the human model to the mouse
model for which we can validate our findings from the human placenta and further support these
findings with additional fetal and maternal tissues. As established in Theis et al. [150], the
evidence necessary in establishing that there exists bacterial communities in placental or fetal
tissues requires: 1) the identification of bacterial DNA in placental or fetal tissues that is distinct
from bacterial DNA detected in technical controls (e.g. DNA extraction kits, PCR reagents,
laboratory environments), 2) confirmation that the bacterial load of placental or fetal tissues
exceeds that of technical controls through quantitative real-time PCR (qPCR), 3) visualization of
bacteria in placental or fetal tissues using microscopy, 4) demonstration of the viability of
bacteria in these tissues through culture, and 5) ecological plausibility (i.e. the detected bacteria
could survive and reproduce in these tissues) [100]. To date, these criteria have not been met in
any one study. In the previous chapter, we evaluated the human placenta thoroughly addressing
the first, second, fourth, and fifth criteria and were unable to find evidence supporting the
existence of a placental microbiota. The objective of this chapter is to validate those findings by
thorough evaluation of placental and fetal tissues from mice, similar to our human study, via
bacterial culture, qPCR, and 16S rRNA gene sequencing, and by comparing them to background
technical controls and maternal tissues for additional contrast.
III. Methods and Materials
Study subjects and sample collection
Eleven pregnant C57BL/6 (B6) mice were anesthetized with isoflurane at 17.5 days
gestation. The dam’s abdomen was shaved, and alcohol was liberally applied to the abdomen.
Maternal blood was collected by cardiac puncture and death was assured by cervical dislocation.
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The dam was then placed on a surgical platform within a biological safety cabinet. Study
personnel (i.e. myself or Dr. Theis) donned sterile surgical gowns, masks, full hoods, and
powder-free exam gloves during sample collection. The oral cavity and vagina were swabbed
with Dacron and ESwabs for molecular microbiology and bacterial culture, respectively. For the
abdomen, a Dacron swab was collected, iodine was applied and, after the iodine dried, an ESwab
was collected. A midline incision was made along the full length of the abdomen. The
peritoneum was sampled with a Dacron swab. The uterine horns were separated from the cervix
and placed within a sterile petri dish, wherein they were immediately processed by a different
investigator within the biological safety cabinet. Uterine horns were dissected and fetuses (the
fetus inside the amniotic sac attached to the placenta) were placed in individual Petri dishes.
Uterine tissues were collected for both molecular microbiology and bacterial culture. Two
fetuses from each dam were selected for analysis; tissues from one were used for molecular
microbiology and tissues from the other for bacterial culture. From each fetus, the placenta, lung,
liver, intestine, and brain (molecular microbiology was performed on fetal brain samples from all
11 mice; bacterial culture was completed on fetal brain samples from mice E-K) were collected.
The fetal spleen and tail were also collected for molecular microbiology.
Next, the maternal cervix, liver, and lung were sectioned and one sample of each was
placed into a sterile 1.5 ml microcentrifuge tube and an anaerobic transport medium tube for
molecular microbiology and bacterial culture, respectively. Lastly, after all placental and fetal
tissues were sampled and stored, the maternal heart and the maternal proximal and distal
intestine were collected for molecular microbiology, and the maternal middle intestine was
collected for bacterial culture. Procedures were approved by the Institutional Animal Care and
Use Committee at Wayne State University (Protocol 18-03-0584).
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Mouse tissue processing
Maternal and fetal mouse tissue samples within anaerobic transport containers or ESwabs
were delivered to the lab immediately after surgery was completed on the final mouse of the day.
Upon receipt into the lab, samples were brought into a hypoxic chamber under 5% CO2, 5% O2,
90% N2 atmospheric conditions and processed in the following order processed in the following
order: placenta, fetal liver, fetal lung, fetal brain, fetal intestine, maternal uterus, maternal liver,
maternal lung, maternal cervix, maternal skin post-sterilization, maternal vagina, maternal oral
cavity, and the maternal mid-intestine. While processing samples for bacterial culture within the
chamber, study personnel wore sterile sleeve protectors, nitrile exam gloves, and sterile nitrile
gloves over the top of the nitrile exam gloves. Tissues were removed from anaerobic transport
medium tubes using a sterile disposable inoculating loop, placed into a dounce reservoir (2ml or
5 ml) containing 1ml of sterile PBS, and carefully homogenized for one minute. The tissue
homogenates were then transferred into a 5 ml tube containing 1.5 ml of sterile PBS. Maternal
lung and maternal mid-intestine tissues for mice E-K were homogenized in sterile 5ml tubes
using 0.5ml PBS and a sterile disposable scalpel. Each ESwab sample was vortexed thoroughly
and the container’s medium was transferred into a 5ml tube containing 1.5ml of sterile PBS
using sterile disposable transfer pipettes. After the last tissue was processed for a mouse, each
tissue homogenate was split between 3 sterile tubes for culturing under three atmospheric
conditions.
During the processing of each mouse’s samples for culture, three chocolate agar plates
were left in the hypoxic chamber to serve as negative controls; they were subsequently incubated
for seven days under oxic, hypoxic, and anoxic conditions. Additionally, for each mouse the PBS
stock used for tissue homogenization was plated on blood agar, chocolate agar, and MacConkey
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agar, and was further added to SP4 broth containing urea and arginine. The PBS-control blood
agar and chocolate agar plates were incubated under all three atmospheric conditions, and the
MacConkey agar plates and SP4 brothers were incubated under oxic conditions only. These
negative controls were incubated for seven days.
Mouse tissue cultivation methods
Tissue homogenates and swab solutions were cultured for 7 days under three atmospheric
conditions: anoxic (5% CO2, 10% H2, 85% N2), hypoxic (5% CO2, 5% O2, 90% N2), and oxic
(ambient). Every tissue was plated on tryptic soy agar with 5% sheep’s blood and chocolate agar
plates in duplicate under each atmospheric condition; under oxic conditions all tissues were also
plated on MacConkey’s agar, also in duplicate. For each plate, 100ul of tissue or swab
homogenate was pipetted onto the center and thoroughly spread over the plate until dry using an
L-shaped spreader. 100ul of each fetal tissue and maternal reproductive tissue were inoculated in
SP4 broth with urea and SP4 broth with arginine. For each atmosphere and media type a PBS
control was included following the same protocol as above by inoculating 100ul of sterile PBS.
Agar plates and SP4 broth tubes were observed for days 1-4 and day 7 (each day
represents ~24 hours after plating). Colonies were counted when appropriate (< ~25 colonies)
and any colonies observed on placental tissues, fetal tissues, and negative control plates were
restreaked for isolation and purity. Pure colonies from restreaked plates were saved in 2mL
cryovial tubes containing PBS with 15% glycerol, in triplicate when possible, and stored at -80
℃. An additional colony was saved in a 1.5ml tube containing ≤ 500ul of sterile PCR-grade H2O
for downstream taxonomic identification via Sanger sequencing of the 16S rRNA gene
(described below). Contiguous growth was observed on a single plate for one placental sample
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(mouse J); the isolates all had the same morphotype, so only representative isolate was streaked
for purity and downstream taxonomic identification.
The negative-control plates yielded five total bacterial isolates over the course of the
experiment. Four were successfully sequenced: two were identified as Cutibacterium acnes, and
two were identified as Staphylococcus hominis. If a specific bacterium was cultured on a
technical control plate on the day a mouse’s samples were processed as well as on a placental or
fetal sample plate for that mouse (i.e., there was a 100% 16S rRNA gene sequence match
between the bacterial isolates recovered on the two plates), that bacterium was not included in
analyses. Overall, this included 11 bacterial isolates for three mice (D, J, and K). Of these 11
isolates, four were C. acnes, and seven were S. hominis. If a specific bacterium was cultured on a
mouse’s placental or fetal sample plate as well as on a technical control plate from another
sample processing day, but not on a control plate from that mouse’s sampling day, the bacterium
was included in analyses.
For maternal cervix, uterus, and liver samples, the unique isolate morphotypes on each
plate were streaked for purity and taxonomically identified through Sanger sequencing of the
16S rRNA gene. Maternal samples from the intestine, vagina, mouth, and lung and any other
plates with contiguous growth (either too many colonies to count or a lawn of growth) were
saved for downstream plate wash PCR and 16S rRNA gene sequencing (detailed below).
Taxonomic identification of individual bacterial isolates
After the bacterial isolates were streaked for purity, the isolates from placental, fetal, and
maternal uterine, cervical, and liver samples were stored in nuclease-free water and frozen at -20
℃ until colony PCR targeting the 16S rRNA gene was performed. The 16S rRNA gene of each
isolate was first amplified using the 27F/1492R primer set and then bi-directionally Sanger
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sequenced through GeneWiz using the 515F/806R primer set, which targets the V4
hypervariable region of the 16S rRNA gene. Forward and reverse reads were trimmed using
DNA Baser software (http://www.dnabaser.com/) with default settings and assembled using the
CAP (contig assembly program) of BioEdit software (v7.0.5.3), also with default settings. The
taxonomic identities of individual bacterial isolates were determined using the Basic Local
Alignment Search Tool (BLAST) [205]. 16S rRNA gene sequence similarities between isolates
and their top match on BLAST were ≥ 99.5%, unless otherwise noted (Table 3.1, Table 3.2).
DNA extraction from plate washes of cultured bacteria
Plate wash was performed by pipetting 1-2 ml of PBS onto the agar plate and dislodging
bacterial colonies with either sterile L-shaped spreaders or inoculating loops. The PBS wash was
then transferred into cryovials and stored at -80°C until DNA was extracted. DNA was extracted
from plate wash samples using Qiagen DNeasy PowerSoil extraction kits. Washes from maternal
samples that yielded growth under multiple atmospheres for the same media type were pooled
prior to the extraction process. Purified DNA was stored at -20 ℃.
16S rRNA gene sequencing of plate wash extracts
The 16S rRNA genes in plate wash extracts were sequenced at Wayne State University
on an Illumina MiSeq system using a 2 X 250 cycle V2 kit, and following Illumina sequencing
protocols [219]. The 515F/806R primer set was used to target the V4 region of the 16S rRNA
gene. The 16S rRNA gene sequences from the paired fastq files for these samples were
processed as previously described [150].
DNA extraction from swab and tissue samples
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All Dacron swab and tissue samples collected for molecular microbiology were stored at
-80 ℃ until DNA extractions were performed. DNA extractions were performed in a biological
safety cabinet by study personnel donning sterile surgical gowns, masks, full hoods, and powderfree exam gloves. Extractions of tissues generally included 0.015 – 0.100 grams of tissue, except
for the fetal tail and spleen, whose masses were very low.
DNA was extracted from swabs, tissues, and background technical controls (i.e. sterile
Dacron swabs (N = 11) and blank DNA extraction kits (N = 23)) using the DNeasy PowerLyzer
PowerSoil Kit (Qiagen, Germantown, MD) with minor modifications to the manufacturer’s
protocol. Specifically, 400 μl of bead solution, 200 μl of phenol:chloroform:isoamyl alcohol (pH
7–8), and 60 μl of Solution C1 were added to the supplied bead tube. Cells within samples were
lysed by mechanical disruption for 30 seconds using a bead beater. After centrifugation, the
supernatants were transferred to new tubes, and 100 μl of solution C2, 100 μl of solution C3, and
one μl of RNase A enzyme were added, and tubes were incubated at 4° C for five minutes. After
centrifugation, the supernatants were transferred to new tubes that contained 650 μl of solution
C4 and 650 μl of 100% ethanol. The lysates were loaded onto filter columns, centrifuged for one
minute, and the flow-through was discarded. This step was repeated until all sample lysates were
spun through the filter columns. Five hundred μl of solution C5 were added to the filter columns,
centrifuged for one minute, the flow-through was discarded, and the tube was centrifuged for an
additional three minutes as a dry-spin. Finally, 60 μl of solution C6 were placed on the filter
column and incubated for five minutes before centrifuging for 30 seconds to elute the extracted
DNA. Purified DNA was stored at -20° C.
Purified DNA was quantified using a Qubit 3.0 fluorometer with a Qubit dsDNA BR
Assay kit (Life Technologies, Carlsbad, CA), according to the manufacturer’s protocol. All
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purified DNA samples were then normalized to 80 ng/µl (when possible) by diluting each
sample with the Qiagen elution buffer (Solution C6).
16S rRNA gene quantitative real-time PCR (qPCR)
A preliminary test was performed to investigate whether DNA amplification inhibition
existed among the different sample types. For this test, 4.7 μl of purified Escherichia coli ATCC
25922 (GenBank accession: CP009072) genomic DNA (0.005 ng/µl) containing seven 16S
rDNA copies per genome was spiked into 7.0 μl of purified DNA from mouse samples that were
serially diluted with Solution C6 by a factor of 1:3 (i.e. 1:0, 1:3, 1:9). For tissue sample types
with a mean DNA concentration above 250 ng/µl, DNA concentrations were normalized to 80
ng/μl by dilution with Solution C6 before being serially diluted and spiked with E. coli genomic
DNA. Genomic DNA was quantified using a Qubit 3.0 fluorometer with a Qubit dsDNA HS
Assay kit (Life Technologies, Carlsbad, CA) according to the manufacturer’s protocol. Three μl
of each spiked sample were then used as a template for qPCR. For all samples, spiked reactions
contained approximately 1.0 x 103 E. coli 16S rDNA copies. There was no evidence of DNA
amplification inhibition (data not shown).
Total bacterial DNA abundance within samples was measured via amplification of the V1
- V2 region of the 16S rRNA gene according to the protocol of Dickson et al [70] with minor
modifications. These modifications included the use of a degenerative forward primer (27f-CM:
5’-AGA GTT TGA TCM TGG CTC AG-3’) [123] and a degenerate probe containing locked
nucleic acids (+) (BSR65/17: 5’-56FAM-TAA +YA+C ATG +CA+A GT+C GA-BHQ1-3’).
Each 20 μl reaction contained 0.6 μM of 27f-CM primer, 0.6 μM of 357R primer (5’-CTG CTG
CCT YCC GTA G-3’), 0.25 μM of BSR65/17 probe, 10.0 μl of 2X TaqMan Environmental
Master Mix 2.0 (Life Technologies, Carlsbad, CA), and 3.0 μl of either purified DNA (diluted to
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80 ng/µl when possible), elution buffer, or nuclease-free water. The total bacterial DNA qPCR
was performed using the following conditions: 95° C for 10 min, followed by 45 cycles of 94° C
for 30 sec, 50° C for 30 sec, and 72° C for 30 sec. Duplicate reactions were run for all samples.
All samples were run across a total of five runs.
Raw amplification data were normalized to the ROX passive reference dye and analyzed
using the on-line platform Thermo Fisher Cloud: Standard Curve (SR) 3.3.0-SR2-build15 with
automatic threshold and baseline settings. Cycle of quantification (Cq) values were calculated for
samples based on the mean number of cycles required for normalized fluorescence to
exponentially increase.
After plotting a regression of log(E. coli 16S rRNA gene copy number) and Cq value for
standard curves included in each qPCR run, 16S rRNA gene copy number in mouse samples was
calculated according to Gallup [220] using the equation Xo = EAMP(b-Cq), where EAMP is the
exponential amplification value for the qPCR assay, calculated as EAMP = 10(-1/m) and b and m are
the intercept and slope of the regression.
16S rRNA gene sequencing of swab and tissue sample extracts
Amplification and sequencing of the V4 region of the 16S rRNA gene was performed at
the University of Michigan’s Center for Microbial Systems as previously described [109], except
that library builds were performed in triplicate and pooled for each individual sample prior to
the equimolar pooling of all sample libraries for multiplex sequencing. Sample-specific MiSeq
run files have been deposited on the NCBI Sequence Read Archive (BioProject ID
SUB6641162).
Raw sequence reads were processed using mothur software (v1.39.5) [41] following the
Standard Operating Procedure provided by Schloss et al. (www.mothur.org/wiki/MiSeq_SOP).
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Paired-end reads were assembled into contiguous sequences, quality checked (maximum
length = 275, maximum ambiguous base pairs = 0, and maximum number of homopolymers = 8),
and aligned against the SILVA 16S rDNA reference database (release 102) [221, 222];
sequences falling outside the target alignment space were removed. Quality sequences were preclustered (diffs = 2) and chimeric sequences were identified with VSEARCH [223] and removed.
The remaining sequences were taxonomically classified using the SILVA reference database
with a k-nearest neighbor approach and a confidence threshold of 80%. Sequences derived from
an unknown domain, Eukaryota, Archaea, chloroplasts, or mitochondria were removed.
Operational taxonomic units (OTUs) were defined by clustering sequences at a 97% sequence
similarity cutoff using the average neighbor method.
Statistical analysis
The bacterial loads, as assessed through qPCR, of maternal, placental and fetal samples
were compared to those of background technical controls (i.e. sterile Dacron swabs and blank
DNA extraction kits) using t-tests or Mann-Whitney U tests with sequential Bonferroni
corrections applied. The bacterial loads of placental and fetal tissues were compared to one
another using Wilcoxon matched pairs tests, again corrected for multiple comparisons.
The beta diversity of 16S rRNA gene profiles among maternal, placental, fetal and
technical control samples were characterized using the Bray-Curtis similarity index. Bray-Curtis
similarities in sample profiles were visualized using Principal Coordinates Analysis (PCoA)
plots and statistically evaluated using non-parametric multivariate ANOVA (NPMANOVA).
These analyses were limited to samples that yielded a 16S rRNA gene library with ≥ 250 qualityfiltered sequences and a Good’s coverage ≥ 95%. All data analysis was completed in PAST
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software (v 3.25) [202]. Heat maps of sample bacterial profiles were generated using the opensource software program Morpheus (https://software.broadinstitute.org/morpheus) [204].
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IV. Results
Bacterial culture from placental and fetal tissues
Growth of bacterial isolates from placental and fetal tissues was rare (Figure
3.1A, Figure 3.2). Only 3/11 mice (F, H & J) yielded more than two total bacterial isolates
across all their cultured placental and fetal samples under all growth conditions (Table 3.1).
Most of the bacterial isolates from placental and fetal samples were Staphylococcus spp. (mostly
S. hominis) (Figure 3.1A). Staphylococcus spp. were cultured from the mouth, intestine, and
vagina of mouse dams (Figure 3.1B); however, two of the five bacterial isolates recovered from
the 114 negative control plates included in this study were also Staphylococcus, specifically S.
hominis. The non-staphylococci bacteria cultured from placental or fetal samples were Bacillus,
Corynebacterium, Paenibacillus, Propionibacterium, and unclassified bacilli (Table 3.1). These
bacteria were rarely, if ever, cultured from maternal samples (Figure 3.1A & B).
In general, only one or two placental or fetal sites within a given fetus yielded a bacterial
isolate, and there was little consistency among the fetuses in terms of which site yielded an
isolate (Table 3.1, Figure 3.1A). For example, of the 132 blood and chocolate agar plates on
which placental tissue homogenates were spread, only nine (6.8%) yielded even a single
bacterial isolate, and five of these plates came from a single placental sample (Mouse H) (Figure
3.2). All of the bacterial isolates from Mouse H’s placental sample were Staphylococcus (either
S. hominis or S. epidermidis / caprae / capitis). There were no exact matches of the 16S rRNA
genes of these isolates within the 16S rRNA gene surveys of placental tissues from Mouse H, nor
were there any matches within the 16S rRNA gene surveys of any of the sampled maternal body
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Figure 3.1. Bacterial cultivation results for A) placental and fetal tissues in relation to those
for B) maternal intestinal, mouth, vaginal, and lung samples, and C) a comparison of the
bacterial loads of individual placental samples and blank extraction kit controls in light of
the cultivation results. Panel A indicates the recovery of any bacterial isolates from placenta
and/or fetal tissues, by mouse and across different growth media and atmosphere conditions. The
taxonomic assignments of these isolates were determined by comparing their 16S rRNA gene
sequences to those of the operational taxonomic units (OTUs) of molecular surveys of the mixed
bacterial communities cultured from maternal intestinal, oral, vaginal, and lung samples
(sequence identity was ≥ 97.2%). Panel B provides the results of 16S rRNA gene molecular
surveys of the plate washes of bacterial growth from maternal intestinal, oral, vaginal, and lung
samples, as well as of blank extraction kit controls processed alongside the plate washes. OTUs
were included in the heat map in Panel B if they had an average percent relative abundance ≥
0.5% across all plate washes or if they were the best 16S rRNA gene sequence match to bacterial
isolates in Panel A (indicated by an asterisk). The bolded OTUs represent the best 16S rRNA
gene sequence matches to placental and fetal isolates in Panel A. Panel C illustrates similarities
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in bacterial load, as assessed by 16S rRNA gene quantitative real-time PCR (qPCR), between
placental samples yielding at least one bacterial isolate and blank DNA extraction kit controls.

Figure 3.2. Heat maps illustrating bacterial cultivation results for A) placenta and B) fetal
intestinal tissues. Each column of the heat map represents a single agar plate. The x-axis
indicates the mouse identity, atmospheric condition, growth medium, and paired replicate for
each agar plate. The vast majority of blood and chocolate agar plates did not yield any bacterial
growth over seven days for placental (93.2%) and fetal intestinal (99.2%) samples. The
operational taxonomic units (OTUs) on the y-axis are those that represent the best 16S rRNA
gene sequence matches to bacterial isolates recovered from any placental or fetal sample in this
study overall (i.e. the OTUs in bold font in Figure 1B).
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Table 3.1. Bacterial cultivation results for placental and fetal brain, lung, liver, and
intestinal samples.
Bacterial culture
Mouse

Placental or
fetal body
site

Total # of
isolates
recovered

A

Placenta
Lung
Liver
Intestine
Placenta
Lung
Liver
Intestine
Placenta
Lung

0
0
0
0
1
0
1
0
0
1

Liver
Intestine
Placenta
Lung
Liver
Intestine
Placenta

0
0
0
0
0
0
1

Brain
Lung
Liver
Intestine
Placenta
Brain

1
0
0
0
1
7

Lung
Liver
Intestine

0
1
1

Placenta
Brain
Lung
Liver
Intestine
Placenta

0
1
0
1
0
16

Brain

3

Lung
Liver

0
1

Intestine
Placenta
Brain
Lung
Liver
Intestine
Placenta
Brain
Lung
Liver
Intestine
Placenta
Brain
Lung
Liver
Intestine

0
0
0
1
0
0
TMTC*
0
0
0
0
0
0
0
0
0

B

C

D

E

F

G

H

I

J

K

Top NCBI BLAST
taxonomic designation (≥
99.5% 16S rRNA gene
sequence identity unless
otherwise indicated)

Cutibacterium acnes
Cutibacterium acnes

Bacillus simplex /
frigoritolerans

Corynebacterium
tuberculostearicum (98.5%)
Bacillus halosaccharovorans

Staphylococcus hominis
Bacillus circulans; Bacillus
megaterium / flexus; Bacillus
spp.; Ornithinibacillus sp.
Marseille-P3601;
Paenibacillus spp.
Bacillus sonorensis
Staphylococcus hominis
(99.4%)
Staphylococcus hominis
Staphylococcus hominis
Staphylococcus hominis;
Staphylococcus epidermidis /
caprae / capitis
Staphylococcus hominis;
Staphylococcus warneri;
Staphylococcus epidermidis /
caprae / capitis
Paenibacillus timonensis
(98.0%)

Cutibacterium acnes (99.0%)

Staphylococcus caprae

16S rRNA gene
qPCR
Was sample
bacterial load >
that of blank kit
controls?

16S rRNA gene sequence match between the isolate and ≥ 1 sequence
within a 16S rRNA gene library
Library for that specific tissue
Library for any maternal body site
type in that Mouse
in that Mouse

No
No
No
Yes
No
No
No
No
No
No

n/a
n/a
n/a
n/a
No
n/a
No
n/a
n/a
No

n/a
n/a
n/a
n/a
No
n/a
No
n/a
n/a
No

No
No
No
No
No
No
Yes

n/a
n/a
n/a
n/a
n/a
n/a
No

n/a
n/a
n/a
n/a
n/a
n/a
No

Yes
No
No
No
No
Yes

No
n/a
n/a
n/a
No
No

No
n/a
n/a
n/a
Yes (blood, lung, skin)
Yes, for 1/7 isolates (skin)

No
No
No

n/a
No
No

n/a
No
Yes (blood, lung, skin)

No
No
No
No
No
No

n/a
No
n/a
No
n/a
No

n/a
Yes (peritoneum, skin)
n/a
Yes (peritoneum, skin)
n/a
No

No

No

No

No
No

n/a
No

n/a
No

Yes
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No

n/a
n/a
n/a
No
n/a
n/a
Yes
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a

n/a
n/a
n/a
No
n/a
n/a
Yes (heart, mouth, intestine)
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
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sites for Mouse H, which included the maternal skin, blood, heart, mouth, lung, liver, proximal
intestine, distal intestine, peritoneum, cervix, and vagina (Table 3.1). The placental sample from
Mouse J yielded many colonies of Staphylococcus caprae on one chocolate agar plate under
hypoxic conditions; yet there were no bacterial colonies on the replicate chocolate agar plate
incubated under hypoxic conditions or on any other plate for this sample (Table 3.1, Figure 3.2).
An exact match of the 16S rRNA gene of this Staphylococcus caprae isolate was identified in the
16S rRNA gene survey of placental tissues from Mouse J, as well as in the 16S rRNA gene
surveys of the maternal heart, mouth, and proximal intestine samples for Mouse J. However, the
bacterial load of the placental sample from Mouse J, as assessed by 16S rRNA gene qPCR, was
not high – it was less than the bacterial load of 14/23 (60.9%) DNA extraction kit controls
(Figure 3.1C).
Of the 132 blood and chocolate agar plates on which fetal intestinal tissue homogenates
were spread, only one yielded growth – a single bacterial colony of Staphylococcus hominis
(Figure 3.2). The 16S rRNA gene of this bacterial isolate was not detected in the molecular
survey of fetal intestines from this mouse (Mouse F), but it was identified in the 16S rRNA gene
surveys of maternal blood, lung, and skin from Mouse F (Table 3.1). This sample had the lowest
bacterial load of any fetal intestinal sample in the study, and had a bacterial load less than that of
14/23 (60.9%) DNA extraction kit controls (Figure 3.3).
Bacterial culture from maternal compartments
Bacterial cultures of the maternal intestine, mouth, vagina, and lung often yielded lawns
of

bacterial

growth

dominated

by

unclassified

Pasteurellaceae,

Lactobacillus,

and

Staphylococcus (Figure 3.1B). Body site-specific variation in the structure of cultured bacterial
communities from maternal samples was evident (Figure 3.1B). For instance, the vast majority
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Figure 3.3. Quantitative real-time PCR (qPCR) analyses illustrating variation in bacterial
load among A) maternal swab samples and Dacron swab controls, and B) maternal,
placental, and fetal tissue samples and blank DNA extraction kit controls. Bars indicate the
median and quartile log-16S rRNA gene copy values for each sample and control type. Points,
color-coded by mouse identity, indicate the mean values of two replicate qPCR reactions. An
asterisk indicates that bacterial loads of that sample type were greater than those of
corresponding technical controls.
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of bacteria cultured from the vagina were unclassified Pasteurellaceae, while Bacteroides and a
distinct strain of Lactobacillus were consistently cultured from the maternal intestine in addition
to the unclassified Pasteurellaceae, Lactobacillus, and Staphylococcus isolated from other body
sites (Figure 3.1B).
Bacterial cultures of the maternal cervix yielded isolates in 6/11 (54.5%) mice (Table
3.2). The most common bacterium cultured from the murine cervix was Pasteurella caecimuris;
it was recovered in culture from 5/11 cervical samples. In each case, an exact match for the 16S
rRNA gene of the Pasteurella caecimuris isolate was identified in the 16S rRNA gene survey of
the corresponding cervical sample (Table 3.2).
Bacteria were rarely cultured from the uterus (2/11 mice) and maternal liver (4/11 mice)
(Table 3.2). The two bacteria cultured from the uterus were Bacillus niabensis and
Staphylococcus aureus. An exact match of the 16S rRNA gene of these isolates was not
identified in the 16S rRNA gene surveys of the respective uterine samples. The bacteria cultured
from maternal liver samples were primarily Lactobacillus and Staphylococcus species. Of the
nine distinct bacterial morphotypes cultured from maternal liver tissues, only 3 (33%) had an
exact match of their 16S rRNA gene identified in the 16S rRNA gene surveys of their respective
samples (Table 3.2).
Quantitative real-time PCR (qPCR) of murine and control samples
Bacterial load, as characterized by 16S rRNA gene copy abundance, varied greatly across
maternal, placental, and fetal body sites (Figure 3.3). The bacterial loads of swabs of the
maternal mouth, vagina, and skin exceeded those of sterile Dacron swabs (Figure 3.3A).
Similarly, the bacterial loads of tissues of the maternal proximal and distal intestine, lung, cervix,
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Table 3.2. Bacterial cultivation results for maternal cervical, uterine, and liver samples.
Bacterial culture

Mouse

A

B

C

D

E

F

G

H

I

J

K

16S rRNA
gene qPCR

16S rRNA gene sequence
match between the isolate
and ≥ 1 sequence within a
16S rRNA gene library
Library for that specific
tissue type in that Mouse

Low
microbial
biomass
maternal
body site
Cervix
Uterus
Liver
Cervix
Uterus
Liver
Cervix
Uterus
Liver

# of unique
colony
morphotypes
recovered

Top NCBI BLAST taxonomic
designation (≥ 99.5% 16S rRNA gene
sequence identity unless otherwise
indicated)

Was sample
bacterial load
> that of blank
kit controls?

1
1
0
0
0
2
0
0
5

Rodentibacter pneumotropicus (98.0%)
Bacillus niabensis

No
No
No
No
No
No
No
No
Yes

Yes
No
n/a
n/a
n/a
Yes, for 1/2 morphotypes
n/a
n/a
Yes, for 2/5 morphotypes

Cervix
Uterus
Liver
Cervix
Uterus
Liver
Cervix
Uterus
Liver

0
0
0
1
0
0
0
0
1

No
No
No
Yes
No
No
Yes
No
No

n/a
n/a
n/a
Yes
n/a
n/a
n/a
n/a
No

Cervix

5

Yes

Yes, for 5/5 morphotypes

Uterus
Liver
Cervix
Uterus
Liver
Cervix

0
0
0
0
0
6

No
No
Yes
No
No
No

n/a
n/a
n/a
n/a
n/a
Yes, for 4/6 morphotypes

Uterus
Liver
Cervix
Uterus
Liver

0
0
1
1
1

No
No
No
No
No

n/a
n/a
Yes
No
No

Cervix
Uterus
Liver

1
0
0

Yes
Yes
No

Yes
n/a
n/a

Lactobacillus gasseri; L. murinus

Bacteroides sartorii (98.0%); Klebsiella
variicola; L. gasseri / L. johnsonii; L.
murinus; Staphylococcus hominis

Pasteurella caecimuris

Staphylococcus epidermidis / S. caprae
/ S. capitis
Bacteroides sartorii; Faecalibaculum
rodentium (97.9%); Lactobacillus
murinus; L. reuteri (99.2%);
Pasteurella caecimuris

Bacillus circulans; Pasteurella
caecimuris; Rodentibacter
pneumotropicus (98.1%);
Staphylococcus hominis; S. xylosus;
Streptococcus thoraltensis (99.3%)

Pasteurella caecimuris
Staphylococcus aureus
Staphylococcus epidermidis / S. caprae
/ S. capitis
Pasteurella caecimuris
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heart, liver, and uterus exceeded those of blank DNA extraction kits (Figure 3.3B). In contrast,
bacterial loads of the maternal peritoneum, the placenta, and the fetal lung, liver, brain, and
intestine did not exceed those of their respective background technical controls (Figure 3.3A &
B). The spleen and tail were the only fetal tissues with bacterial loads exceeding those of blank
DNA
extraction kits (Figure 3.3B). However, only 1/11 (9.1%) fetal tail and 2/11 (18.2%) fetal spleen
samples had bacterial loads exceeding those of each of the blank DNA extraction kits. Corrected
for multiple comparisons, no placental or fetal tissue, including the tail and spleen, had a
bacterial load exceeding that of any other placental or fetal tissue (Wilcoxon matched pairs, p ≥
0.68).
16S rRNA gene sequencing of murine and control samples
Six of the 23 (26.1%) blank DNA extraction kits, and 8/11 (72.7%) sterile swab controls,
yielded a 16S rRNA gene library with ≥ 250 quality-filtered sequences and a Good’s coverage ≥
95%. The prominent (i.e. ≥ 2.25% relative abundance) operational taxonomic units (OTUs) in
the bacterial profiles of the DNA extraction kit controls were identified as Ralstonia, unclassified
Bacillales, Flavobacterium, S24-7, Brevibacterium, Pelomonas, unclassified Bacteroidetes, and
Acinetobacter (Figure 3.4). However, only two of these prominent OTUs, identified as Ralstonia
and Pelomonas, were present in the bacterial profiles of more than half of the DNA extraction kit
controls. A decontam analysis indicated that the OTUs identified as Ralstonia, Pelomonas,
Pseudomonas, and Acinetobacter were likely background DNA contaminants (Figure 3.4).
The bacterial profiles of placental and fetal samples could not be compared to those of
background technical controls because only two of the 77 (2.6%) placental and fetal brain, lung,
liver, intestine, spleen, and tail samples included in this study, yielded a 16S rRNA gene library
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Figure 3.4 Heatmap illustrating the 16S rRNA gene profiles of maternal swab and tissue
samples and background technical controls featuring the relative abundances of prominent
(≥ 2.25% average relative abundance) operational taxonomic units (OTUs). The four OTUs
in red font were identified as background DNA contaminants by the R package decontam.
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with ≥ 250 sequences and a Good’s coverage ≥ 95%. These two samples were the placenta from
Mouse I and the fetal spleen from Mouse B. The placenta from Mouse I had an average bacterial
load in comparison to that of other placentas (Figure 3.3), and no bacteria were cultured from
the placental tissues of this mouse (Table 3.1, Figure 3.1, Figure 3.2). The prominent OTUs in
the bacterial profile of the placental sample from Mouse I were identified as Bacteroides,
Akkermansia, S24-7, Lactobacillus, and Escherichia. The fetal spleen from Mouse B had the
highest bacterial load of any fetal spleen sample; its bacterial load was 58% higher than any
other spleen sample (Figure 3.3). The prominent OTUs in the bacterial profile of the fetal spleen
from Mouse B were Lactobacillus, S24-7, and unclassified Lachnospiraceae.
All maternal skin, mouth, proximal and distal intestinal samples yielded a 16S rRNA
gene library with ≥ 250 sequences and a Good’s coverage ≥ 95%. Six (54.5%), four (36.4%), and
three (27.3%) maternal peritoneal, cervical, and lung samples, respectively, yielded a 16S rRNA
gene library with ≥ 250 sequences and a Good’s coverage ≥ 95%. However, no maternal liver or
uterine samples, and only one (9.1%) maternal heart sample, yielded a 16S rRNA gene library.
The structure of the bacterial profiles of the maternal body sites with at least three 16S rRNA
gene libraries were compared with those of background technical controls (Figure 3.4, Figure
3.5).
The taxonomic identities of prominent OTUs varied among maternal body sites (Figure
4). Maternal proximal and distal intestinal samples had the most OTU-rich bacterial profiles. The
maternal proximal intestine was characterized by Bacteroides, Desulfovibrio, Helicobacter,
Lachnospira, unclassified Lachnospiraceae, Lactobacillus, and S24-7, while the maternal distal
intestine had bacterial profiles consistently comprised of “Candidatus Arthromitus,”
Bacteroides, Lactobacillus, Parasutterella, unclassified Prevotellaceae, and S24-7. Maternal
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Figure 3.5. Principal Coordinates Analysis (PCoA) of maternal samples and controls
illustrating variation in 16S rRNA gene profiles among A) maternal swab samples and
Dacron swab controls, and B) maternal tissue samples and blank DNA extraction kit
controls. 16S rRNA gene profiles were characterized using the Bray-Curtis similarity index.
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vaginal and cervical bacterial profiles were dominated by unclassified Pasteurellaceae; the
vagina also consistently contained Helicobacter. Maternal lung bacterial profiles were typified
by Lactobacillus and S24-7, while those of the maternal mouth were dominated by
Streptococcus, Mannheimia, Lactobacillus, and unclassified Pasteurellaceae. Maternal skin, a
low microbial biomass site (Figure 3.3A), and the peritoneum, a very low to nonexistent
microbial biomass site (Figure 3.3A), had bacterial profiles that overlapped with those of
background technical controls more so than did the profiles of higher microbial biomass sites
(Figure 3.4A). Specifically, skin bacterial profiles consistently contained Bifidobacterium,
Helicobacter, unclassified Pasteurellaceae, Ralstonia, S24-7, Staphylococcus, and Streptococcus.
Ralstonia was the dominant OTU in the bacterial profiles of the maternal peritoneum, as well as
in the profiles of the background technical controls (Figure 3.4). Indeed, the bacterial profiles of
the maternal peritoneum were not distinguishable from those of background technical controls
(Bray-Curtis similarity index; NPMANOVA, F = 0.974, p = 0.467) (Figure 3.5).
Comprehensive consideration of individual placental and fetal tissues across microbiological
inquiries
Of the 165 total bacterial cultures of placentas from the 11 mice, only nine (5.5%)
yielded even a single colony, and five of those nine positive cultures came from a single mouse;
2) of the 165 total bacterial cultures of fetal intestinal tissues, only one (0.6%) was positive,
yielding a single isolate of Staphylococcus hominis; 3) the bacterial loads of placental and fetal
brain, lung, liver, and intestinal samples were not higher than those of DNA extraction kit
controls; 4) only two (2.6%) placental or fetal tissue samples yielded a 16S rRNA gene library
with at least 250 sequences and a Good's coverage value of 95%; 5) the 16S rRNA gene libraries
of each maternal skin, mouth, vaginal, and proximal and distal intestinal sample met these
criteria, as did at least 25% of maternal lung, cervical, and peritoneum samples; 6) similar to the
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placental and fetal tissues samples, maternal heart, liver, and uterine samples did not yield 16S
rRNA gene libraries with at least 250 sequences and a Good's coverage value of 95%; 7) overall,
from all placental or fetal tissues, there was only a single bacterial isolate (Bacillus circulans,
cultured from the fetal brain tissue of Mouse F) that was cultured from a placental or fetal tissue
that had a bacterial load higher than that of background technical controls, and that was
identified in the 16S rRNA gene surveys of at least one of that fetus’ maternal samples (Table
3.1).
V. Discussion
As the era of microbiome discovery and research progresses out of its infancy, many gaps
of knowledge still exist. The Human Microbiome Project [42] was the first concerted and
collaborative effort to describe the healthy microbiota of humans, and while many environments
have had their microbiota characterized, many animals have not received the same degree of
attention in terms of their microbiota. While there are many reports of various microbial
communities for a wide range of animals, they are rarely described to the degree seen in the
HMP, and even rarer, for multiple body sites of a particular animal to be described. Various
issues, such as a lack of standardized methodologies and tools for describing microbiota, are
difficult to overcome given the current limitations of technology and the relatively early stage of
the field. One seminal effort was made to describe a portion of the murine microbiota, that of the
intestine [224]. Investigators utilized culture, metagenomics, and 16S rRNA gene sequencing to
extensively characterize bacteria associated with the mouse intestine. Through culture, they
identified a new family, ten genera, and four species, as characterized by 16S rRNA gene
sequencing, and even found two species with high prevalence among multiple strains of mice
from several animal facilities. The importance of a fully characterized and understood mouse
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microbiota is undeniable given that the majority of animal-driven, human-translatable research
relies on the mouse model.
Despite this limited knowledge of the broader murine microbiome, several studies have
focused on investigating the murine placenta and fetal intestine for evidence of a microbiota. For
instance, Martinez et al. [214] performed bacterial culture, 16S rRNA gene qPCR, and 16S
rRNA gene sequencing on the placenta and fetal intestines of 13 mice at day 17 of gestation
(same gestational age was used in our study). No bacteria were recovered from culture surveys;
however, they did find higher bacterial loads of the fetal intestine to be higher than those of the
placentas via qPCR. The bacterial profiles of placenta and fetal intestines were found to be
different from each other after removing any OTUs detected in the background technical control
samples of the 16S rRNA gene surveys. While Martinez et al. found no evidence that murine
fetuses are populated by microbial communities, they are exposed to bacterial DNA in utero.
Although limited to molecular surveys, another study by Kuperman et al. [225] investigated 24
murine placental samples at gestational day 19 and was unable to detect 16S rRNA gene
amplicons after PCR, similar to the limited detection of 16S rRNA gene signals we found in our
study [212].
In contrast, Younge et al. observed bacterial signals in the murine placenta and fetal
intestines from mice at early, mid, and late gestations. Bacteria cultured predominantly from
fetuses at mid-gestation and were most commonly Lactobacillus, Escherichia, Enterococcus,
Bacteroides, and Bacillus. Additionally, bacteria were visualized in fetal intestines using
fluorescent in situ hybridization (FISH) with a universal probe targeting the bacterial 16S rRNA
gene. The possibility that the cultured and visualized bacteria originated from maternal tissues
due to contamination during sampling is unlikely and was addressed in mechanistic studies
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utilizing surgical techniques and inoculations with two different antibiotic-resistant strains of E.
coli. Using 16S rRNA gene sequencing, the bacterial profiles of placenta and fetal intestines
were similar to each other, while variation was observed when comparing early gestation
samples to mid and late gestation samples. Sourcetracker analyses indicated that the bacterial
signals from early gestation fetal intestines were most likely originating from background
technical controls or unknown sources, while mid and late gestation samples were attributed to
the placenta or amniotic membrane. Younge et al. [213] concluded that fetal exposure to
microbial communities is occurring, and that the exposure is likely coming from the placenta and
extraplacental membranes in utero.
Similar to the debate over a microbiota in the human placenta, there is contradictory
evidence regarding a murine placental microbiota and in utero colonization. The data presented
in this chapter are more consistent with the prior reports of Martinez et al. [214] and Kuperman
et al. [225] and are contradictory to the evidence reported by Younge et al. [213] regarding in
utero colonization. In our study, culture of bacteria from placental and fetal tissues was generally
rare. Most of the bacterial isolates were identified as Staphylococcus hominis. The origin of these
bacteria could be maternal sites, as Staphylococcus spp. were routinely cultured from maternal
sites and Staphylococcus hominis specifically was identified in molecular surveys of the maternal
skin. Alternatively, these bacteria could potentially be contaminants from laboratory personnel,
given that two of the five bacterial isolates recovered from negative control plates in this study
were also Staphylococcus hominis. The other bacteria (Bacillus, Corynebacterium,
Paenibacillus, and Propionibacterium) cultured from placental and fetal samples were rarely, if
ever, cultured from maternal samples or identified in the molecular surveys of maternal samples.
Given that the only possible source of placental and fetal microbiota is microorganisms in the
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maternal compartments, the latter finding suggests that these bacteria were likely contaminants.
Furthermore, there was no consistent recovery in culture of specific microorganisms (aside from
Staphylococcus hominis) from multiple placental and fetal tissues from the same fetus or in the
same tissue types among fetuses from different litters. Notably, the taxonomic identities of
bacteria cultured in the current study generally differed, with the exception of Staphylococcus,
Bacillus, and Paenibacillus, from those initially reported by Younge et al. [213] in placental and
fetal tissues. Therefore, across studies culture has not provided consistent evidence for a
placental or fetal microbiota.
Furthermore, qPCR revealed that the bacterial loads of the placenta, fetal lung, liver,
brain, and intestine did not exceed those of background technical controls, whereas samples from
maternal sites, excluding the peritoneum, did exceed those of controls. In addition, there was no
variation in bacterial load among placental and fetal tissues. These results are in contrast to those
of Martinez et al. [214] in which the bacterial loads of the fetal intestine exceeded those of the
placenta. To our knowledge, no other studies have directly compared the bacterial loads of the
placenta and fetal intestine in mammals. However, the qPCR results in our study agree with prior
qPCR investigations of human placental tissues – the bacterial loads of placentas are
indistinguishable from those of background technical controls [128, 150, 167]. Hence, there
remains disagreement among studies with respect to the extent of bacterial biomass in placental
and fetal tissues.
Herein, the murine placenta and fetal tissues did not yield substantive 16S rRNA gene
sequence libraries, while the maternal sites other than the uterus, heart, and liver consistently did
so. These results are consistent with those of Kuperman et al. [225], in which 30 cycles of PCR
did not yield discernible amplicons from murine placental tissue. Notably, in our study, triple
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library preparations were performed and pooled for each sample, and still minimal amplicons
were generated after 30 cycles of PCR. Martinez et al. [214] also used 30 cycles of PCR in their
sequence library preparations and included samples in their analyses if they yielded at least 200
quality-filtered sequences, reporting a distinct bacterial DNA signal in the placenta and fetal
intestine. In this study, we only included samples in analyses if they yielded at least 250 qualityfiltered sequences with a Good’s coverage value of at least 95%. If we had used the criterion of
200 sequences, independent of any consideration of Good’s coverage, only one additional fetal
sample would have been included in analyses. Younge et al. [213] generated substantive
sequence libraries for placental and fetal intestine samples; however, their library preparation
protocol was based on that of the Earth Microbiome Project (i.e. 35 cycles of PCR). The
discrepancies among murine studies may therefore be due to underlying differences in the
sequence library protocols used. Nevertheless, as with culture and qPCR approaches, we did not
find consistent evidence of a bacterial signal in placental and fetal tissues using DNA
sequencing.
Notably, in this study, there was only one case in which a bacterial isolate (i.e. Bacillus
circulans) from a placental or fetal sample (i.e. fetal brain) had a bacterial load exceeding that of
all background technical controls, and in which the bacterium was also identified in molecular
surveys of at least one corresponding maternal sample (i.e. maternal skin). Therefore, in this one
case, there may have been hematogenous transfer from a distant maternal site to the fetus.
However, overall, there was not consistent evidence of resident bacterial communities in the
murine placenta or the fetus.
Although the context of this chapter has shifted from humans to mice, it is important to
highlight that our work and the works of others [213, 214, 225] are challenging paradigms of
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sterility. That being stated, the value of finding consistent and reproducible evidence cannot be
neglected, nor can the caveats of working with low microbial biomass tissues. Our study
emphasizes the importance of including appropriate background technical controls, as well as
positive and negative tissue controls, in all microbiological approaches from culture to
sequencing when reevaluating paradigms of sterility. Ultimately, while several studies, including
our own, have included multiple methodologies of microbiologic inquiry, no studies have thus
far met all the criteria put forth in Theis et al. [150] for establishing the presence of a resident
microbiota. One major oversight in the work thus far has been the lack of inclusion of a germfree mice cohort compared to a wild type cohort, which presents an opportunity to investigate in
utero exposure and colonization that is uniquely available to animal studies and should be
included in future work.
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CHAPTER 4: A URINARY MICROBIOTA IN PREGNANCY: CULTIVATION- AND
MOLECULAR-BASED COMPARISON OF FOLEY CATHETERIZED URINE, CLEAN
CATCH URINE, AND VAGINAL SWABS FROM THE SAME WOMEN
Note: Ali Alhousseini, a former PhD student in the Department of Physiology and the Theis
laboratory at Wayne State University contributed equally to this chapter. I am responsible for all
analyses, generation of tables and figures, writing of the Abstract, Methods, and Results, and
revision of the Introduction and Discussion. Dr. Alhousseini collected all the clinical samples,
participated in the processing of these samples, and originally wrote the Introduction and
Discussion sections. A prior version of this study was included in his dissertation thesis as well.
I. Abstract
Urine and the bladder have historically been considered sterile, especially in the context
of clinical assessment. Recent work has been capitalizing on enhanced culture techniques and
next-generation molecular sequencing surveys to re-assess the sterility of urine. Indeed, the
scientific community has been shifting towards accepting that the bladder does contain
microorganisms in healthy individuals, yet further investigation is warranted, as demonstrated in
Chapters 2 and 3 of this dissertation. My focus these past five years has been on paradigms of
sterility in perinatal medicine, and studies on the urine of pregnant women have been limited
thus far. This is surprising given that pregnant women are at an increased risk of urinary tract
infections (UTIs) and UTIs can lead to pregnancy complications. Because of these
vulnerabilities, investigating the bladders and urine of pregnant women is critical in evaluating
shifting paradigms of urine sterility.
To better understand the existence and potential role of a bladder microbiota during
pregnancy, we must first establish suitable approaches to its study and characterize which
bacteria inhabit the bladder. To do so, we characterized the urinary microbiota of 25 pregnant
women (delivering after 35 weeks gestation) by comparing the bacterial profiles of paired
catheter urine, clean catch urine, and vaginal swabs using cultivation and molecular
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microbiological survey methods. For culture, three bacterial taxa were detected in at least 20% of
all urine samples (Lactobacillus species, coagulase negative Staphylococcus species, and
Ureaplasma urealyticum), and all three taxa were detected less frequently in Foley catheter urine
than in CC urine. Ureaplasma urealyticum was the most frequently recovered bacteria in Foley
catheter urine (13/25 women). 16S rRNA gene surveys showed that the microbial profiles of
Foley catheter urine and vaginal swabs differed in composition and structure, but that the profiles
of clean catch urine and vaginal swabs were similar. For all three sample types, bacterial profiles
were abundant in Lactobacillus and Gardnerella species, but there was variation in lower
abundance taxa among these three sample types, especially with regards to Foley catheter urine,
which is presumably most closely representative of a bladder microbial community, if one exists.
Overall, our data suggest that residential bacterial communities exist in the female
bladder and urine during pregnancy, and that there is overlap between those communities and
those in the vagina. Aside from Lactobacillus and Gardnerella species, which were frequently
detected in molecular surveys of Foley catheter urine obtained directly from the bladder, there
was high inter-individual variability of less abundant taxa. Several lower abundance taxa that
were differentially more abundant in catheter urine than vaginal swabs in molecular
microbiology surveys were Ureaplasma, Finegoldia, Anaerococcus, and Fenollaria species. Of
these, Ureaplasma was detected by cultivation in a majority of women. The remaining bacteria
are anaerobes, which would require targeted or enhanced culture methods for their detection.
Future directions include validating these findings in a larger cohort and pursuing more robust
cultivation methods that are efficient for capturing low abundance anaerobes in clinical samples,
especially Gram-positive anaerobic cocci (including Finegoldia, Anaerococcus, Peptoniphilus,
and Atopobium). Additionally, investigation of the bladder of women delivering preterm
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(especially early preterm, < 32 weeks of gestation) is warranted for comparisons of bladder
microbial communities to women delivering at term will allow us to assess influences of resident
bacterial communities on perinatal health and pregnancy outcomes, which can ultimately be used
to identify specific bacteria or bacterial communities whose presence or absence can serve as
potential risk indicators for adverse pregnancy outcomes, especially spontaneous preterm birth.
II. Introduction
The bladder and urine have historically been regarded as sterile [115, 169]. However, this
perception is being reconsidered [69, 114, 117, 118, 133, 226, 227]. Given appropriate
cultivation conditions, based on atmospheric and metabolic requirements, microorganisms can be
cultured from urine in healthy patients [64, 228]. Furthermore, capitalizing on contemporary
advances in next-generation sequencing technologies, urinary microorganisms have been
identified and characterized among asymptomatic non-pregnant women [69, 114, 117, 118, 133,
226, 227], and, in a single study, among pregnant women [169]. Collectively, these studies have
suggested that bacteria reside in the human bladder as commensals, and even potentially as
mutualists [69]. For example, a current hypothesis is that microbes residing within the bladder
and urine of healthy people competitively exclude potential pathogens and that dysbiosis of these
resident microbial communities could lead to an overgrowth of opportunistic pathogens,
resulting in urinary tract infections (UTIs), urinary urge incontinence, and other urinary tract
disorders [63, 64, 67].
Despite recent work, the existence of a urinary microbiota has not yet been effectively
investigated using contemporary molecular microbiology techniques in the context of pregnancy
outcomes. Bacterial presence in the urinary tract has been considered pathologic and has been
classified into asymptomatic bacteriuria (ASB), urinary tract infection, or pyelonephritis [137,
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169, 229, 230]. Pregnant women are an important population in which to assess any potential
influences of a urinary microbiota due to vulnerabilities associated with the urinary tract during
pregnancy [162, 163, 231]. Specifically, women experience physiological and morphological
changes during pregnancy, including ureteral dilation, decreased bladder tone, displacement and
compression of the bladder, increased renal length, and decreased peristalsis. The consequences
of these alterations can include urinary stasis, vesicoureteral reflux, and hydronephrosis [162,
231], each of which contribute to conditions that are conducive to microbial growth [163],
thereby increasing the risk of ascending UTIs. In fact, UTIs are the most common bacterial
infection in women during pregnancy, occurring in up to 8% of pregnancies, with approximately
5% of women experiencing at least one UTI event during a given pregnancy [232]. Urinary tract
infections can lead to significant maternal and perinatal complications, including preterm birth,
low birth weight, maternal sepsis, and disturbance of the immune system, including an increase
in inflammation [157, 158, 233-243]. While women diagnosed with having asymptomatic
bacteriuria (ASB) are at similar risk for adverse pregnancy outcomes as UTIs, the main
difference between these two diagnoses, aside from symptom presentation, has been the
magnitude of detectable bacteria in urine, or colony forming units (CFUs) from urine culture,
which is still the clinical diagnostic standard along with urinalysis. Notably, asymptomatic
bacteriuria has been reported in up to 10% of pregnancies [244-248], and, if left untreated, ASB
can lead to symptomatic UTIs, including pyelonephritis in 30-40 % of the cases [249]. A recent
Cochrane review therefore recommended treatment of ASB to reduce the incidence of
pyelonephritis during pregnancy [244]. This is in line with typical clinical practice as a positive
urine culture (> 10,000 colony forming units per ml) during pregnancy has traditionally elicited
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antibiotic treatment and a repeat of culture within 1-2 months to confirm resolution of the
infection [137].
An important consideration that needs to be addressed is that asymptomatic bacteriuria,
and to a lesser extent UTIs, have historically hinged on the long-held belief that the upper
urinary tract is sterile. While this now stands contradictory to multiple studies that have been
published using enhanced culture and 16S rRNA gene sequencing surveys suggesting the
existence of a urinary tract or bladder microbial community in healthy individuals, there are two
important caveats inherent in characterizing urinary microbiota profiles. First, urine samples are
susceptible to vulvovaginal contamination, so there is risk that characterized microbes were not
actually residing in the bladder or the urine. Studies by Wolfe and colleagues [48, 115, 118]
found many genera, although the most represented were Lactobacillus, Prevotella,
Staphylococcus, Atopobium, Corynebacterium, and Gardnerella, which are all commonly
associated with the vagina and human skin. Second, if there are indeed resident urinary microbial
communities, they are present in very low abundances and thus, when characterizing them
through next-generation sequencing, there is risk of amplifying and characterizing background
bacterial DNA contamination from DNA extraction kits and PCR reagents [98, 99, 128, 149,
189]. 16S rRNA gene sequences are ubiquitous in the environment and do not indicate viability
of any surveyed bacteria. From our analysis of the current literature, we found that most of the
publications investigating the urinary tract microbiota did not include appropriate technical
controls to properly account for background DNA. Many of the less abundant genera detected in
recent studies represent species that are not captured by routine cultures or have never been
successfully cultured. It is also important to perform viability assays, such as expanded
quantitative urine culture (EQUC) methods, to demonstrate viability of bacteria from these
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samples because molecular surveys do not differentiate between ubiquitous environmental 16S
rRNA gene sequences and those from living bacteria [115]. Additionally, some of the data
provided in studies were low in sample size (e.g., n = 2), and conducted viability assays on only
a subset of samples [117, 118]. Therefore, it is important for future work in this area to include
larger sample sizes, more rigorous and extensive culture techniques, and ample background
technical controls to draw a proper conclusion on the existence of microbial communities in the
bladder.
Our broad objective is to further investigate and resolve the ambiguities surrounding the
presumed presence of urinary tract microbial communities among normal asymptomatic
pregnant women, and to ultimately ascertain potential influences of these communities on
women’s reproductive health. By investigating the presence of microbial communities in the
bladder of pregnant women, follow-up studies can elucidate any associations that certain
microbial species or community structures may have with pregnancy outcomes. Should we find
that urine samples are not significantly different from technical controls, the medical community
can reassess diagnostic criteria to address the asymptomatic presence of bacteria as an indicator
of subclinical infection that can be addressed with prophylactic measures. Additionally, this
result should reduce or stop the publication of studies alluding to urinary microbiota without
including necessary technical controls. Conversely, if we find that there is a resident microbial
community within the female urinary tract, it is critical that current paradigms of a sterile urinary
tract be revised to accommodate these resident microbes and the corresponding microbiome.
Additionally, given that infection in non-sterile sites may indicate disruption of microbial
homeostasis, understanding of the underlying microbial community is critical for addressing and
preventing urinary tract infections. This would also render the term bacteriuria obsolete and
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require new approaches for handling the updated context of urinary tract disorders. In particular,
women’s reproductive health serves to benefit most by this paradigm shift through better risk
indicators through screening of these communities. If we find distinct community types
associated with particular disease states or increased risks for obstetric or gynecologic
complications, preventative measures can be taken to either alter the community or replace it
with probiotics, antibiotics, or a combination of the two (i.e. synbiotics).
The specific and principal objective of this study was to determine if there is a viable
microbiota in the bladder and urine during pregnancy and, if so, to characterize it. Secondary
objectives were to: 1) assess similarity of culture and next-generation sequencing
characterizations of urinary microbial profiles; 2) assess the microbial load of urine sampled
using catheter and clean catch collection methods via quantitative real-time PCR; 3) compare the
composition and structure of the microbial profiles of urine from pregnant women obtained using
catheter and clean catch collection approaches with those of background technical controls; and
4) contrast the microbial profiles of the urine of pregnant women obtained through these two
collection approaches with those of the vagina to assess potential vulvovaginal contamination.
These objectives were achieved by collecting 3 sample types, catheter urine, clean catch urine,
and vaginal swabs, from pregnant women and characterizing their urine and vaginal microbiota
profiles through both culture and next-generation sequencing surveys. To accomplish our
objectives, our study was divided into two components. In Study Component 1, we evaluate
whether the urine of pregnant women has bacterial loads and bacterial profiles distinct from
those of technical controls, as assessed by quantitative real-time PCR and 16S rRNA gene
sequencing. Additionally, we determine what is an appropriate volume of urine to use for
effective surveys of potential bladder microbial communities. In Study Component 2, after
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establishing that urine samples are distinct from technical controls and identifying an appropriate
urine volume for assessing microbial communities, we compare urine collection methods to
assess the most informative and accurate method for detecting and characterizing
microorganisms in the bladder, while controlling for vulvovaginal and background DNA
contamination. Finally, we detail the evidence of a bladder microbiota in this cohort and identify
the bacteria that are likely members of the bladder microbiota during pregnancy.
III. Methods and Materials
Clinical specimens
Urine and vaginal swab samples were obtained at the Perinatology Research Branch, an
intramural program of the Eunice Kennedy Shriver National Institute of Child Health and Human
Development, National Institutes of Health, U.S. Department of Health and Human Services,
Wayne State University (Detroit, MI), and the Detroit Medical Center (Detroit, MI). The
collection and use of human materials for research purposes were approved by the Institutional
Review Boards of the National Institute of Child Health and Human Development and Wayne
State University. All participating women provided written informed consent prior to sample
collection.
Study design
This was a cross-sectional study in which the urinary and vaginal microbiota were
examined in 25 women admitted for delivery after 35 weeks gestation. There were two
components to the study. First, the bacterial loads and bacterial profiles of urine samples
collected using Foley catheter and clean catch sampling methods were compared in a subset of
women ( n = 8 ). These comparisons were made across a range of urine volumes (1 ml, 1.8 ml,
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5.4 ml, 10 ml, and 25 ml).Second, the bacterial loads and bacterial profiles of 5.4 ml of Foley
catheter urine, clean catch urine, and vaginal swabs were compared across all women and were
contrasted with those of background contamination controls.
Inclusion and exclusion criteria
Inclusion criteria: 1) delivery after 35 weeks of gestation, and 2) intact membranes at the time of
collection of vaginal swabs and clean catch urine samples. Exclusion criteria: 1) any maternal or
fetal condition that requires termination of pregnancy; 2) known major fetal anomaly or fetal
demise; 3) active vaginal bleeding; 4) serious medical illness (e.g. renal insufficiency, congestive
heart disease, chronic respiratory insufficiency, etc.); 5) asthma requiring systemic steroids; 6)
patient requiring anti-platelet or non-steroidal anti-inflammatory drugs; 7) active hepatitis; and 8)
signs or symptoms of urinary tract infection, asymptomatic bacteriuria, and pyelonephritis at the
time of sampling.
A urinary tract infection (UTI) is bacterial growth of more than 10,000 colonies of a
single bacterial type per milliliter (CFU/ml) of urine coincident with one of the following
symptoms: hematuria, dysuria frequency, urgency or suprapubic pressure [229, 230]. However,
because others have recommended a much lower threshold of 100 CFU/ml for diagnosing
symptomatic UTIs [250], we applied the latter definition. Asymptomatic bacteriuria (ASB) is the
presence of 100,000 CFU/ml without any associated symptoms [137, 229, 230]. Pyelonephritis is
infection of the kidneys and the presence of systemic signs or symptoms such as fever, nausea
and vomiting, chills or flank pain [137, 229, 230]. Again, no woman in this study had a urinary
tract infection, asymptomatic bacteriuria, or pyelonephritis.
In the first component of the study, which assessed bacterial load and profiles of urine
samples at multiple volumes compared to background contamination, no subject had received
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antibiotics in the last week. In the second component of the study, evaluating differences in
bacterial load and profiles of Foley catheter urine and clean catch urine and vaginal swabs, no
subject had received antibiotics in the last month.
Sample collection
On admission, each woman provided a mid-stream clean catch urine specimen (CC). A
speculum exam was performed, and a sample of vaginal fluid was collected from the posterior
vaginal fornix under direct visualization by an obstetrician using a FLOQSwab (Copan
Diagnostics, Murrieta, CA, USA). During labor or prior to a cesarean delivery, a sterile Foley
catheter was inserted, and a second urine specimen was collected (Foley catheter was placed 8.36
± 1.93 (mean ± SE) hours after the clean catch sample was collected). Urine (excluding the
aliquot for culture, see below) and vaginal swabs were frozen at -80°C within one hour of
collection.
Bacterial culture of urine
A 2 ml aliquot of urine was sent for bacterial culture. Aliquots of urine were delivered to
the University Laboratories Microbiology Core in the Detroit Medical Center, wherein they were
processed and cultured under aerobic and anaerobic conditions that day. A genital mycoplasma
assay (Mycofast US; Logan, UT) was also conducted for each urine sample [251]. Incubation for
aerobic, anaerobic and Mycoplasma/Ureaplasma cultures was performed at 35°C. Aerobic plates
were TSA 5% SB (Trypticase Soy Agar w/5% Sheep's Blood), Columbia CNA SB, MacConkey
and MTM II (Modified Thayer Martin). Anaerobic plates used were Brucella OxyPRAS Plus,
KVL/BBE Biplate (Brucella Laked Blood Agar with Kanamycin and Vancomycin/Bacteroides
Bile Esculin Agar) and CDC ANA BLD (CDC Anaerobic Blood Agar). Aerobic cultures were
grown in an incubator with 8% CO2, anaerobic cultures were grown in a plastic anaerobic culture
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chamber in a non-CO2 incubator, and the Mycoplasma/Ureaplasma cultures were grown in an
oxic environment without CO2 supplementation. In each case, one drop of urine, equivalent to
approximately 0.05 ml, was used. Urine samples were incubated for 48 hours. The taxonomies of
resultant isolates were characterized using Matrix-assisted laser desorption/ionization time-offlight mass spectrometry (MALDI-TOF) within the University Laboratories Microbiology Core
[252].
Genomic DNA extractions
Preparation of urine samples for DNA extraction: For 1, 1.8, and 5.4 ml sample volumes, DNA
extractions were performed as follows: Urine samples were originally stored at -80°C in either 2
ml cryovials or in 15 ml centrifuge tubes. Samples were thawed at room temperature and
thoroughly vortexed before aliquoting into 1.8 ml mini-centrifuge tubes (one tube for 1 and 1.8
ml sample volumes, and three tubes for the 5.4 ml sample volume). Samples were spun in a
mini-centrifuge in a 4oC cold room for 30 minutes at 17,000 g. After centrifugation, each sample
had the majority of supernatant removed. For the 1 ml sample, approximately 750 µl of
supernatant was carefully removed with a 1 ml pipette tip, avoiding the pellet, thereby leaving
about 250 µl of the supernatant and the pellet for DNA extraction. For the 1.8 ml sample, 775 µl
was removed twice, again being careful to avoid disturbing the pellet, leaving about 250 µl of the
supernatant and the pellet for DNA extraction. For the three 1.8 ml tubes constituting the 5.4 ml
sample, 860 µl was removed twice from each tube, carefully avoiding the pellet, leaving 80 µl of
supernatant and the pellet in each tube for DNA extraction. The initial step of the DNA
extraction protocol requires adding 500 µl of the kit’s PowerBead Solution to the sample; the
PowerBead Solution was added directly to these 1.8 ml tubes. The tubes were then thoroughly
mixed through vortexing and by pipetting the solution up and down to ensure that the pellet was
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dislodged into solution and would be transferred to the bead tube in the next extraction step. For
the 5.4 ml sample, 500 µl of PowerBead Solution was added to the first 1.8 ml tube, the tube was
then mixed, transferred to the second tube, mixed, transferred to the third tube, and mixed again
before being transferred to the PowerBead Tube in the next extraction step.
For DNA extractions performed on 10 and 25 ml samples: Urine samples were originally
stored at -80°C in either 2 ml cryovials or in 15 ml centrifuge tubes. Samples were thawed at
room temperature and thoroughly vortexed before transferring 10 or 25 ml into 50 ml centrifuge
tubes. These samples were spun at 4oC at 17,000g for 30 minutes. After centrifugation,
supernatant was removed without disturbing the pellet. The initial step of the DNA extraction
protocol requires adding 500 µl of PowerBead Solution to the sample, so the PowerBead
Solution was added directly to these 50mL tubes. These tubes were then thoroughly mixed
through vortexing and pipetting the sample up and down to ensure that the pellet was dislodged
into solution and would be transferred to the bead tube for the following step in the extraction
protocol.
Extraction protocol: Genomic DNA was extracted from urine and vaginal swab samples using
QIAGEN DNeasy PowerLyzer PowerSoil Kits according to the manufacturer’s protocol with the
following modifications: 1) instead of adding 750 μl of PowerBead Solution to each sample, 500
μl of PowerBead Solution and 200 μl of phenol/chloroform:isoamyl alcohol were added and the
sample was incubated in the PowerBead Tubes at room temperature for 10 minutes, 2) steps that
entail adding Solutions C2 and C3 were combined into one step; 1 μl of RNase A enzyme was
also added, 3) instead of adding 1200 μl of Solution C4, 650 μl of C4 and 650 μl of 100%
ethanol were added, 4) the dry-spin after Solution C5 was extended from 1 to 2 minutes, 5)
Solution C6 was heated to 60°C prior to elution of DNA, and 6) 60 μl instead of 100 μl of
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Solution C6 were added to the Spin Column and incubated for 5 minutes before final
centrifugation. Blank DNA extraction kits with no urine sample added (n = 12) were processed
alongside urine samples. Purified DNA was stored at -20°C.
Quantitative real-time PCR (qPCR) of 16S rRNA genes in samples
Bacterial DNA abundance within samples was determined via quantitative real-time PCR
(qPCR) amplification of the V1 – V2 region of the 16S rRNA gene according to a protocol
described by Dickson et al [70] with minor modifications. These modifications included the use
of a degenerative forward primer (27f-CM: 5’-AGA GTT TGA TCM TGG CTC AG-3’) and a
degenerate probe containing locked nucleic acids (+) (BSR65/17: 5’-56FAM-TAA +YA+C ATG
+CA+A GT+C GA-BHQ1-3’). All qPCR reactions were performed in triplicate (20 μl each),
with each reaction containing 0.6 μM of 27f-CM primer, 0.6 μM of 357R primer (5’-CTG CTG
CCT YCC GTA G-3’), 0.25 μM of BSR65/17 probe, 10.0 μl of 2X TaqMan Environmental
Master Mix 2.0 (Life Technologies, Carlsbad, CA), and 4.0 μl purified DNA. Cycling conditions
were as follows: 95°C for 10 min, and 45 cycles of 94°C for 30 s, 50°C for 30 s, and 72°C for 30
s. Fluorescent readings were taken at the end of each cycle on an ABI 7500 Real-Time PCR
System (Applied Biosystems, Waltham, MA). Raw amplification data were normalized to the
ROX passive reference dye and analyzed with Standard Curve 3.3.0-SR2-build15 (Thermo
Fisher Cloud), using automatic threshold and baseline settings. Cycle of quantification (Cq)
values, defined as the average number of cycles required for normalized fluorescence to
exponentially increase, were calculated. DNA derived from Escherichia coli ATCC 25922
containing seven 16S rRNA gene copies per genome (GenBank accession: CP009072) was
quantified using a Qubit 3.0 fluorometer with a Qubit dsDNA HS Assay kit (Life Technologies,
Carlsbad, CA) according to the manufacturer’s instructions and used for the generation of
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standard curves. To estimate qPCR efficiency, a standard curve containing seven 10-fold serial
dilutions (three replicates each) ranging from 1.99 X 107 to 1.99 X 101 copies was included in
each run. Prior to analyzing qPCR data with the on-line platform Thermo Fisher Cloud (Standard
Curve (SR) 3.3.0-SR2-build15), an external master standard curve was generated by performing
a regression of the standard curve data from all six qPCR runs. The regression values for the
master external standard curve were: slope = -3.4629, y-intercept = 40.122, R2 = 0.9798.
16S rRNA gene sequencing
16S rRNA gene sequencing was completed on an Illumina MiSeq (San Diego, CA)
instrument at the University of Michigan’s Center for Microbial Systems (Ann Arbor, MI). The
V4 region of the 16S gene was amplified using a modified PCR approach (95° for 2 min,
followed by 32 cycles of 95° for 30 s, 55° for 30 s, and 72° for 30 s, with a final elongation step
at 72° for 10 min). DNA template volumes were 5 μl for urine and blank DNA extraction kits,
and 3 μl for vaginal swabs. The MiSeq sequencing protocol was performed using the dual
indexing sequencing strategy developed by Schloss and colleagues [219, 253].
16S rRNA gene sequence processing
Sequence data were processed using Mothur software (v1.39.5) [41]. Specifically, paired
reads were assembled, quality-filtered (no ambiguous base calls, homopolymers ≤ 8 bases long),
and aligned to the SILVA 16S rDNA reference database (release 102) [221, 222]. Sequences in
the final dataset had an average length of 253 bp. We performed a preclustering step (diffs = 2)
to reduce potential influence of sequencing errors and removed chimeras identified by UCHIME
[254]. For taxonomic classification, the SILVA reference database [222] was used with a
confidence threshold of 80% [255]. Sequences from an unknown domain, Eukaryota,
Chloroplasts, Mitochondria, or Archaea were removed. Operational taxonomic units (OTUs)

108
were defined using a 3% sequence dissimilarity cutoff. Good’s coverage values for all urine and
vaginal samples exceeded 99%.
Statistical analyses
Bacterial culture: The rate of cultivation of bacterial phylotypes (as identified via MALDI-TOF,
e.g. Lactobacilllus, coagulase negative Staphylococcus, Ureaplasma urealyticum) from urine
was compared between Foley catheter and clean catch collection methods using generalized
estimating equation models assuming a binomial distribution (i.e. detected or non-detected).
Only bacterial phylotypes detected in at least 20% of the samples, regardless the method of
collection, were tested. Significance of the odds ratios was assessed via Wald tests, implemented
in the geepack package in R (v 3.4) [256]. The paired differences in the total numbers of
bacterial phylotypes detected within the Foley catheter and clean catch urine samples among the
women were assessed using a Poisson generalized estimating equation model.
16S rRNA gene qPCR: To assess differences in 16S rDNA abundance between each urine
volume and collection method and blank DNA extraction kit controls, differences in cycle of
quantification (Cq) were evaluated via Mann-Whitney tests. To assess variation in 16S rDNA
abundance among urine samples of different volumes from the same women, variation in Cq
values was evaluated via repeated-measures analysis of variance (ANOVA) followed by Tukey’s
tests for pair-wise comparisons or Friedman’s ANOVA followed by Wilcoxon matched pairs
tests. In component 2, differences in 16S rDNA abundance between sample types were assessed
using Friedman’s ANOVA followed by Wilcoxon matched pairs tests. Statistical analyses were
performed using PAST software (v3.16) [202].
16S rRNA gene profile alpha and beta diversity: For Study Component 1, blank DNA extraction
kit controls were sequenced twice and subsequently pooled bioinformatically. The controls with
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Good’s coverage values exceeding 98% were retained for analysis [n = 5, additional controls
were processed during DNA extractions for Study Component 2 and used as part of the LEfSe
analysis (n = 7)]. Alpha diversity in Study Component 1 was analyzed after subsampling
individual libraries to 447 sequences, which corresponds to the sequence number of the least
represented background technical control sample. After subsampling, Good’s coverage remained
above 95% for all but one sample (91%).
Alpha diversity in Study Component 2 was analyzed after subsampling individual
libraries to 2007 sequences, which corresponds to the number of sequences in the second least
represented sample. A sample with 445 sequences was excluded from these analyses. In
Component 2, after subsampling, Good’s coverage values for urine and vaginal samples
remained greater than or equal to 98%.
Alpha diversity was assessed using the Chao1 index as an indicator of richness and the
Shannon and Inverse Simpson indices as indicators of heterogeneity (evenness). Differences in
alpha diversity between urine and background technical control samples were evaluated through
t-tests or Mann-Whitney tests. For comparisons among different urine volumes (Component 1: 1
ml, 1.8 ml, 5.4 ml, 10 ml, 25 ml) or between sample types (Component 2: Foley catheter urine,
clean catch urine, vaginal swabs) variation in alpha diversity was evaluated through repeated
measures ANOVA followed by Tukey’s matched-pairs or their non-parametric equivalents.
To evaluate differences in beta diversity of 16S rRNA gene profiles, Jaccard (i.e.
composition) and Bray-Curtis (i.e. structure) similarity index values were calculated using OTU
percent relative abundance data within samples and were visualized through Principal
Coordinates Analyses (PCoA). Non-parametric MANOVA (NPMANOVA) tests were
performed on Jaccard and Bray-Curtis similarity indices to assess differences between
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background technical controls and different urine volumes (Component 1), and variation among
catheter urine, clean catch urine, and vaginal samples (Component 2).
Alpha diversity indices were generated in mothur (v1.39.5) and statistically evaluated in
PAST (v3.16). Beta diversity indices and PCoA plots were generated using PAST software
(v3.16). Non-parametric MANOVA [257-259] tests were performed in R (version 3.4.2) with
adonis in the vegan package. The “strata” parameter in adonis was used to control for repeatedmeasures. Heatmaps were generated via the Morpheus online tool [204].
SourceTracker analysis: SourceTracker software [121] was used to identify what percentage of
OTUs found in urine samples could be attributed to contamination from vaginal samples. For
each urine collection method, SourceTracker analysis was done in triplicate with a rarefaction
depth of 500 and the proportions from the three model runs were averaged to give the mean
percentage of OTUs predicted to be from vaginal samples. Singletons and doubletons were
removed from 16S rRNA gene datasets prior to these analyses. Wilcoxon paired tests of the
averaged SourceTracker runs were evaluated in PAST (v3.16).
LEfSe analysis: Linear discriminant analysis effect size, or LEfSe, was used to identify any
OTUs that differed in relative abundance between each of the three biological sample types
(Foley catheter urine, clean catch urine, vaginal swabs) and blank DNA extraction kits (n = 7).
Singleton OTUs were removed from the datasets prior to analyses and the default settings for
LEfSe were used except that the LDA score cutoff was set to 3.0.
IV. Results
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Study Component 1: Comparing the bacterial load and 16S rRNA gene profiles of different
volumes of urine from the same women
Patient characteristics
Eight women were included in Component 1 of the study. The median and interquartile
range for age, body mass index (BMI), gestational age at sampling, and neonatal birthweight
were 27.5 (25.2-28.2) years, 31.6 (28.5-45.8) kg/m2, 39.7 (38.8-40.8) weeks, and 3,392 (3,2563,882) grams, respectively (Table 4.1).
Quantitative real-time PCR (qPCR) of 16S rRNA gene abundance in urine samples
Quantitative real-time PCR demonstrated that the median cycle of quantification (Cq)
values for each volume of urine were significantly lower than the median Cq values for blank
DNA extraction kit controls, regardless whether the urine was collected via Foley catheter
(Mann-Whitney; U = 0, p = 0.0058) or the mid-stream clean catch method (U = 0, p = 0.0081).
The volume of urine processed had an effect on Cq value for Foley catheter (repeated measures
ANOVA; F = 9.805, p < 0.0001) and clean catch (F = 28.01, p < 0.0001) urine samples. For both
urine collection methods, a urine volume of 5.4 ml was the lowest volume to yield Cq values that
did not significantly differ from 25 ml of urine (Tukey-adjusted comparisons; Figure 4.1), which
was the highest volume of urine investigated in this study.
16S rRNA gene profiles of urine samples
Alpha Diversity: Bacterial profile richness (Chao1 index) and heterogeneity (Shannon and
Inverse Simpson indices) did not differ between any volume of catheter or clean catch urine and
blank DNA extraction kits after correcting for multiple comparisons (Table 4.2). A global effect
of sample volume on heterogeneity was observed for Foley catheter urine; however no pairwise
comparisons were significant after correcting for multiple comparisons (Table 4.2).
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Table 4.1. Descriptive and clinical characteristics of subjects for Study Components 1 and
2.
Study Component 1
N=8
Age (yrs)
BMIb (kg/m2)
GAc at sampling (wks)
Birthweight (g)

Median
27.5
31.6
39.7
3392

Race
African American

8 (100 %)

IQRa
25.2 – 28.2
28.5 – 45.8
38.8 – 40.8
3256 – 3882

Study Component 2
N = 25
Age (yrs)
BMIb (kg/m2)
GAc at sampling (wks)
Birthweight (g)
Race
African American
White
Other
a
Interquartile range
b
Body Mass Index
c
Gestational Age

Median
24.0
31.7
39.3
3165

22 (88.0 %)
2 (8.0 %)
1 (4.0 %)

IQRa
21.0 – 29.0
26.3 – 35.8
39.0 – 39.85
2892.5 – 3615
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Figure 4.1. Quantitative real-time PCR (qPCR) of the 16S rRNA gene results from urine
sample volumes of 1.0, 1.8, 5.4, 10, and 25 ml. Seven and six women contributed Foley
catheter and clean catch urine samples, respectively. Both Foley catheter and clean catch urine
collection methods yielded samples with microbial burdens exceeding those of blank DNA
extraction kits (Foley catheter, N = 4, clean catch N = 5). Letters correspond to pairwise
comparisons where p > 0.05, suggesting the microbial load in those volumes were not different
from each other. Plotted values are mean ± standard error.
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Table 4.2. Comparisons of alpha diversity of Foley catheter urine and clean catch urine
processed at 5 different volumes and blank controls.
t-test or Mann-Whitney U test
Foley catheter v Blank controls
1.0 ml
1.8 ml
5.4 ml
10 ml
25 ml
Clean catch v Blank controls
1.0 ml
1.8 ml
5.4 ml
10 ml
25 ml
Repeated-measures ANOVA
or Friedman’s ANOVA
Foley catheter
Volume
Pairwise comparisons
Clean catch
Volume
Pairwise comparisons
*Mann-Whitney U; **chi2

Chao1

Shannon

Inverse Simpson

t
0.2860
1.4256
2.0131
2.4313
1.4779
t
0.4407
0.0219
0.7251
0.2532
0.0377
F

P
0.7814
0.1877
0.0746
0.0379
0.1736
P
0.6688
0.9830
0.4850
0.8053
0.9707
P

t
1.6081
1.3154
14*
1.9453
1.4726
t
2.1093
2.2362
2.3172
2.5737
2.8564
F

P
0.1423
0.2209
0.9247
0.0836
0.1750
P
0.0611
0.0493
0.0430
0.0277
0.0171
P

t
1.5260
1.1052
0.8111
1.6474
1.5136
t
1.7277
1.7596
1.8545
2.0930
2.1924
F

P
0.1613
0.2978
0.4382
0.1339
0.1644
P
0.1147
0.1090
0.0934
0.0628
0.0531
P

1.7700

0.1998

10.45**

4.215

F
0.5478

P
0.7033

F
1.462

0.0349
All > 0.01
P
0.2600

0.0233
All > 0.01
P
0.1578

F
1.911

115
Beta Diversity: The composition (Jaccard index) and structure (Bray Curtis index) of the
bacterial profiles of all five volumes of Foley catheter and clean catch urine samples differed
from those of blank DNA extraction kit controls (Table 4.3, Table 4.4, Figure 4.2, Figure 4.3).
Subject identity, not urine sample volume, principally influenced the composition and structure
of urine bacterial profiles, regardless the method of collection (Table 4.3, Table 4.4, Figure
4.3).
Study Component 1 Outcome
Given that a sample volume of 5.4 ml was the lowest volume of urine to yield Cq values
that did not differ from those of 25 ml of urine, regardless collection method, a urine sample
volume of 5.4 ml was used in Component 2 of the study.
Study Component 2: Evaluating differences in microbial burden and 16S rRNA gene
profiles between Foley catheter and mid-stream clean catch urine in relation to those of
vaginal swabs
Patient characteristics
Table 4.1 describes the demographic and clinical characteristics of the 25 women
included in Component 2 of the study [the median and interquartile range for age were 24 (2129) years, for body mass index were 31.7 (26.3-35.8) kg/m2, for gestational age were 39.3 (3939.85) weeks, and for neonatal birthweight were 3,165 (2,892.5-3,615) grams]. Twenty-two
women were African-American, two were Caucasian, and one was self-reported as Other. Seven
women (28%) had a history of at least one lifetime UTI, and two (8%) experienced a UTI
episode earlier during this pregnancy. However, none had a UTI within 30 days of
sampling/delivery.

116
Table 4.3. Statistical analysis of bacterial community composition (Jaccard similarity
index) for Foley catheter urine and clean catch urine processed at five different volumes
and compared to blank controls.
Jaccard NPMANOVA
Foley catheter v Blank controls
1.0 ml
1.8 ml
5.4 ml
10 ml
25 ml
Clean catch v Blank controls
1.0 ml
1.8 ml
5.4 ml
10 ml
25 ml
Foley catheter
Subject (n = 4)
Volume
Clean catch
Subject (n = 5)
Volume

F

R2

P

1.0893
1.1143
1.1300
1.2040
1.1190

0.0901
0.0920
0.0932
0.0912
0.0923

0.0056
0.0046
0.0019
0.0008
0.0086

1.1223
1.1113
1.1021
1.0916
1.0863

0.0926
0.1000
0.0993
0.0903
0.0980

0.0026
0.0031
0.0041
0.0062
0.0095

1.5412
1.0023

0.2241
0.1943

0.0001
0.4393

1.7169
1.0028

0.2555
0.1492

0.0001
0.4313

Table 4.4. Statistical analysis of bacterial community structure (Bray-Curtis similarity
index) for Foley catheter urine and clean catch urine processed at five different volumes
and compared to blank controls.
Bray-Curtis NPMANOVA
Foley catheter v Blank controls
1.0 ml
1.8 ml
5.4 ml
10 ml
25 ml
Clean catch v Blank controls
1.0 ml
1.8 ml
5.4 ml
10 ml
25 ml
Foley catheter
Subject (n = 4)
Volume

F

R2

2.7119
2.5168
2.4866
3.4612
2.4820

0.1978
0.1862
0.1844
0.2239
0.1841

0.0011
0.0011
0.0009
0.0008
0.0011

2.2496
1.6062
1.6077
2.3175
1.6200

0.1698
0.1384
0.1385
0.1740
0.1394

0.0012
0.0321
0.0299
0.0020
0.0353

12.5868
1.0389

0.7004
0.0771

0.0001
0.4032

P
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Clean catch
Subject (n = 5)
Volume

27.4836
1.1295

0.8427
0.0346

0.0001
0.3222

Figure 4.2. Principal Coordinates Analysis (PCoA) plots: using A) Jaccard and B) BrayCurtis similarity indices illustrating that the composition and structure of the bacterial profiles of
all urine samples, independent of sample volume or collection method, were distinct from those
of DNA extraction kit controls. Subject identity, indicated by color, was the principal driver of
urine bacterial profiles.

Figure 4.3. Heatmap illustrating variation in the profiles of prominent OTUs (≥1% average
relative abundance) among urine samples from subjects, ordered by urine collection
method and sample volume. Urine volume had little influence on bacterial profiles, while
subject identity was the primary driver. The bacterial profiles of blank DNA extraction kits are
distinct from urine and are indicated on the left.
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Bacterial cultivation
Only three types of bacteria (Lactobacilllus species, coagulase negative Staphylococcus
species, and Ureaplasma urealyticum) were cultured from at least 20% of all urine samples.
Each was cultured less frequently from urine obtained through a Foley catheter than through
mid-stream clean catch urine (Table 4.5; Figure 4.4). On average, urine collected with a Foley
catheter yielded three less types of bacteria than paired urine samples collected through clean
catch (Poisson generalized estimating equations model; p < 0.001). Ureaplasma urealyticum was
the most frequently detected bacteria in Foley catheter urine (13/25 women).
Quantitative real-time PCR (qPCR) of 16S rRNA gene abundance in urine and vaginal swab
samples
The bacterial load of clean catch urine exceeded that of catheter urine (Figure 4.5;
Wilcoxon matched-pairs: W = 325, p < 0.0001). The relationship was the same for vaginal swabs
and catheter urine (Figure 4.5; W = 321, p < 0.0001).
16S rRNA gene profiles of paired catheter urine, clean catch urine, and vaginal swab samples
Alpha Diversity: Catheter urine, clean catch urine, and vaginal swab samples did not vary in
richness (Chao1 index; Friedman’s ANOVA: p > 0.05), but they did vary in heterogeneity based
on Shannon (Chi2 = 7.28, p = 0.027) and Inverse Simpson (Chi2 = 7.44, p = 0.025) indices
(Figure 4.6A & B). The bacterial profiles of Foley catheter and clean catch urine were more
heterogeneous than those of vaginal swabs (Wilcoxon matched pairs with Bonferroni corrections
applied: Foley catheter, Shannon index: W = 266, p = 0.0054, Inverse Simpson index: W = 257,
p = 0.011; clean catch, Shannon index: W = 277, p = 0.0021, Inverse Simpson index: W = 253, p
= 0.015). The heterogeneity of catheter and clean catch urine bacterial profiles did not differ (p >
0.05).
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Table 4.5. Odds ratios of detecting bacterial phylotypes through culture in urine obtained
from a Foley catheter compared to urine collected through the mid-stream clean catch
method.
Bacterial phylotype
identified by MALDI-TOF

Odds
Ratio

p

q

Lactobacilllus species
Coagulase negative Staphylococcus species
Ureaplasma urealyticum

0.11
0.03
0.34

0.000
0.000
0.007

0.000
0.000
0.007

Figure 4.4. Urine bacterial cultivation results indicating differential recovery of bacterial
phylotypes from catheter urine, clean catch urine, or both. Subject identity is indicated by
color. In all but two occurrences, Staphylococcus species recovered were coagulase negative, the
exception being S. aureus recovered in both urine samples of one patient and the clean catch
urine of the other patient.

120

Figure 4.5. Quantitative real-time PCR (qPCR) of the 16S rRNA gene results from Foley
catheter urine, clean catch urine, and vaginal swabs. 25 women contributed paired Foley
catheter urine, clean catch urine, and vaginal swab samples. Color represents subject identity,
Cycle of quantification (Cq) values were averaged over multiple runs.
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Figure 4.6. Jitter and Principal Coordinates Analysis (PCoA) plots illustrating alpha and
beta diversities of Foley catheter urine, clean catch urine, and vaginal swabs collected from
the same women. Panels A and B show differences in heterogeneity between sample types, with
catheter urine having the greatest diversity for both indices. Panels C and D illustrate the
composition and structure of the bacterial profiles of the three sample types. Several subjects are
highlighted to illustrate the influence of individual identity on the bacterial profiles. Subject
identity is indicated by the same color scheme across the 4 panels.
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Beta Diversity: Overall, subject identity was the principal driver of the composition and structure
of the bacterial profiles of Foley catheter urine, clean catch urine, and vaginal swabs (Table 4.6,
Table 4.7, Figure 4.6C & D, Figure 4.7). Nevertheless, controlled for subject identity, the
composition of the three sample types differed from one another (Table 4.6, Figure 4.6C). With
respect to structure, the bacterial profiles of catheter urine differed from those of clean catch
urine and vaginal swabs, but the profiles of clean catch urine did not differ from the profiles of
their paired vaginal swabs (Table 4.7, Figure 4.6D).
SourceTracker analyses: SourceTracker analysis found there was a greater contribution of OTUs
explained by vaginal swabs in clean catch urine than in catheter urine (Figure 4.8; Wilcoxon
paired test: W = 279, p < 0.001).
Bacterial profiles in detail: The bacterial profiles of catheter urine, clean catch urine, and vaginal
swabs were dominated by Lactobacillus and Gardnerella (Figure 4.7). BLAST analyses
indicated that OTUs 1 and 2 were Lactobacillus iners and Gardnerella vaginalis, respectively.
OTUs 3, 5, and 12 were each identified as multiple species of Lactobacillus. OTU 3 was
identified as Lactobacillus crispatus (most likely [48, 68, 115, 118, 133, 169]), acidophilus, or
gallinarum, OTU 5 was identified as Lactobacillus jensenii (most likely [48, 68, 115, 118, 133,
169]) or fornicalis, and OTU 12 was identified as Lactobacillus gasseri (most likely [48, 68,
115, 118, 133, 169]) or johnsonii. Thus, consistent with prior observations [50, 51, 68, 133, 227],
the urogenital bacterial profiles of pregnant women were largely comprised of three community
state types: 1) dominance by Lactobacillus crispatus; 2) dominance by Lactobacillus iners; or, 3)
co-dominance by Lactobacillus iners and Gardnerella vaginalis. Both Lactobacillus and
Gardnerella were rarely detected in the cultivation surveys of urine, suggesting their molecular
signals may have been due to contamination, although both genera often require specialized
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Table 4.6. Statistical analysis of bacterial community composition (Jaccard similarity
index) for Foley catheter urine, clean catch urine, and vaginal swabs.
Jaccard NPMANOVA

F

R2

P

Foley Catheter v Clean Catch v Vaginal Swab
Subject (n = 25)

1.02349

0.32957

0.0019

Sample Type

0.98388

0.02640

0.7941

1.0515

0.02144

0.0022

1.1345

0.02309

0.0014

1.1306

0.02301

0.0027

Foley Catheter v Clean Catch
Sample Type within subject
Clean Catch v Vaginal Swab
Sample Type within subject
Foley Catheter v Vaginal Swab
Sample Type within subject

Table 4.7. Statistical analysis of community structure (Bray-Curtis similarity index) for
Foley catheter urine, clean catch urine, and vaginal swabs.
Bray-Curtis NPMANOVA

F

R2

P

Foley Catheter v Clean Catch v Vaginal Swab
Subject (n = 25)

1.55064

0.42797

0.0002

Sample Type

0.87084

0.02003

0.6228

0.88327

0.01807

0.0222

0.92679

0.01894

0.4834

1.9757

0.03953

0.0460

Foley Catheter v Clean Catch
Sample Type within subject
Clean Catch v Vaginal Swab
Sample Type within subject
Foley Catheter v Vaginal Swab
Sample Type within subject
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Figure 4.7. Heatmap illustrating variation in the profiles of prominent OTUs (≥1% average
relative abundance) among paired Foley catheter urine, clean catch urine, and vaginal
swab samples from 25 pregnant subjects. The order was determined by hierarchical clustering
of Bray-Curtis similarity indices of clean catch samples. Bars along the bottom horizontal axis
mark the catheter sample of each patient.

Figure 4.8. SourceTracker analysis comparing the percentage of OTUs explained by
vaginal swabs among Foley catheter urine and clean catch urine. Colors represent subject
identity.
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media even when recovering them from pure culture. Besides Lactobacillus and Gardnerella,
the bacterial profiles of catheter urine also variably contained a high relative abundance (at least
one sample with >50% relative abundance) of 5 additional OTUs: an unclassified
Mycoplasmataceae (OTU7), Escherichia (OTU 9), Buttiauxella (OTU 9), Streptococcus (OTU
10), and Veillonella (OTU 13). Notably, 5 additional OTUs, not previously discussed, were
detected in at least 12 catheter urine samples and had a relative abundance of ≥ 10% in at least
one sample. These OTUs included an unclassified Coriobacteriaceae (OTU 11), Staphylococcus
(OTU 17), Finegoldia (OTU 19), Ureaplasma (OTU 26), and Peptoniphilus (OTU 27).
LEfSe analysis: Linear discriminant analysis effect size (LEfSe) analyses identified eight OTUs
that were consistently more abundant in controls than any of the biological sample types,
suggesting these OTUs are likely contaminants (Figure 4.9). These OTUs were identified as
Escherichia (OTU 9), Staphylococcus (OTU 17), Pelomonas (OTU 53), Massilia (OTU 86),
Haemophilus (OTU 90), Virgibacillus (OTU 102), Acinetobacter (OTU 107), Cloacibacterium
(OTU 329). Analyses comparing catheter urine to vaginal swabs identified 17 OTUs more
relatively abundant in catheter urine (Figure 4.10). While this analysis did not control for patient
identity, four of these seventeen OTUs were also more relatively abundant in catheter urine than
negative controls (Figure 4.10, highlighted in blue). These included Finegoldia (OTU 19),
Ureaplasma (OTU 26), Anaerococcus (OTU 49), and an unclassified Clostridiales [OTU 43
(BLAST query identified it as Fenollaria massiliensis)].
After identifying these four OTUs as potentially indicative as members of a bladder
microbiota (i.e. more relatively abundant in catheter urine than in controls, and possibly more
than vaginal samples as well), their abundances in catheter urine and vaginal swabs were
compared directly through paired testing. All four OTUs were more abundant in catheter urine
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Figure 4.9. Linear discriminant analysis Effect Size analyses identified several bacteria that
were more relatively abundant in blank extraction kits. Analyses of 16S rRNA gene
sequence datasets from DNA extraction compared to each sample type. OTUs highlighted in red
were more relatively abundant in extractions kits than in all 3 biological samples suggesting
them as likely contaminant sequences.
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Figure 4.10. Linear discriminant analysis Effect Size analyses identified several bacteria
that were more relatively abundant in Foley catheter urine over vaginal samples,
suggesting they are members of a urine and bladder microbiota. Analyses of sequence
datasets from Foley catheter urine with DNA extraction kits, clean catch urine, and vaginal
swabs. Highlighted in blue are taxa identified as being more relatively abundant in catheter urine
than in both extraction kit controls and vaginal swabs.
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than vaginal swabs with sequential Bonferroni corrections applied (Wilcoxon matched pairs:
OTU 19, W = 152, p = 0.02; OTU 26, W = 134, p = 0.006; OTU 43, W = 69, p = 0.019; OTU
49, W = 74, p = 0.046). Notably, vaginal swab samples did not have any OTUs that were more
relatively abundant than they were in Foley catheter urine samples, which can be explained
because the vaginal samples were less diverse overall – they were dominated by a few OTUs,
accounting for over 90% of the average OTU abundance, and these OTUs were also identified in
the urine samples (OTU 1 Lactobacillus, OTU 2 Gardnerella, OTU 3 Lactobacillus, OTU 4
unclassified Lachnospiraceae, OTU 5 Lactobacillus, and OTU 16 Bifidobacterium).
V. Discussion
Principal findings of the study
(1) Quantitative real-time PCR showed that the bacterial load of urine exceeded technical
controls regardless of the urine collection method (Foley catheter or clean catch) or the volume
of urine processed; (2) A urine volume of 5.4 ml was the lowest to yield a similar 16S rRNA
gene load and profile as 25 ml of urine, which was the largest urine volume we investigated; (3)
Via cultivation, three isolates were detected in at least 20% of all samples (Lactobacilllus
species, Staphylococcus species coagulase negative, and Ureaplasma urealyticum) and all three
were detected less frequently in catheter than clean catch urine; (4) An average of three less
isolates were recovered from catheter urine clean catch urine; (5) Molecular sequencing
techniques showed that the bacterial profiles of clean catch urine were more similar to vaginal
swabs than catheter urine, suggesting a greater influence of vulvovaginal contamination on clean
catch samples; (6) Lactobacillus iners, L. crispatus, and Gardnerella vaginalis were the most
relatively abundant bacteria among all 3 sample types; (7) Ureaplasma (detected in culture and
molecular surveys) and multiple Gram-positive species including elusive Gram-positive
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anaerobic cocci (GPAC) such as Finegoldia and Anaerococcus were more relatively abundant in
in catheter urine than clean catch urine or vaginal swabs.
Overall, our study suggests that resident bacterial communities exist in the bladder and
urine of pregnant women, and that while there is overlap with the vaginal microbiota, there are
also distinct lower abundance taxa in the bladder.
Urinary Tract Infections (UTIs) and Pregnancy
Approximately 10% of women report having at least one episode of UTI in the previous
12 months and the lifetime probability of a woman having at least one UTI event is around 60%
[230, 260-262]. Among women with culture-confirmed UTIs, around 28% had recurrence within
six months [230, 263]. The bacterium most responsible for UTIs is Escherichia coli, followed by
Staphylococcus saprophyticus, Streptococcus agalactiae, and Klebsiella and Enterococcus
species [158, 233, 244, 249]. The occurrence of a UTI during pregnancy is associated with
significant odds ratios of 1.4 for low birth weight, 1.3 for preterm birth (< 37 weeks), 1.4 for
maternal hypertension and preeclampsia, 1.6 for maternal anemia (hematocrit less than 30%),
and 1.4 for chorioamnionitis [157, 158]. The risk of occurrence of these complications is higher
among patients with pyelonephritis [158, 264]. Acute pyelonephritis occurs in 2% of pregnant
women and recurs in 33% of them [134, 158].
In 2017, a European interdisciplinary group consisting of 17 representatives of 12
medical societies was formed to update the diagnosis and management of uncomplicated UTIs in
non-pregnant premenopausal women and concluded that the diagnosis of uncomplicated cystitis
be based on clinical criteria evaluating the symptoms of the patient and the course of the disease
[265]. They also recommended that no microbiological examination is needed in asymptomatic
non-pregnant patients [265]. In pregnancy, asymptomatic bacteriuria is to be detected and treated

130
because of the potential serious complications, including pyelonephritis in 30-40 % of the cases
[249]. The American college of Obstetricians and Gynecologists (ACOG) and other societies
recommend urine culture as one of the routine tests to be obtained early in pregnancy [266, 267],
with mid-stream clean catch being the most common collection approach. If mid-stream clean
catch urine culture is performed, the detection of Escherichia coli is predictive of bacterial UTI
while the detection of other bacteria such as enterococci and group B streptococci is not
predictive [265]. Negative urine dipsticks and urine microscopy are useful to rule out the
likelihood of presence of UTI in asymptomatic non-pregnant women [265]. Urine culture is
useful if only one type of bacteria was cultivated [265].
Vulvovaginal contamination of urine samples
Prior culture-based studies concluded that clean catch urine samples obtained from
female patients have poor ability to detect UTI because of contamination from the skin and
vaginal microbiota [268-270]. A study of 113 asymptomatic pregnant women showed a high
level of contamination in clean catch samples [268]. Baerheim et al. [269] found that employing
precautions such as cleaning the perineum or obtaining mid-stream samples led to similar
contamination rates as obtaining samples without any precautions [269]. Lifshitz et al. [270]
evaluated 242 symptomatic female patients divided into 3 groups 1) no cleaning, 2) perineal
cleaning and midstream sampling, and 3) perineal cleaning, midstream sampling and vaginal
tampon. Contamination rates in the three groups were all similar at approximately 30% [270].
In women undergoing cesarean deliveries, two randomized clinical trials showed an
increase in the incidence of UTIs in the indwelling bladder catheterization group compared to the
no catheterization group [271-273]. Mid-stream clean catch remains a more convenient approach
for patients and health care staff; however, culture results of clean catch samples need careful
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interpretation since around 30 percent of clean catch samples showed contamination in previous
studies [268-270]. Our cultivation studies confirmed that Foley catheter samples yield less
cultivars than clean catch samples and are less likely to be contaminated by vaginal microbiota
than are clean catch samples.
In the context of next-generation sequencing, it is important that: 1) vulvovaginal
contamination be limited during urine sample collection; 2) collected urine specimens be
promptly frozen to mitigate growth and replication of acquired contaminants; 3) a sufficient
volume of urine is collected for effective DNA extraction; and 4) that background technical
controls be included to account for potential DNA contamination.
5.4 ml of urine is an appropriate volume for 16S rRNA sequencing
Previous urine microbiota studies have utilized different sample volumes of urine for 16S
rRNA gene analysis [69, 114, 117, 118, 226, 227]. Component 1 of our study showed that a
volume of 5.4 ml represents an appropriate volume for molecular survey analysis. While a
bacterial signal was obtained from all volumes (1, 1.8, 5.4, 10 and 25 ml), there were higher
bacterial loads detected (lower Cq) in the 5.4, 10.0, and 25.0 ml groups compared to the 1.0 and
1.8 ml groups. There was no statistical significance between 5.4 ml and either the 10.0 or 25.0 ml
groups. These results show that 5.4 ml urine volume yields an appropriate quantity of DNA for
16S rRNA gene sequencing and that the DNA yield would not substantively change with a
greater volume of urine processed (at least up to 25 ml). Clean catch urine samples consistently
had a greater bacterial load than catheter urine samples indicating that the biological source of
the sample (clean catch versus Foley catheter) has a greater influence on bacterial load than the
volume of the sample.
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Both urine collection methods resulted in bacterial profiles that were significantly
different than controls regardless of the urine volume processed. While urine samples primarily
exhibited dominance of 2 to 3 OTUs, controls showed a more even spread between various
OTUs including common contaminants such as Escherichia, Streptococcus and Staphylococcus.
Our results suggest that a bladder microbiota exists during pregnancy
For Study Component 2, while individual identity was the primary influence on 16S
rRNA gene profiles, differences were found for both beta diversity indices (i.e. Jaccard and Bray
Curtis) between the three sample types: catheter urine, clean catch urine, and vaginal swabs.
Pairwise comparisons showed that the bacterial profiles of catheter urine were different than
those of both clean catch urine and vaginal swabs in composition and structure, whereas the
profiles of clean catch urine were different from vaginal swabs only in structure. This suggests
that urine collected via the clean catch method has a bacterial profile more similar to that of the
vagina due to proximity and increased likelihood of vulvovaginal contamination. In this way,
clean catch urine likely represents a dynamic mix of members of the skin and vaginal microbial
communities in addition to those of a resident bladder microbial community. Whilst urine
collected via a catheter is still likely subject to some degree of vulvovaginal contamination, our
data suggest a microbial community in the bladder is distinct in several lesser abundant
microbes.
LEfSe analyses identified seven OTUs that were more relatively abundant in Foley
catheter urine than in blank extraction controls, and four of these OTUs were also more relatively
abundant in catheter urine than in vaginal swab samples, suggesting that these OTUs may be
representative of members of the bladder microbiota, at least in some women. While only
Ureaplasma was recovered from cultivation surveys, Finegoldia and Anaerococcus species are
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Gram-positive anaerobic cocci recalcitrant to culture, typically requiring long incubation times
and complex growth requirements [274]. This may explain why they were not recovered in
culture. Other groups investigating urine via molecular surveys have also identified Finegoldia
and Anaerococcus species in non-pregnant females, in healthy cohorts as well as among women
with non-UTI urinary disorders [48, 67, 116, 118, 153, 275]. The fourth OTU, while originally
described as an unclassified Clostridiales, was a 100% sequence match to the newly identified
genus and species Fenollaria massiliensis gen. nov., sp. nov [276, 277]. Its relatively recent
discovery may explain why it was not detected by culture as most clinical microbiology
laboratories are likely unfamiliar with this organism. This microorganism is discussed in more
detail below.
Ureaplasma species, like other members of the class Mollicutes, lack a cell wall, require
specialized media, and can require long incubation times [248, 278]. Ureaplasma is welldocumented in its association with diseases of the urinary tract [48, 63, 64, 67, 278, 279] as well
as adverse pregnancy outcomes, including preterm birth [49, 140, 280-283] and diseases of the
neonate [284-287]. In fact, it is the most common microorganism found in the amniotic cavity
[140, 288]. Despite its associations with disease, Ureaplasma is frequently detected by culture
and molecular surveys in urine of asymptomatic women, pregnant [65, 137, 156, 169, 246, 248]
and non-pregnant [48, 67, 68, 116], suggesting its potential role in a bladder microbiota. The
various consequences associated with the presence of Ureaplasma in the bladder of pregnant
women is likely multifactorial, of which adverse outcomes are likely associated with a
combination of the individual’s own immune response [289], the composition and structure of
the broader microbial community [69, 171], and the specific strain of Ureaplasma [290-293].
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Finegoldia has been associated with the genitourinary tract, gastrointestinal tract, and
skin as a commensal but has also been isolated from and attributed to infections from wounds
and various body sites making it an opportunistic pathogen. Difficulty in cultivation has been
evident in clinical reports where accurate diagnoses were dependent on detection via PCR
despite cultures yielding negative results [294-296].
Anaerococcus species are also commensals of the skin, gastrointestinal tract, and oral
cavity and members have been isolated from vaginal secretions and purulent wounds [274, 297,
298]. Literature reports successful growth of Anaerococcus species on standard anaerobic plate
types [299, 300] by some groups, while others indicate the addition of supplemental nutrients
such as hemin and vitamin K [274, 299-302]. Reported incubation times have also varied from 2
days up to 7 days [300, 302].
Fenollaria massiliensis is a newly discovered and understudied anaerobic rod recovered
and characterized from osteoarticular, genital, and tissue samples, and is suggested to be a
genital-associated microbe [276, 277]. The two studies describing this organism report growth on
several enriched media types after 72 hours and on supplemented Brucella Blood Agar after 48
hours under anaerobic conditions.
Our study showed that catheter urine samples do yield a 16S rRNA gene signal beyond
that evident in controls and suggest catheterization may be an appropriate sampling method for
evaluating any microbial communities that may exist in the bladder. Also, our results suggest
that the vaginal microbiota influences or contaminates clean catch urine to a larger degree than
catheter urine, and that while some catheter samples are still influenced by vaginal microbes, a
potentially unique signal may exist in some individuals. Our evidence suggests that underlying
Lactobacillus and Gardnerella abundance in the urine of pregnant women, anaerobic organisms
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like Finegoldia, Anaerococcus, and Peptoniphilus may be low abundant members of a bladder
microbial community. However, to more confidently assert that the bladder contains microbiota
in pregnancy, a suprapubic sampling approach would provide better insight. We suspect that the
gold standard for investigating a potential bladder microbiota would be suprapubic aspiration of
urine in concert with tissue sampling of the bladder epithelium. Culture should be performed to
discriminate live bacteria from remnant DNA from dead bacteria.
Strengths and limitations
This is the first extensive study that attempts to characterize the urinary microbiota in
pregnancy by comparing Foley catheter, clean catch, and vaginal samples from 25 women. In
addition, this is the first study that compared different volumes of urine to determine the optimal
volume for performing 16S rRNA gene surveys. Furthermore, this study utilized cultivation,
qPCR, and sequencing approaches to study the existence and viability of microbiota in the
bladder. The main limitation of the study is that our population mainly consists of one ethnic
group (i.e. African American). It is possible that other ethnic groups may have a different bladder
microbiota. Non-pregnant women were not included in this study, therefore differences and
similarities between a healthy female bladder microbiota and a pregnant female bladder
microbiota cannot be addressed. Additionally, is difficult to assess if and how much of the
bacterial signal in catheter urine was due to vulvovaginal contamination, specifically regarding
the top 3 most abundant taxa. More extensive culture methods may have allowed the lower
abundance anaerobic organisms to be recovered.
Conclusions
Our study suggests that resident bacterial communities exist in the bladder and urine, and
that there is overlap with the vaginal microbiota. While the most frequent microorganisms
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recovered by Foley catheter samples were Ureaplasma, molecular surveys identified low
abundance anaerobic bacteria in addition to Ureaplasma as potential members of a bladder
microbiota.
Future directions
Future research should endeavor to evaluate the typical presence of a microbial
community within the urinary tract of pregnant women by comparing and analyzing 16S rRNA
gene sequence data from pregnant women delivering preterm (condition; defined as delivering ≤
37 weeks) and at term (biological control; defined as delivering > 37 weeks) and the appropriate
technical controls. In doing so, we can assess influences of resident microbiota on perinatal
health and pregnancy outcomes and identify bacteria or bacterial communities whose presence or
absence can serve as potential risk indicators. Ultimately, being able categorize and describe
bladder microbial communities and their associations with preterm birth should lead to potential
targets, therapeutic interventions, and other methods for treating or modifying the bladder
microbiota and lessening the impact of urinary tract-associated pregnancy complications.
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CHAPTER 5: GENERAL CONCLUSIONS
Contemporary sequencing technologies have allowed for the examination, in some cases
re-examination, and deep characterization of microorganisms in a multitude of environments,
from the seemingly inhospitable (e.g., deep sea hydrothermal vents and Antarctic permafrost) to
the clearly hospitable and heavily populated (e.g., sea water and the human gut). The use of 16S
rRNA gene and metagenomic sequencing has become so widespread that it would be difficult to
enumerate the amount of exploratory studies that have relied on these technologies or to find an
environment whose microbiota and/or microbiome has not yet been at least preliminarily
characterized. Indeed, many have begun reexamining classic paradigms of sterility surrounding
various anatomical sites of the human body. Researchers have been investigating environments
of progressively lower microbial biomass to the point where these investigations have reached
the limits of detection for these molecular surveys [98, 103, 104, 119]. Numerous studies have
now been published that fail to address and/or account for the limitations of sequencing
technologies and this has shaped the various controversies laid out in this document, especially
with respect to the existence of a placental and/or bladder microbiome.
In the context of the placenta, by pushing molecular techniques to their limits, premature
conclusions have likely been drawn regarding the existence of a placental microbiome [44, 84,
95, 110-113]. If widely accepted, these conclusions have the potential to influence how clinicians
perceive the microbiology of the placenta and the intra-amniotic environment and to alter current
understanding of microbial invasion of the amniotic cavity and its effect on pregnancy outcomes
[129, 136, 140, 143, 217, 303-307]. Our investigations of low microbial biomass sites address
and account for the limitations of current molecular technologies through the inclusion of
multiple microbiologic methodologies and extensive background technical controls.
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We first investigated the human placenta and found no evidence to support the existence
of a placental microbiome. We then extended our investigations to a mouse model. The value of
a mouse model is that more than just the placenta can be sampled and interrogated for the
existence of a microbiome – samples can be collected from the placenta, the fetus, and sites of
the mother that are both typically colonized or presumed sterile. Again, we found no evidence of
a placental microbiome, and further we found no evidence for in utero colonization of the fetus.
Our results from our human and mouse model studies are largely congruent with the results of
other recent studies [128, 167, 213, 225]: when appropriate measures are taken to address the
caveats associated with investigations of low microbial biomass sites and the limitations of
current technologies, there is no consistent evidence for a placental microbiome or in utero
colonization of the fetus.
Alternatively, our investigations of the potential existence of a bladder microbiome,
which also addressed and accounted for the limitations of current molecular technologies through
the inclusion of multiple microbiologic methodologies and extensive background technical
controls, revealed that the bladder is not likely a sterile organ. By following a similar study
design to our human placental work [150], we successfully cultured bacteria from the bladders of
pregnant women and detected molecular signals in the bladders through qPCR and 16S rRNA
gene surveys that exceeded those of background technical controls. Additionally, by accounting
for the possible influence of vulvovaginal contamination on the microbial profiles of urine
samples, we were able to identify low abundance bacteria that are likely members of a bladder
microbiota during pregnancy. Ureaplasma (detected through both culture and molecular surveys)
and multiple Gram-positive anaerobic cocci (detected in molecular surveys, e.g Finegoldia and
Anaerococcus), despite being present in low abundances, were identified as distinct features of
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catheterized urine over clean catch urine and vaginal swabs. Despite the negative impacts
Ureaplasma can have on pregnancy outcome in some women, it is regularly detected in the
bladder and vagina of women that are asymptomatic [48, 248, 275], suggesting that while under
some circumstances it may cause disease, it may also be a common commensal member of the
microbial communities of these body sites. Although prior studies characterizing a bladder
microbiome have not emphasized Ureaplasma, it is present at only low relative abundances in
molecular surveys and may therefore be overlooked and it requires specific growth media which
are typically not included in cultivation efforts of urine [115, 118]. Our research presented here
provides a unique opportunity for future studies investigating Ureaplasma in the context of the
bladder microbiome, as well elucidating potential genetic differences that may contribute to its
being a commensal or a pathogen. The Gram-positive anaerobic cocci detected in our study are
often detected in the bladder microbiome studies of others [48, 115, 118, 227, 275]. However,
they are infrequently recovered in culture [118]. This is likely due to their fastidious growth
requirements and long incubation periods [248, 274, 294]. These Gram-positive anaerobic cocci
also present a unique opportunity for future investigations of their potential contributions to a
bladder microbiome. Ultimately, efforts to identify and characterize the specific bacteria that are
most closely associated with the uro-epithelium, such as intracellular or biofilm-producing
bacteria,

are necessary for developing

a

complete understanding of the

bladder

microenvironment and its potential role in human health and disease.
It is important to appreciate contemporary sequencing technologies for their facilitating
our ability to characterize the microbial communities in all environments, including the human
body. However, when seeking to overturn paradigms of sterility, we must employ multiple
microbiologic methodologies and address and account for background DNA contamination. The
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burden of proof for overturning longstanding paradigms of sterility is high; there must be clear
and consistent evidence for the existence of a microbiome across multiple microbiologic
methodologies and the signal of this microbiome must exceed that of controls and rise above the
limits of detection of the different methodologies employed.

141

REFERENCES
1.

Williams, D.W., The Germ-Theory. British medical journal, 1871. 1(536): p. 368-368.

2.

Lippi, D., Gotuzzo, E., and Caini, S., Cholera. Microbiol Spectr, 2016. 4(4).

3.

Pitt, D. and Aubin, J.-M., Joseph Lister: father of modern surgery. Canadian journal of
surgery. Journal canadien de chirurgie, 2012. 55(5): p. E8-E9.

4.

Sanders, E.R., Aseptic laboratory techniques: plating methods. J Vis Exp, 2012(63): p.
e3064.

5.

Link, T., Guideline Implementation: Sterile Technique. Aorn j, 2019. 110(4): p. 415-425.

6.

Hart, S., Using an aseptic technique to reduce the risk of infection. Nursing Standard
(through 2013), 2007. 21(47): p. 43-8.

7.

Overhauling Aseptic Technique. British Medical Journal, 1941. 1(4180): p. 246-247.

8.

Pennington, T.H., Listerism, its decline and its persistence: the introduction of aseptic
surgical techniques in three British teaching hospitals, 1890-99. Medical history, 1995.
39(1): p. 35-60.

9.

Bykowski, T. and Stevenson, B., Aseptic Technique. Curr Protoc Microbiol, 2020. 56(1):
p. e98.

10.

Coté, R.J., Aseptic technique for cell culture. Curr Protoc Cell Biol, 2001. Chapter 1: p.
Unit 1.3.

11.

Copley, J., All at sea. Nature, 2002. 415(6872): p. 572-574.

12.

Microbiology by numbers. Nature Reviews Microbiology, 2011. 9(9): p. 628-628.

13.

Louca, S., et al., A census-based estimate of Earth's bacterial and archaeal diversity.
PLoS Biol, 2019. 17(2): p. e3000106.

142
14.

Prosser, J.I., et al., The role of ecological theory in microbial ecology. Nat Rev
Microbiol, 2007. 5(5): p. 384-92.

15.

Troussellier, M. and Legendre, P., A functional evenness index for microbial ecology.
Microb Ecol, 1981. 7(4): p. 283-96.

16.

Marchesi, J.R. and Ravel, J., The vocabulary of microbiome research: a proposal.
Microbiome, 2015. 3(1): p. 31.

17.

Jannasch, H.W. and Mottl, M.J., Geomicrobiology of Deep-Sea Hydrothermal Vents.
Science, 1985. 229(4715): p. 717-725.

18.

Mason, O.U., et al., First Investigation of the Microbiology of the Deepest Layer of
Ocean Crust. PLoS One, 2010. 5(11): p. e15399.

19.

Kuang, J.-L., et al., Contemporary environmental variation determines microbial
diversity patterns in acid mine drainage. The ISME Journal, 2013. 7(5): p. 1038-1050.

20.

Suzuki, S., et al., Physiological and genomic features of highly alkaliphilic hydrogenutilizing

Betaproteobacteria

from

a

continental

serpentinizing

site.

Nature

Communications, 2014. 5(1): p. 3900.
21.

Sender, R., Fuchs, S., and Milo, R., Revised Estimates for the Number of Human and
Bacteria Cells in the Body. PLoS Biol, 2016. 14(8): p. e1002533.

22.

Roser, M., Ritchie, H., and Ortiz-Ospina, E. World Population Growth. 2013; Available
from: https://ourworldindata.org/world-population-growth.

23.

Qin, J., et al., A human gut microbial gene catalogue established by metagenomic
sequencing. Nature, 2010. 464.

24.

Snyder, W., et al., Introduction. Annals of the ICRP/ICRP Publication, 1975. OS_23(1):
p. i-xix.

143
25.

Sender, R., Fuchs, S., and Milo, R., Are We Really Vastly Outnumbered? Revisiting the
Ratio of Bacterial to Host Cells in Humans. Cell, 2016. 164(3): p. 337-340.

26.

Laupland, K.B. and Valiquette, L., The changing culture of the microbiology laboratory.
Can J Infect Dis Med Microbiol, 2013. 24(3): p. 125-8.

27.

Didelot, X., et al., Transforming clinical microbiology with bacterial genome sequencing.
Nat Rev Genet, 2012. 13(9): p. 601-12.

28.

Hamady, M. and Knight, R., Microbial community profiling for human microbiome
projects: Tools, techniques, and challenges. Genome Res, 2009. 19(7): p. 1141-52.

29.

Hiergeist, A., et al., Analyses of Intestinal Microbiota: Culture versus Sequencing. ILAR
J, 2015. 56(2): p. 228-40.

30.

Human Microbiome Project, C., A framework for human microbiome research. Nature,
2012. 486(7402): p. 215-21.

31.

Knight, R., et al., The Microbiome and Human Biology. Annu Rev Genomics Hum
Genet, 2017.

32.

Kell, D.B., et al., Viability and activity in readily culturable bacteria: a review and
discussion of the practical issues. Antonie Van Leeuwenhoek, 1998. 73(2): p. 169-87.

33.

Greub, G., Culturomics: a new approach to study the human microbiome. Clin Microbiol
Infect, 2012. 18(12): p. 1157-9.

34.

Browne, H.P., et al., Culturing of 'unculturable' human microbiota reveals novel taxa and
extensive sporulation. Nature, 2016. 533(7604): p. 543-6.

35.

Stewart, E.J., Growing unculturable bacteria. J Bacteriol, 2012. 194(16): p. 4151-60.

36.

Vartoukian, S.R., Palmer, R.M., and Wade, W.G., Strategies for culture of 'unculturable'
bacteria. FEMS Microbiol Lett, 2010. 309(1): p. 1-7.

144
37.

Spiegelman, D., Whissell, G., and Greer, C.W., A survey of the methods for the
characterization of microbial consortia and communities. Can J Microbiol, 2005. 51(5):
p. 355-86.

38.

Rhoads, D.D., et al., Comparison of culture and molecular identification of bacteria in
chronic wounds. Int J Mol Sci, 2012. 13(3): p. 2535-50.

39.

Rhoads, D.D., et al., Clinical identification of bacteria in human chronic wound
infections: culturing vs. 16S ribosomal DNA sequencing. BMC Infect Dis, 2012. 12: p.
321.

40.

Larsen, M.K., et al., Use of cultivation-dependent and -independent techniques to assess
contamination of central venous catheters: a pilot study. BMC Clin Pathol, 2008. 8: p.
10.

41.

Schloss, P.D., et al., Introducing mothur: open-source, platform-independent,
community-supported software for describing and comparing microbial communities.
Appl Environ Microbiol, 2009. 75(23): p. 7537-41.

42.

NIH HMP Working Group, et al., The NIH Human Microbiome Project. Genome Res,
2009. 19(12): p. 2317-23.

43.

Ding, T. and Schloss, P.D., Dynamics and associations of microbial community types
across the human body. Nature, 2014. 509(7500): p. 357-60.

44.

Aagaard, K., et al., The placenta harbors a unique microbiome. Science Translational
Medicine, 2014. 6(237): p. 237ra65.

45.

Antony, K.M., et al., The preterm placental microbiome varies in association with excess
maternal gestational weight gain. Am J Obstet Gynecol, 2015. 212(5): p. 653 e1-16.

145
46.

Arrieta, M.C., et al., The intestinal microbiome in early life: health and disease. Front
Immunol, 2014. 5: p. 427.

47.

Chu, D.M., et al., Maturation of the infant microbiome community structure and function
across multiple body sites and in relation to mode of delivery. Nat Med, 2017. 23(3): p.
314-326.

48.

Pearce, M.M., et al., The female urinary microbiome: a comparison of women with and
without urgency urinary incontinence. MBio, 2014. 5(4): p. e01283-14.

49.

Prince, A.L., et al., The placental membrane microbiome is altered among subjects with
spontaneous preterm birth with and without chorioamnionitis. Am J Obstet Gynecol,
2016. 214(5): p. 627.e1-627.e16.

50.

Romero, R., et al., The vaginal microbiota of pregnant women who subsequently have
spontaneous preterm labor and delivery and those with a normal delivery at term.
Microbiome, 2014. 2: p. 18.

51.

Romero, R., et al., The composition and stability of the vaginal microbiota of normal
pregnant women is different from that of non-pregnant women. Microbiome, 2014. 2(1):
p. 4.

52.

Turnbaugh, P.J., et al., A core gut microbiome in obese and lean twins. Nature, 2009.
457(7228): p. 480-4.

53.

Turnbaugh, P.J., et al., An obesity-associated gut microbiome with increased capacity for
energy harvest. Nature, 2006. 444(7122): p. 1027-31.

54.

Kassam, Z., et al., Fecal microbiota transplantation for Clostridium difficile infection:
systematic review and meta-analysis. Am J Gastroenterol, 2013. 108.

146
55.

Mallozzi, M., Viswanathan, V.K., and Vedantam, G., Spore-forming Bacilli and
Clostridia in human disease. Future Microbiology, 2010. 5(7): p. 1109-1123.

56.

Nood, E., et al., Duodenal infusion of donor feces for recurrent Clostridium difficile. N
Engl J Med, 2013. 368.

57.

Wu, X., et al., Molecular Characterisation of the Faecal Microbiota in Patients with
Type II Diabetes. Current Microbiology, 2010. 61(1): p. 69-78.

58.

Larsen, N., et al., Gut Microbiota in Human Adults with Type 2 Diabetes Differs from
Non-Diabetic Adults. PLoS One, 2010. 5(2): p. e9085.

59.

Furet, J.-P., et al., Differential Adaptation of Human Gut Microbiota to Bariatric
Surgery–Induced Weight Loss. Links With Metabolic and Low-Grade Inflammation
Markers, 2010. 59(12): p. 3049-3057.

60.

Dashper, S.G., et al., Temporal development of the oral microbiome and prediction of
early childhood caries. Scientific Reports, 2019. 9(1): p. 19732.

61.

Baker, J.L. and Edlund, A., Exploiting the Oral Microbiome to Prevent Tooth Decay:
Has Evolution Already Provided the Best Tools? Frontiers in microbiology, 2019. 9: p.
3323-3323.

62.

Hurley, E., et al., Comparison of the salivary and dentinal microbiome of children with
severe-early childhood caries to the salivary microbiome of caries-free children. BMC
Oral Health, 2019. 19(1): p. 13.

63.

Brubaker, L., et al., Urinary bacteria in adult women with urgency urinary incontinence.
Int Urogynecol J, 2014. 25(9): p. 1179-84.

64.

Brubaker, L. and Wolfe, A.J., The female urinary microbiota, urinary health and
common urinary disorders. Ann Transl Med, 2017. 5(2): p. 34.

147
65.

Liu, F., et al., Alterations in the Urinary Microbiota Are Associated With Cesarean
Delivery. Frontiers in Microbiology, 2018. 9(2193).

66.

Ollberding, N.J., et al., Urinary Microbiota Associated with Preterm Birth: Results from
the Conditions Affecting Neurocognitive Development and Learning in Early Childhood
(CANDLE) Study. PLoS One, 2016. 11(9): p. e0162302.

67.

Pearce, M.M., et al., The female urinary microbiome in urgency urinary incontinence.
Am J Obstet Gynecol, 2015. 213(3): p. 347 e1-11.

68.

Thomas-White, K.J., et al., Urinary microbes and postoperative urinary tract infection
risk in urogynecologic surgical patients. International urogynecology journal, 2018.
29(12): p. 1797-1805.

69.

Whiteside, S.A., et al., The microbiome of the urinary tract--a role beyond infection. Nat
Rev Urol, 2015. 12(2): p. 81-90.

70.

Dickson, R.P., et al., Changes in the Lung Microbiome following Lung Transplantation
Include the Emergence of Two Distinct Pseudomonas Species with Distinct Clinical
Associations. Plos One, 2014. 9(5): p. 15.

71.

Chehoud, C., et al., Fungal signature in the gut microbiota of pediatric patients with
inflammatory bowel disease. Inflamm Bowel Dis, 2015. 21.

72.

Cho, I. and Blaser, M.J., The human microbiome: at the interface of health and disease.
Nat Rev Genet, 2012. 13(4): p. 260-70.

73.

Frank, D.N., et al., Molecular-phylogenetic characterization of microbial community
imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A, 2007.
104(34): p. 13780-5.

148
74.

Lee, D., et al., Diet in the pathogenesis and treatment of inflammatory bowel diseases.
Gastroenterology, 2015. 148.

75.

Michail, S., et al., Alterations in the gut microbiome of children with severe ulcerative
colitis. Inflamm Bowel Dis, 2012. 18(10): p. 1799-808.

76.

Round, J.L. and Mazmanian, S.K., The gut microbiota shapes intestinal immune
responses during health and disease. Nat Rev Immunol, 2009. 9(5): p. 313-23.

77.

Shaw, K.A., et al., Dysbiosis, inflammation, and response to treatment: a longitudinal
study of pediatric subjects with newly diagnosed inflammatory bowel disease. Genome
Med, 2016. 8.

78.

Arrieta, M.C., et al., Early infancy microbial and metabolic alterations affect risk of
childhood asthma. Sci Transl Med, 2015. 7(307): p. 307ra152.

79.

Hilty, M., et al., Disordered microbial communities in asthmatic airways. PLoS One,
2010. 5(1): p. e8578.

80.

Huang, Y.J. and Boushey, H.A., The microbiome in asthma. J Allergy Clin Immunol,
2015. 135(1): p. 25-30.

81.

Arumugam, M., et al., Enterotypes of the human gut microbiome. Nature, 2011. 473.

82.

Bäckhed, F., et al., Dynamics and stabilization of the human gut microbiome during the
first year of life. Cell Host Microbe, 2015. 17.

83.

Borghi, E., et al., Antenatal Microbial Colonization of Mammalian Gut. Reproductive
Sciences, 2019. 26(8): p. 1045-1053.

84.

Collado, M.C., et al., Human gut colonisation may be initiated in utero by distinct
microbial communities in the placenta and amniotic fluid. Sci Rep, 2016. 6.

149
85.

Dave, M., et al., The human gut microbiome: current knowledge, challenges, and future
directions. Transl Res, 2012. 160.

86.

David, L.A., et al., Diet rapidly and reproducibly alters the human gut microbiome.
Nature, 2014. 505.

87.

Debelius, J.W., et al., Turning participatory microbiome research into usable data:
lessons from the american gut project. J Microbiol Biol Educ, 2016. 17.

88.

Dethlefsen, L., et al., The pervasive effects of an antibiotic on the human gut microbiota,
as revealed by deep 16S rRNA sequencing. PLoS Biol, 2008. 6.

89.

Dogra, S., et al., Rate of establishing the gut microbiota in infancy has consequences for
future health. Gut Microbes, 2015. 6.

90.

Dollive, S., et al., Fungi of the murine gut: episodic variation and proliferation during
antibiotic treatment. PLoS One, 2013. 8.

91.

Dore, J. and Blottiere, H., The influence of diet on the gut microbiota and its
consequences for health. Curr Opin Biotechnol, 2015. 32.

92.

Fallucca, F., et al., Influence of diet on gut microbiota, inflammation and type 2 diabetes
mellitus. First experience with macrobiotic Ma-Pi 2 diet. Diabetes Metab Res Rev, 2014.
30.

93.

Forslund, K., et al., Disentangling type 2 diabetes and metformin treatment signatures in
the human gut microbiota. Nature, 2015. 528.

94.

Gill, S.R., et al., Metagenomic analysis of the human distal gut microbiome. Science,
2006. 312.

150
95.

Gomez-Arango, L.F., et al., Contributions of the maternal oral and gut microbiome to
placental microbial colonization in overweight and obese pregnant women. Scientific
Reports, 2017. 7: p. 10.

96.

Ley, R.E., et al., Microbial ecology: human gut microbes associated with obesity. Nature,
2006. 444(7122): p. 1022-3.

97.

Caruso, V., et al., Performance of Microbiome Sequence Inference Methods in
Environments with Varying Biomass. mSystems, 2019. 4(1): p. e00163-18.

98.

Kim, D., et al., Optimizing methods and dodging pitfalls in microbiome research.
Microbiome, 2017. 5(1): p. 52.

99.

Salter, S.J., et al., Reagent and laboratory contamination can critically impact sequencebased microbiome analyses. BMC Biol, 2014. 12.

100.

de Goffau, M.C., et al., Recognizing the reagent microbiome. Nat Microbiol, 2018. 3(8):
p. 851-853.

101.

Jervis-Bardy, J., et al., Deriving accurate microbiota profiles from human samples with
low bacterial content through post-sequencing processing of Illumina MiSeq data.
Microbiome, 2015. 3.

102.

Laurence, M., Hatzis, C., and Brash, D.E., Common contaminants in next-generation
sequencing that hinder discovery of low-abundance microbes. PLoS One, 2014. 9.

103.

O’Callaghan, J., et al., Re-assessing microbiomes in the low-biomass reproductive niche.
BJOG: An International Journal of Obstetrics & Gynaecology, 2020. 127(2): p. 147-158.

104.

Karstens, L., et al., Controlling for Contaminants in Low-Biomass 16S rRNA Gene
Sequencing Experiments. mSystems, 2019. 4(4): p. e00290-19.

151
105.

Emery, D.C., et al., 16S rRNA Next Generation Sequencing Analysis Shows Bacteria in
Alzheimer’s Post-Mortem Brain. Frontiers in Aging Neuroscience, 2017. 9(195).

106.

Païssé, S., et al., Comprehensive description of blood microbiome from healthy donors
assessed by 16S targeted metagenomic sequencing. Transfusion, 2016. 56(5): p. 11381147.

107.

Potgieter, M., et al., The dormant blood microbiome in chronic, inflammatory diseases.
FEMS Microbiology Reviews, 2015. 39(4): p. 567-591.

108.

Moreno, I., et al., Evidence that the endometrial microbiota has an effect on implantation
success or failure. Am J Obstet Gynecol, 2016. 215(6): p. 684-703.

109.

Winters, A.D., et al., Does the endometrial cavity have a molecular microbial signature?
Sci Rep, 2019. 9(1): p. 9905.

110.

Doyle, R.M., et al., Term and preterm labour are associated with distinct microbial
community structures in placental membranes which are independent of mode of
delivery. Placenta, 2014. 35.

111.

Zheng, J., et al., The placental microbiome varies in association with low birth weight in
full-term neonates. Nutrients, 2015. 7.

112.

Bassols, J., et al., Gestational diabetes is associated with changes in placental microbiota
and microbiome. Pediatr Res, 2016. 80(6): p. 777-784.

113.

Parnell, L.A., et al., Microbial communities in placentas from term normal pregnancy
exhibit spatially variable profiles. Sci Rep, 2017. 7(1): p. 11200.

114.

Brubaker, L. and Wolfe, A.J., The new world of the urinary microbiota in women. Am J
Obstet Gynecol, 2015. 213(5): p. 644-9.

152
115.

Hilt, E.E., et al., Urine is not sterile: use of enhanced urine culture techniques to detect
resident bacterial flora in the adult female bladder. J Clin Microbiol, 2014. 52(3): p. 8716.

116.

Siddiqui, H., et al., Assessing diversity of the female urine microbiota by high throughput
sequencing of 16S rDNA amplicons. BMC Microbiol, 2011. 11: p. 244.

117.

Wolfe, A.J. and Brubaker, L., "Sterile Urine" and the Presence of Bacteria. Eur Urol,
2015. 68(2): p. 173-4.

118.

Wolfe, A.J., et al., Evidence of uncultivated bacteria in the adult female bladder. J Clin
Microbiol, 2012. 50(4): p. 1376-83.

119.

Glassing, A., et al., Inherent bacterial DNA contamination of extraction and sequencing
reagents may affect interpretation of microbiota in low bacterial biomass samples. Gut
Pathog, 2016. 8.

120.

Davis, N.M., et al., Simple statistical identification and removal of contaminant
sequences in marker-gene and metagenomics data. Microbiome, 2018. 6(1): p. 226.

121.

Knights, D., et al., Bayesian community-wide culture-independent microbial source
tracking. Nat Methods, 2011. 8.

122.

Segata, N., et al., Metagenomic biomarker discovery and explanation. Genome Biology,
2011. 12(6): p. 18.

123.

Frank, J.A., et al., Critical evaluation of two primers commonly used for amplification of
bacterial 16S rRNA genes. Applied and Environmental Microbiology, 2008. 74(8): p.
2461-2470.

153
124.

Klindworth, A., et al., Evaluation of general 16S ribosomal RNA gene PCR primers for
classical and next-generation sequencing-based diversity studies. Nucleic Acids Res,
2013. 41(1): p. e1.

125.

Wang, Y. and Qian, P.-Y., Conservative Fragments in Bacterial 16S rRNA Genes and
Primer Design for 16S Ribosomal DNA Amplicons in Metagenomic Studies. PLoS One,
2009. 4(10): p. e7401.

126.

Volpi, E.V. and Bridger, J.M., FISH glossary: an overview of the fluorescence in situ
hybridization technique. BioTechniques, 2008. 45(4): p. 385-409.

127.

Levsky, J.M. and Singer, R.H., Fluorescence in situ hybridization: past, present and
future. Journal of Cell Science, 2003. 116(14): p. 2833-2838.

128.

Lauder, A.P., et al., Comparison of placenta samples with contamination controls does
not provide evidence for a distinct placenta microbiota. Microbiome, 2016. 4.

129.

Blanc, W.A., Amniotic infection syndrome; pathogenesis, morphology, and significance
in circumnatal mortality. Clin Obstet Gynecol, 1959. 2: p. 705-34.

130.

Fernandez-Feo, M., et al., The cultivable human oral gluten-degrading microbiome and
its potential implications in coeliac disease and gluten sensitivity. Clin Microbiol Infect,
2013. 19.

131.

Garrett, W.S., Cancer and the microbiota. Science, 2015. 348(6230): p. 80-6.

132.

Lewis, J.D., et al., Inflammation, antibiotics, and diet as environmental stressors of the
gut microbiome in pediatric crohn’s disease. Cell Host Microbe, 2015. 18.

133.

Thomas-White, K., et al., Culturing of female bladder bacteria reveals an interconnected
urogenital microbiota. Nat Commun, 2018. 9(1): p. 1557.

154
134.

Gilstrap, L.C., 3rd, Cunningham, F.G., and Whalley, P.J., Acute pyelonephritis in
pregnancy: an anterospective study. Obstet Gynecol, 1981. 57(4): p. 409-13.

135.

Eschenbach, D.A., et al., Bacterial vaginosis during pregnancy. An association with
prematurity and postpartum complications. Scand J Urol Nephrol Suppl, 1984. 86: p.
213-22.

136.

Gravett, M.G., et al., Preterm labor associated with subclinical amniotic fluid infection
and with bacterial vaginosis. Obstet Gynecol, 1986. 67(2): p. 229-37.

137.

Patterson, T.F. and Andriole, V.T., Bacteriuria in pregnancy. Infect Dis Clin North Am,
1987. 1(4): p. 807-22.

138.

Romero, R. and Mazor, M., Infection and preterm labor. Clin Obstet Gynecol, 1988.
31(3): p. 553-84.

139.

Hillier, S.L., et al., A case-control study of chorioamnionic infection and histologic
chorioamnionitis in prematurity. N Engl J Med, 1988. 319(15): p. 972-8.

140.

Romero, R., et al., Infection and labor. VI. Prevalence, microbiology, and clinical
significance of intraamniotic infection in twin gestations with preterm labor. Am J Obstet
Gynecol, 1990. 163(3): p. 757-61.

141.

Hillier, S.L., et al., Microbiologic causes and neonatal outcomes associated with
chorioamnion infection. Am J Obstet Gynecol, 1991. 165(4 Pt 1): p. 955-61.

142.

Andrews, W.W., Goldenberg, R.L., and Hauth, J.C., Preterm labor: emerging role of
genital tract infections. Infectious Agents and Disease, 1995. 4(4): p. 196-211.

143.

Horowitz, S., et al., Infection of the amniotic cavity with Ureaplasma urealyticum in the
midtrimester of pregnancy. J Reprod Med, 1995. 40.

155
144.

Goldenberg, R.L., Hauth, J.C., and Andrews, W.W., Intrauterine infection and preterm
delivery. N Engl J Med, 2000. 342(20): p. 1500-7.

145.

Yoon, B.H., et al., Clinical implications of detection of Ureaplasma urealyticum in the
amniotic cavity with the polymerase chain reaction. Am J Obstet Gynecol, 2000. 183(5):
p. 1130-7.

146.

Romero, R., et al., The role of infection in preterm labour and delivery. Paediatr Perinat
Epidemiol, 2001. 15 Suppl 2: p. 41-56.

147.

Falagas, M.E., Betsi, G.I., and Athanasiou, S., Probiotics for the treatment of women with
bacterial vaginosis. Clin Microbiol Infect, 2007. 13.

148.

Rautava, S., et al., Probiotics modulate host-microbe interaction in the placenta and fetal
gut: a randomized, double-blind, placebo-controlled trial. Neonatology, 2012. 102.

149.

Perez-Munoz, M.E., et al., A critical assessment of the "sterile womb" and "in utero
colonization" hypotheses: implications for research on the pioneer infant microbiome.
Microbiome, 2017. 5: p. 19.

150.

Theis, K.R., et al., Does the human placenta delivered at term have a microbiota? Results
of cultivation, quantitative real-time PCR, 16S rRNA gene sequencing, and
metagenomics. American Journal of Obstetrics & Gynecology, 2019. 220(3): p. 267.e1267.e39.

151.

Schloss, P.D. and Handelsman, J., Introducing DOTUR, a computer program for defining
operational taxonomic units and estimating species richness. Applied and Environmental
Microbiology, 2005. 71.

152.

Callahan, B.J., et al., DADA2: High-resolution sample inference from Illumina amplicon
data. Nature Methods, 2016. 13(7): p. 581-583.

156
153.

Lewis, D.A., et al., The human urinary microbiome; bacterial DNA in voided urine of
asymptomatic adults. Front Cell Infect Microbiol, 2013. 3: p. 41.

154.

Kogan, M.I., et al., Human urine is not sterile - shift of paradigm. Urol Int, 2015. 94(4):
p. 445-52.

155.

Colgan, R. and Williams, M., Diagnosis and treatment of acute uncomplicated cystitis.
Am Fam Physician, 2011. 84(7): p. 771-6.

156.

Gilbert, G.L., et al., Bacteriuria due to ureaplasmas and other fastidious organisms
during pregnancy: prevalence and significance. Pediatr Infect Dis, 1986. 5(6 Suppl): p.
S239-43.

157.

Pfau, A. and Sacks, T.G., Effective prophylaxis for recurrent urinary tract infections
during pregnancy. Clin Infect Dis, 1992. 14(4): p. 810-4.

158.

Delzell, J.E., Jr. and Lefevre, M.L., Urinary tract infections during pregnancy. Am Fam
Physician, 2000. 61(3): p. 713-21.

159.

Schnarr, J. and Smaill, F., Asymptomatic bacteriuria and symptomatic urinary tract
infections in pregnancy. Eur J Clin Invest, 2008. 38 Suppl 2: p. 50-7.

160.

Farkash, E., et al., Acute antepartum pyelonephritis in pregnancy: a critical analysis of
risk factors and outcomes. Eur J Obstet Gynecol Reprod Biol, 2012. 162(1): p. 24-7.

161.

Piatek, J., et al., Urinary tract infection during pregnancy affects the level of leptin,
ghrelin and insulin in maternal and placental blood. Scand J Clin Lab Invest, 2014.
74(2): p. 126-31.

162.

Glaser, A.P. and Schaeffer, A.J., Urinary Tract Infection and Bacteriuria in Pregnancy.
Urol Clin North Am, 2015. 42(4): p. 547-60.

157
163.

Matuszkiewicz-Rowinska, J., Malyszko, J., and Wieliczko, M., Urinary tract infections
in pregnancy: old and new unresolved diagnostic and therapeutic problems. Arch Med
Sci, 2015. 11(1): p. 67-77.

164.

Easter, S.R., et al., Urinary tract infection during pregnancy, angiogenic factor profiles,
and risk of preeclampsia. Am J Obstet Gynecol, 2016. 214(3): p. 387 e1-7.

165.

Romero, R., et al., Meta-analysis of the relationship between asymptomatic bacteriuria
and preterm delivery/low birth weight. Obstet Gynecol, 1989. 73(4): p. 576-82.

166.

Leuck, A.-M., et al., Complications of Foley Catheters—Is Infection the Greatest Risk?
The Journal of Urology, 2012. 187(5): p. 1662-1666.

167.

Leiby, J.S., et al., Lack of detection of a human placenta microbiome in samples from
preterm and term deliveries. Microbiome, 2018. 6(1): p. 196.

168.

Chen, C., et al., The microbiota continuum along the female reproductive tract and its
relation to uterine-related diseases. Nat Commun, 2017. 8(1): p. 875.

169.

Jacobs, K.M., et al., Microorganisms Identified in the Maternal Bladder: Discovery of the
Maternal Bladder Microbiota. AJP Rep, 2017. 7(3): p. e188-e196.

170.

Lamont, R.F., et al., The vaginal microbiome: new information about genital tract flora
using molecular based techniques. BJOG, 2011. 118(5): p. 533-49.

171.

Ravel, J., et al., Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci U S
A, 2011. 108 Suppl 1: p. 4680-7.

172.

Gajer, P., et al., Temporal dynamics of the human vaginal microbiota. Sci Transl Med,
2012. 4.

173.

Elovitz, M.A., et al., Cervicovaginal microbiota and local immune response modulate the
risk of spontaneous preterm delivery. Nat Commun, 2019. 10(1): p. 1305.

158
174.

Fettweis, J.M., et al., The vaginal microbiome and preterm birth. Nat Med, 2019. 25(6):
p. 1012-1021.

175.

Seferovic, M.D., et al., Visualization of microbes by 16S in situ hybridization in term and
preterm placentas without intraamniotic infection. American Journal of Obstetrics &
Gynecology, 2019. 221(2): p. 146.e1-146.e23.

176.

Robbins, J.R. and Bakardjiev, A.I., Pathogens and the placental fortress. Curr Opin
Microbiol, 2012. 15.

177.

DiGiulio, D.B., et al., Prevalence and diversity of microbes in the amniotic fluid, the fetal
inflammatory response, and pregnancy outcome in women with preterm pre-labor
rupture of membranes. Am J Reprod Immunol, 2010. 64(1): p. 38-57.

178.

Blanc, W.A., Pathways of fetal and early neonatal infection. Viral placentitis, bacterial
and fungal chorioamnionitis. J Pediatr, 1961. 59: p. 473-96.

179.

Aquino, T.I., et al., Subchorionic fibrin cultures for bacteriologic study of the placenta.
Am J Clin Pathol, 1984. 81.

180.

Svensson, L., Ingemarsson, I., and MÅrdh, P.-a., Chorioamnionitis and the isolation of
microorganisms from the placenta. Obstetrics & Gynecology, 1986. 67(3): p. 403-409.

181.

Ovalle, A., et al., Placental histopathology in premature rupture of membranes. Its
relationship with microbiological findings, maternal, and neonatal outcome. Rev Médica
Chile, 1998. 126.

182.

Stout, M.J., et al., Identification of intracellular bacteria in the basal plate of the human
placenta in term and preterm gestations. Am J Obstet Gynecol, 2013. 208(3): p. 226 e17.

159
183.

Prince, A.L., et al., The perinatal microbiome and pregnancy: moving beyond the vaginal
microbiome. Cold Spring Harb Perspect Med, 2015. 5(6).

184.

Funkhouser, L.J. and Bordenstein, S.R., Mom knows best: the universality of maternal
microbial transmission. PLoS Biol, 2013. 11.

185.

Pelzer, E., et al., Review: Maternal health and the placental microbiome. Placenta, 2017.
54: p. 30-37.

186.

Koleva, P.T., et al., Microbial programming of health and disease starts during fetal life.
Birth Defects Res C Embryo Today, 2015. 105.

187.

Cao, B., et al., Placental Microbiome and Its Role in Preterm Birth. Neoreviews, 2014.
15(12): p. e537-e545.

188.

Zaura, E., et al., Acquiring and maintaining a normal oral microbiome: current
perspective. Front Cell Infect Microbiol, 2014. 4: p. 85.

189.

Weiss, S., et al., Tracking down the sources of experimental contamination in
microbiome studies. Genome Biol, 2014. 15.

190.

Caporaso, J.G., et al., QIIME allows analysis of high-throughput community sequencing
data. Nat Methods, 2010. 7.

191.

Nearing, J.T., et al., Denoising the Denoisers: an independent evaluation of microbiome
sequence error-correction approaches. PeerJ, 2018. 6: p. e5364.

192.

Callahan, B.J., McMurdie, P.J., and Holmes, S.P., Exact sequence variants should
replace operational taxonomic units in marker-gene data analysis. Isme j, 2017. 11(12):
p. 2639-2643.

193.

R Core Team, R: A Language and Environment for Statistical Computing. 2020, R
Foundation for Statistical Computing: Vienna, Austria.

160
194.

Meyer, F., et al., The metagenomics RAST server - a public resource for the automatic
phylogenetic and functional analysis of metagenomes. BMC Bioinformatics, 2008. 9: p.
386.

195.

Mason, O.U., et al., Metagenomics reveals sediment microbial community response to
Deepwater Horizon oil spill. ISME J, 2014. 8(7): p. 1464-1475.

196.

Kopylova, E., Noe, L., and Touzet, H., SortMeRNA: fast and accurate filtering of
ribosomal RNAs in metatranscriptomic data. Bioinformatics, 2012. 28(24): p. 3211-3217.

197.

Fu, L.M., et al., CD-HIT: accelerated for clustering the next-generation sequencing data.
Bioinformatics, 2012. 28(23): p. 3150-3152.

198.

Kent, W.J., BLAT - The BLAST-like alignment tool. Genome Research, 2002. 12(4): p.
656-664.

199.

Rho, M.N., Tang, H.X., and Ye, Y.Z., FragGeneScan: predicting genes in short and
error-prone reads. Nucleic Acids Research, 2010. 38(20): p. 12.

200.

Kanehisa, M., et al., KEGG as a reference resource for gene and protein annotation.
Nucleic Acids Research, 2016. 44(D1): p. D457-D462.

201.

RStudio Team, RStudio: Integrated Development for R. 2020, "RStudio, PBC": Boston,
MA.

202.

Hammer, Ø., Harper, D.A.T., and Ryan, P.D., PAST: Paleontological statistics software
package for education and data analysis. Palaeontologia Electronica, 2001. 4(1): p. 1-9.

203.

Dixon, P., VEGAN, a package of R functions for community ecology. Journal of
Vegetation Science, 2003. 14.

204.

Broad Institute, Morpheus. 2020, Broad Institute.

161
205.

Johnson, M., et al., NCBI BLAST: a better web interface. Nucleic acids research, 2008.
36(suppl_2): p. W5-W9.

206.

Zheng, J., et al., The Placental Microbiota Is Altered among Subjects with Gestational
Diabetes Mellitus: A Pilot Study. Frontiers in physiology, 2017. 8: p. 675-675.

207.

Leon, L.J., et al., Enrichment of Clinically Relevant Organisms in Spontaneous PretermDelivered Placentas and Reagent Contamination across All Clinical Groups in a Large
Pregnancy Cohort in the United Kingdom. Appl Environ Microbiol, 2018. 84(14).

208.

Kageyama, A. and Benno, Y., Coprobacillus catenaformis Gen. Nov., Sp. Nov., a New
Genus and Species Isolated from Human Feces. Microbiology and Immunology, 2000.
44(1): p. 23-28.

209.

Cole, J.R., et al., Ribosomal Database Project: data and tools for high throughput rRNA
analysis. Nucleic Acids Res, 2014. 42(Database issue): p. D633-42.

210.

Doyle, R.M., et al., Bacterial communities found in placental tissues are associated with
severe chorioamnionitis and adverse birth outcomes. PLoS One, 2017. 12(7): p.
e0180167.

211.

Marsh, R.L., et al., How low can we go? The implications of low bacterial load in
respiratory microbiota studies. Pneumonia, 2018. 10(1): p. 7.

212.

Theis, K.R., et al., No Consistent Evidence for Microbiota in Murine Placental and Fetal
Tissues. mSphere, 2020. 5(1): p. e00933-19.

213.

Younge, N., et al., Fetal exposure to the maternal microbiota in humans and mice. JCI
Insight, 2019. 4(19).

214.

Martinez, K.A., II, et al., Bacterial DNA is present in the fetal intestine and overlaps with
that in the placenta in mice. PLoS One, 2018. 13(5): p. e0197439.

162
215.

Amarasekara, R., et al., Microbiome of the placenta in pre-eclampsia supports the role of
bacteria in the multifactorial cause of pre-eclampsia. J Obstet Gynaecol Res, 2015. 41.

216.

Egli, G.E. and Newton, M., The transport of carbon particles in the human female
reproductive tract. Fertil Steril, 1961. 12: p. 151-5.

217.

Romero, R., et al., Microbial invasion of the amniotic cavity during term labor.
Prevalence and clinical significance. J Reprod Med, 1993. 38(7): p. 543-8.

218.

Seong, H.S., et al., The frequency of microbial invasion of the amniotic cavity and
histologic chorioamnionitis in women at term with intact membranes in the presence or
absence of labor. Am J Obstet Gynecol, 2008. 199(4): p. 375.e1-5.

219.

Kozich, J.J., et al., Development of a dual-index sequencing strategy and curation
pipeline for analyzing amplicon sequence data on the MiSeq Illumina sequencing
platform. Appl Environ Microbiol, 2013. 79(17): p. 5112-20.

220.

Gallup, J., qPCR inhibition and amplification of difficult templates, in PCR
troubleshooting and optimization: the essential guide, S. Kennedy and N. Oswald,
Editors. 2001, Caister Academic Press: Norfolk, UK. p. 1-59.

221.

Pruesse, E., et al., SILVA: a comprehensive online resource for quality checked and
aligned ribosomal RNA sequence data compatible with ARB. Nucleic acids research,
2007. 35(21): p. 7188-7196.

222.

Quast, C., et al., The SILVA ribosomal RNA gene database project: improved data
processing and web-based tools. Nucleic Acids Res, 2013. 41(Database issue): p. D5906.

223.

Rognes, T., et al., VSEARCH: a versatile open source tool for metagenomics. PeerJ,
2016. 4: p. e2584.

163
224.

Lagkouvardos, I., et al., The Mouse Intestinal Bacterial Collection (miBC) provides hostspecific insight into cultured diversity and functional potential of the gut microbiota.
Nature Microbiology, 2016. 1(10): p. 16131.

225.

Kuperman, A., et al., Deep microbial analysis of multiple placentas shows no evidence
for a placental microbiome. BJOG: An International Journal of Obstetrics &
Gynaecology, 2020. 127(2): p. 159-169.

226.

Lakeman, M.M. and Roovers, J.P., Urinary tract infections in women with
urogynaecological symptoms. Curr Opin Infect Dis, 2016. 29(1): p. 92-7.

227.

Thomas-White, K., et al., The bladder is not sterile: History and current discoveries on
the urinary microbiome. Curr Bladder Dysfunct Rep, 2016. 11(1): p. 18-24.

228.

Basu, S., et al., Evolution of bacterial and fungal growth media. Bioinformation, 2015.
11(4): p. 182-4.

229.

Stamm, W.E. and Hooton, T.M., Management of urinary tract infections in adults. N
Engl J Med, 1993. 329(18): p. 1328-34.

230.

Chin, T.L., et al., Antimicrobial resistance surveillance in urinary tract infections in
primary care. J Antimicrob Chemother, 2016. 71(10): p. 2723-8.

231.

Le, J., et al., Urinary tract infections during pregnancy. Ann Pharmacother, 2004. 38(10):
p. 1692-701.

232.

Souza, R.B., Trevisol, D.J., and Schuelter-Trevisol, F., Bacterial sensitivity to fosfomycin
in pregnant women with urinary infection. Braz J Infect Dis, 2015. 19(3): p. 319-23.

233.

Szweda, H. and Jozwik, M., Urinary tract infections during pregnancy - an updated
overview. Dev Period Med, 2016. 20(4): p. 263-272.

164
234.

Chaemsaithong, P., et al., Soluble TRAIL in normal pregnancy and acute pyelonephritis:
a potential explanation for the susceptibility of pregnant women to microbial products
and infection. J Matern Fetal Neonatal Med, 2013. 26(16): p. 1568-75.

235.

Romero, R., et al., Inflammation in pregnancy: its roles in reproductive physiology,
obstetrical complications, and fetal injury. Nutr Rev, 2007. 65(12 Pt 2): p. S194-202.

236.

Gervasi, M.T., et al., Maternal intravascular inflammation in preterm premature rupture
of membranes. J Matern Fetal Neonatal Med, 2002. 11(3): p. 171-5.

237.

Gervasi, M.T., et al., Phenotypic and metabolic characteristics of monocytes and
granulocytes in preeclampsia. Am J Obstet Gynecol, 2001. 185(4): p. 792-7.

238.

Gervasi, M.T., et al., Phenotypic and metabolic characteristics of maternal monocytes
and granulocytes in preterm labor with intact membranes. Am J Obstet Gynecol, 2001.
185(5): p. 1124-9.

239.

Soto, E., et al., Fragment Bb: evidence for activation of the alternative pathway of the
complement system in pregnant women with acute pyelonephritis. J Matern Fetal
Neonatal Med, 2010. 23(10): p. 1085-90.

240.

Chaiworapongsa, T., et al., Acute pyelonephritis during pregnancy changes the balance
of angiogenic and anti-angiogenic factors in maternal plasma. J Matern Fetal Neonatal
Med, 2010. 23(2): p. 167-78.

241.

Gotsch, F., et al., Maternal serum concentrations of the chemokine CXCL10/IP-10 are
elevated in acute pyelonephritis during pregnancy. J Matern Fetal Neonatal Med, 2007.
20(10): p. 735-44.

242.

Soto, E., et al., Increased concentration of the complement split product C5a in acute
pyelonephritis during pregnancy. J Matern Fetal Neonatal Med, 2005. 17(4): p. 247-52.

165
243.

Kusanovic, J.P., et al., Maternal serum soluble CD30 is increased in pregnancies
complicated with acute pyelonephritis. J Matern Fetal Neonatal Med, 2007. 20(11): p.
803-11.

244.

Widmer, M., et al., Duration of treatment for asymptomatic bacteriuria during
pregnancy. Cochrane Database Syst Rev, 2015(11): p. CD000491.

245.

Sweet, R.L., Bacteriuria and pyelonephritis during pregnancy. Semin Perinatol, 1977.
1(1): p. 25-40.

246.

Patterson, T.F. and Andriole, V.T., Detection, significance, and therapy of bacteriuria in
pregnancy. Update in the managed health care era. Infect Dis Clin North Am, 1997.
11(3): p. 593-608.

247.

Nicolle, L.E., et al., Infectious Diseases Society of America guidelines for the diagnosis
and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis, 2005. 40(5): p. 64354.

248.

McDowall, D.R.M., et al., Anaerobic and Other Fastidious Microorganisms in
Asymptomatic Bacteriuria in Pregnant Women. The Journal of Infectious Diseases, 1981.
144(2): p. 114-122.

249.

Smaill, F.M. and Vazquez, J.C., Antibiotics for asymptomatic bacteriuria in pregnancy.
Cochrane Database Syst Rev, 2015(8): p. CD000490.

250.

Chu, C.M. and Lowder, J.L., Diagnosis and Treatment of Urinary Tract Infections
Across Age Groups. Am J Obstet Gynecol, 2018.

251.

Redelinghuys, M.J., et al., Comparison of the new Mycofast Revolution assay with a
molecular assay for the detection of genital mycoplasmas from clinical specimens. BMC
Infect Dis, 2013. 13: p. 453.

166
252.

Singhal, N., et al., MALDI-TOF mass spectrometry: an emerging technology for
microbial identification and diagnosis. Front Microbiol, 2015. 6: p. 791.

253.

Caporaso, J.G., et al., Ultra-high-throughput microbial community analysis on the
Illumina HiSeq and MiSeq platforms. ISME J, 2012. 6(8): p. 1621-1624.

254.

Edgar, R.C., et al., UCHIME improves sensitivity and speed of chimera detection.
Bioinformatics, 2011. 27(16): p. 2194-200.

255.

Wang, Q., et al., Naive Bayesian classifier for rapid assignment of rRNA sequences into
the new bacterial taxonomy. Applied and environmental microbiology, 2007. 73(16): p.
5261-5267.

256.

Højsgaard, S., Halekoh, U., and Yan, J., The R Package geepack for Generalized
Estimating Equations. 2005, 2005. 15(2): p. 11.

257.

Anderson, M.J., A new method for non-parametric multivariate analysis of variance.
Austral Ecology, 2001. 26(1): p. 32-46.

258.

Quinn, G.P. and Keough, M.J., Experimental Design and Data Analysis for Biologists.
2002, Cambridge: Cambridge University Press.

259.

Gotelli, N.J. and Ellison, A.M., A Primer of Ecological Statistics. 2004, Sunderland, MA:
Sinauer Associates, Inc.

260.

Foxman, B., et al., Urinary tract infection: self-reported incidence and associated costs.
Ann Epidemiol, 2000. 10(8): p. 509-15.

261.

Fihn, S.D., Clinical practice. Acute uncomplicated urinary tract infection in women. N
Engl J Med, 2003. 349(3): p. 259-66.

167
262.

American College of, O. and Gynecologists, ACOG Practice Bulletin No. 91: Treatment
of urinary tract infections in nonpregnant women. Obstet Gynecol, 2008. 111(3): p. 78594.

263.

Foxman, B., Recurring urinary tract infection: incidence and risk factors. Am J Public
Health, 1990. 80(3): p. 331-3.

264.

Loh, K. and Sivalingam, N., Urinary tract infections in pregnancy. Malays Fam
Physician, 2007. 2(2): p. 54-7.

265.

Kranz, J., et al., The 2017 Update of the German Clinical Guideline on Epidemiology,
Diagnostics, Therapy, Prevention, and Management of Uncomplicated Urinary Tract
Infections in Adult Patients: Part 1. Urol Int, 2018.

266.

ACOG. Available from: https://www.acog.org/Patients/FAQs/Routine-Tests-DuringPregnancy#why.

267.

ACOG educational bulletin. Antimicrobial therapy for obstetric patients. Number 245,
March 1998 (replaces no. 117, June 1988). American College of Obstetricians and
Gynecologists. Int J Gynaecol Obstet, 1998. 61(3): p. 299-308.

268.

Schneeberger, C., et al., Contamination rates of three urine-sampling methods to assess
bacteriuria in pregnant women. Obstet Gynecol, 2013. 121(2 Pt 1): p. 299-305.

269.

Baerheim, A., Digranes, A., and Hunskaar, S., Evaluation of urine sampling technique:
bacterial contamination of samples from women students. Br J Gen Pract, 1992. 42(359):
p. 241-3.

270.

Lifshitz, E. and Kramer, L., Outpatient urine culture: does collection technique matter?
Arch Intern Med, 2000. 160(16): p. 2537-40.

168
271.

Abdel-Aleem, H., et al., Indwelling bladder catheterisation as part of intraoperative and
postoperative care for caesarean section. Cochrane Database Syst Rev, 2014(4): p.
CD010322.

272.

Acharya, S., et al., Cesarean section without urethral catheterization: a randomized
control trial. Kathmandu Univ Med J (KUMJ), 2012. 10(38): p. 18-22.

273.

Nasr, A.M., et al., Evaluation of the use vs nonuse of urinary catheterization during
cesarean delivery: a prospective, multicenter, randomized controlled trial. J Perinatol,
2009. 29(6): p. 416-21.

274.

Ezaki, T., Li, N., and Kawamura, Y., The Anaerobic Gram-Positive Cocci, in The
Prokaryotes: Volume 4: Bacteria: Firmicutes, Cyanobacteria, M. Dworkin, et al.,
Editors. 2006, Springer US: New York, NY. p. 795-808.

275.

Siddiqui, H., et al., Alterations of microbiota in urine from women with interstitial
cystitis. BMC microbiology, 2012. 12: p. 205-205.

276.

Pagnier, I., et al., Non-contiguous finished genome sequence and description of
Fenollaria massiliensis gen. nov., sp. nov., a new genus of anaerobic bacterium.
Standards in genomic sciences, 2014. 9(3): p. 704-717.

277.

Boiten, K.E., Jean-Pierre, H., and Veloo, A.C.M., Assessing the clinical relevance of
Fenollaria massiliensis in human infections, using MALDI-TOF MS. Anaerobe, 2018. 54:
p. 240-245.

278.

Birch, D.F., Fairley, K.F., and Pavillard, R.E., Unconventional bacteria in urinary tract
disease: <em>Ureaplasma urealyticum</em>. Kidney International, 1981. 19(1): p. 5864.

169
279.

Schneeberger, C., Kazemier, B.M., and Geerlings, S.E., Asymptomatic bacteriuria and
urinary tract infections in special patient groups: women with diabetes mellitus and
pregnant women. Curr Opin Infect Dis, 2014. 27(1): p. 108-14.

280.

Cox, C., et al., The common vaginal commensal bacterium Ureaplasma parvum is
associated with chorioamnionitis in extreme preterm labor. Journal of Maternal-Fetal
&amp; Neonatal Medicine, 2016. 29(22): p. 3646-3651.

281.

DiGiulio, D.B., Diversity of microbes in amniotic fluid. Semin Fetal Neonatal Med, 2012.
17(1): p. 2-11.

282.

Murtha, A.P. and Edwards, J.M., The Role of Mycoplasma and Ureaplasma in Adverse
Pregnancy Outcomes. Obstetrics and Gynecology Clinics of North America, 2014. 41(4):
p. 615-+.

283.

Romero, R., et al., Sterile and microbial-associated intra-amniotic inflammation in
preterm prelabor rupture of membranes. J Matern Fetal Neonatal Med, 2015. 28(12): p.
1394-409.

284.

Blanchard, A., et al., Detection of Ureaplasma urealyticum by polymerase chain reaction
in the urogenital tract of adults, in amniotic fluid, and in the respiratory tract of
newborns. Clin Infect Dis, 1993. 17 Suppl 1: p. S148-53.

285.

Izraeli, S., et al., Genital mycoplasmas in preterm infants: prevalence and clinical
significance. Eur J Pediatr, 1991. 150(11): p. 804-7.

286.

Ollikainen, J., et al., Ureaplasma urealyticum infection associated with acute respiratory
insufficiency and death in premature infants. J Pediatr, 1993. 122(5 Pt 1): p. 756-60.

170
287.

Cassell, G.H., et al., Association of Ureaplasma urealyticum infection of the lower
respiratory tract with chronic lung disease and death in very-low-birth-weight infants.
Lancet, 1988. 2(8605): p. 240-5.

288.

Romero, R., et al., The preterm parturition syndrome. BJOG, 2006. 113 Suppl 3: p. 1742.

289.

Xiao, L., et al., Detection and characterization of human Ureaplasma species and
serovars by real-time PCR. J Clin Microbiol, 2010. 48.

290.

Hewish, M.J., Birch, D.F., and Fairley, K.F., Ureaplasma urealyticum serotypes in
urinary tract disease. Journal of clinical microbiology, 1986. 23(1): p. 149-154.

291.

Naessens, A., et al., Serotypes of Ureaplasma urealyticum isolated from normal pregnant
women and patients with pregnancy complications. Journal of clinical microbiology,
1988. 26(2): p. 319-322.

292.

Knox, C.L. and Timms, P., Comparison of PCR, nested PCR, and random amplified
polymorphic DNA PCR for detection and typing of Ureaplasma urealyticum in specimens
from pregnant women. Journal of clinical microbiology, 1998. 36(10): p. 3032-3039.

293.

Waites, K.B., et al., Congenital and opportunistic infections: Ureaplasma species and
Mycoplasma hominis. Semin Fetal Neonatal Med, 2009. 14.

294.

Murphy, E.C. and Frick, I.M., Gram-positive anaerobic cocci--commensals and
opportunistic pathogens. FEMS Microbiol Rev, 2013. 37(4): p. 520-53.

295.

Levy, P.Y., et al., Finegoldia magna: a forgotten pathogen in prosthetic joint infection
rediscovered by molecular biology. Clin Infect Dis, 2009. 49(8): p. 1244-7.

296.

Holst, H., et al., Detection of anaerobic prosthetic joint infection by PCR and DNA
sequencing--a case report. Acta Orthop, 2008. 79(4): p. 568-70.

171
297.

Ezaki, T., et al., Proposal of the genera Anaerococcus gen. nov., Peptoniphilus gen. nov.
and Gallicola gen. nov. for members of the genus Peptostreptococcus. Int J Syst Evol
Microbiol, 2001. 51(Pt 4): p. 1521-1528.

298.

Ezaki, T., et al., Transfer of Peptococcus indolicus, Peptococcus asaccharolyticus,
Peptococcus prevotii, and Peptococcus magnus to the Genus Peptostreptococcus and
Proposal of Peptostreptococcus tetradius sp. nov. International Journal of Systematic and
Evolutionary Microbiology, 1983. 33(4): p. 683-698.

299.

Pagnier, I., et al., Non-contiguous finished genome sequence and description of
Anaerococcus provenciensis sp. nov. Stand Genomic Sci, 2014. 9(3): p. 1198-210.

300.

Bowler, P.G. and Davies, B.J., The microbiology of infected and noninfected leg ulcers.
Int J Dermatol, 1999. 38(8): p. 573-8.

301.

Shilnikova, I.I. and Dmitrieva, N.V., Evaluation of Antibiotic Susceptibility of GramPositive Anaerobic Cocci Isolated from Cancer Patients of the N. N. Blokhin Russian
Cancer Research Center. Journal of pathogens, 2015. 2015: p. 648134-648134.

302.

Diop, K., et al., 'Anaerococcus mediterraneensis' sp. nov., a new species isolated from
human female genital tract. New microbes and new infections, 2017. 17: p. 75-76.

303.

Lee, S.E., et al., The intensity of the fetal inflammatory response in intraamniotic
inflammation with and without microbial invasion of the amniotic cavity. Am J Obstet
Gynecol, 2007. 197(3): p. 294 e1-6.

304.

Berg, T.G., et al., Ureaplasma/Mycoplasma-infected amniotic fluid: pregnancy outcome
in treated and nontreated patients. J Perinatol, 1999. 19.

305.

Harwick, H.J., Iuppa, J.B., and Fekety, F.R., Microorganisms and amniotic fluid. Obstet
Gynecol, 1969. 33.

172
306.

Prevedourakis, C., Papadimitriou, G., and Ioannidou, A., Isolation of pathogenic bacteria
in the amniotic fluid during pregnancy and labor. Am J Obstet Gynecol, 1970. 106.

307.

Prevedourakis, C.N., Strigou-Charalabis, E., and Kaskarelis, D.B., Bacterial invasion of
amniotic cavity during pregnancy and labor. Obstet Gynecol, 1971. 37.

173

ABSTRACT
EVALUATING HISTORICAL PARADIGMS OF STERILITY IN PERINATAL
MICROBIOLOGY AND RAMIFICATIONS FOR PREGNANCY OUTCOMES
by
JONATHAN MURRAY GREENBERG
August 2020
Advisor: Dr. Kevin R. Theis
Major: Biochemistry, Microbiology, and Immunology
Degree: Doctor of Philosophy
Next-generation sequencing technologies, especially 16S rRNA gene and metagenomic
sequencing have allowed investigations of low microbial biomass tissues of the human body.
While these sequencing methodologies have provided large amounts of reliable data for higher
microbial biomass sites, such as the mouth, intestine, and vagina, tissues of low microbial
biomass sites are subject to specific caveats that were not appropriately considered in early
investigations of these sites. Low microbial biomass sites of particular interest have included
those of the reproductive and urinary systems. Utilization of DNA sequencing methodologies
have allowed researchers to challenge existing paradigms of sterility around these sites that were
historically considered sterile, including but not limited to the placenta, the endometrium, and the
bladder. While a thorough and complete understanding of the microbial signals in urogenital
compartments is necessary for the best patient care and treatment, premature conclusions that
redefine historical paradigms can have harmful consequences on patient health, especially for
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pregnant women with whom microorganisms have been associated with multiple adverse
pregnancy outcomes.
In this dissertation, I present a lack of evidence for a placental microbiota in humans
using multiple modes of microbiological inquiry. Through culture, quantitative real-time PCR
(qPCR), 16S rRNA gene sequencing, and metagenomics we found no evidence of bacterial
signals beyond those also present in background technical controls. This work with human
subjects was subsequently complemented by work in mice, in which we investigated the
bacterial signals in the murine placenta and fetus, as well as multiple murine tissue control sites;
we again found no consistent evidence of a placental microbiota or in utero colonization through
multiple microbiological methodologies. Conversely, investigations of the urine of pregnant
women revealed evidence of a low abundance bladder microbiota. We found bacterial signals
that clearly exceeded those of technical controls, suggesting that a shift in sterility paradigm for
the upper urinary tract may be warranted. Specifically, through bacterial culture, qPCR, and 16S
rRNA gene sequencing we found evidence of a bladder microbiota in pregnant women that
showed strong variation among individuals and consisted of Ureaplasma urealyticum and Grampositive anaerobic cocci. A more thorough understanding of the bladder microbiota in pregnant
women across gestation will allow healthcare professionals to address urinary and bladder
symptoms in a way that alleviates or prevents pregnancy complications.
This body of work provides strategies for the thorough investigation of low microbial
biomass sites and demonstrates the high degree of evidence necessary to overturn classic
paradigms of sterility in perinatal medicine and host biology in general.
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AUTOBIOGRAPHICAL STATEMENT
As I am finishing my tenure as a graduate student, I can feel a deep-seeded excitement
for what is to come. One of the hallmarks of my personality, even since I was a child, has been
my inquisitive nature. There have been more times than I can count that I have felt the frustration
of others from my relentless questioning, like a child asking “why does this thing do that”, with a
follow-up, “but, why”, and another… and another. This was a time before the internet, when
Googling something was not the answer to any random question a person might have. But
believe me, my questions never stopped. They reached the Googling era, and my mom has used
that line on me on more than a few occasions, “why don’t you Google it?”. My inquisitive nature
is part of what brought be back to science. Having been raised by a young and quick-to-tenure
Psychology professor and a nurse, who later also became a professor of nursing, I always felt an
intrinsic pressure to be an intellectual of some sort. External pressures from my parents were
average at most times; they were wonderfully supportive in any endeavors I chose to pursue, as
long as I was doing something.
I was a lackluster high school student and endeavored on an unconventional and
exaggerated route through college that eventually led me to explore psychology. I enjoyed it, but
again I enjoy most things, but it wasn’t until my final semesters that I re-engaged with the
biological sciences, rediscovering a passion that I experienced in middle school and only briefly
in high school. I was able to channel some of this passion into tutoring other students after
having graduated college. In addition to tutoring, I got a job as a medical laboratory technician at
a local hospital, which allowed me to see the medical and industrial sides of my re-awakened
passion. These experiences culminated into my decision to pursue graduate school, one I had
always assumed I’d do, but we know what they say about assumptions. When I first came to
Wayne State, I had never heard a thing about the microbiome. It was serendipitous that Dr. Theis
was hired the same time that I started my first semester. And I honestly have never looked back.
I am excited for the future, new directions in life and my professional career. I feel an ardent
initiative to take what I have learned and completed as a graduate student and apply it to new
avenues of research and most certainly many new questions.

